Targeting Trehalose and Methylglucose Lipopolysaccharide Biosynthetic Pathways in M. tuberculosis - Structural and Functional Characterisation, and Early-Stage Drug Discovery of OtsA and Rv3030 by Verma, Nupur
Targeting Trehalose and Methylglucose 
Lipopolysaccharide Biosynthetic 
Pathways in M. tuberculosis 
Structural and Functional Characterisation, and 
Early-Stage Drug Discovery of OtsA and Rv3030 
NUPUR VERMA 
Lucy Cavendish College 
September 2016 
 
 
 
This Dissertation is submitted for the Degree of Doctor of Philosophy 
  
 
 
 
 
Undertake difficult tasks by approaching what is easy in them. 
Lao Tzu 
Declaration 
i 
 
DECLARATION 
This dissertation is the result of my own work carried out in the Department of Biochemistry, 
University of Cambridge, between October 2012 and September 2016. It includes nothing 
that is the outcome of work done in collaboration except as declared in the text. It is not 
substantially the same as any that I have submitted, or, is being concurrently submitted for a 
degree or diploma or other qualification at the University of Cambridge or any other 
University or similar institution. I further state that no substantial part of my dissertation has 
already been submitted, or, is being concurrently submitted for any such degree, diploma or 
other qualification at the University of Cambridge or any other University of similar 
institution. It does not exceed the prescribed limit of 60,000 words. 
 
NUPUR VERMA 
September 2016
Acknowledgements 
ii 
 
ACKNOWLEDGEMENTS 
I take this opportunity to express my profound sense of gratitude and respect to all those who 
helped me with my Ph.D. First and foremost, I offer my sincere respect and thanks to my 
supervisor, Prof. Sir Tom Blundell, for a giving me an opportunity to work with him, for his 
guidance and constant encouragement. He has been unhesitant in imparting his valuable 
wisdom, which assisted me in further developing my acumen for research. “In loco parentis”, 
I still remember these kindest words he said to me when I just came to Cambridge. Yes, he 
truly has been one! His resolute support and motivation made these 4-years enjoyable to 
work, even during the dark phases.  
I would like to thank Dr. Vitor Mendes and Dr. Michal Blaszczyk for their valuable help, 
guidance and supervision in the lab, for the stimulating scientific discussions, continous 
motivation and a great deal of learning experience. A big thanks to Dr. Sachin Surade, the 
former member of the lab, who considerably assisted me in settling down in Cambridge, 
imparted valuable scientific knowledge and whose advice kept me moving forward 
throughout. Dr. David Ascher warrants a special recognition; he has been an amazing mentor 
and friend, a person who had an unshakable faith in me and inspired me on various fronts, 
and for his constant willingness to discuss ideas. To Dr. Angela Pacitto for being a wonderful 
friend, and an impressively positive person whom I have always looked up to. I also thank the 
entire Blundell’s group for their suggestions, team spirit, amiability, spreading the smiles 
around and making this journey delightful. 
I am extremely grateful to my collaborator, Dr. Katherine Stott, for teaching me NMR 
spectroscopy and helping me in reviving the project, which seemed impossible otherwise. 
She has been graciously supportive and understanding. It has been an absolute pleasure to 
work with someone so brilliant and down to earth. Her vibrant personality was a confidence 
booster for sure.   
My parents, across half the world, have been the best pillars. Thank you Mum and Dad for 
giving me the strength and encouraging me not to give up. Your tireless efforts, unconditional 
support and prudence have helped me sail through. To my younger brother, for his boundless 
patience in keeping me sane and his continual belief in me. Your presence, silent yet strong, 
and insights have strengthened me. Finally, to my friends, here in Cambridge and back home; 
Acknowledgements 
iii 
 
you have truly made every day bright, jolly and pleasurable! Last but not the least, thanks to 
the Almighty for bestowing upon me his choicest blessings. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
iv 
 
ABSTRACT  
Mycobacterium tuberculosis, the causative agent of tuberculosis in humans, is one of the 
most successful pathogens, with much of its virulence predominantly associated with its 
thick, lipid-rich cellular envelope that modulates the host immune response. Tuberculosis, 
having a long history, has proved to be a challenging disease to eradicate. 
In mycobacteria, trehalose occurs as a free sugar in the cytoplasm, as well as a constituent of 
cell-wall glycolipids, such as cord-factor, sulfolipid-1 and lipooligosaccharides.                             
M. tuberculosis possesses two pathways for synthesis of trehalose, the OtsA-OtsB pathway 
and the TreY-TreZ pathway. Multiple biosynthetic pathways underline the critical role that 
trehalose plays in the bacteria. OtsA-OtsB is the dominant pathway, required for bacterial 
growth in laboratory culture and for virulence in a mouse model. OtsA, a retaining 
glucosyltransferase encoded by the otsA (Rv3490) gene, catalyses the synthesis of trehalose-
6-phosphate from ADP-glucose and glucose-6-phosphate, which is subsequently 
dephosphorylated by a functional homologue of OtsB (encoded by otsB2/Rv3372 gene) to 
yield trehalose. Both otsA and otsB2 gene have been shown to be essential for the growth of                        
M. tuberculosis.  
The present investigation focuses on this pathway, more specifically on OtsA. The 
recombinant orthologous protein from M. thermoresistibile was structurally and functionally 
characterised. The crystal structure revealed that there are two domains, with the catalytic site 
at their interface. The biochemical and structural data indicated that the enzyme had high 
preference for ADP-glucose as a glucose-donor. The protein activity was also shown to be 
regulated by feedback inhibition. Furthermore, a structure-guided, fragment-based drug-
discovery exercise was carried out against the target, which led to identification of fragment 
hits that have an inhibitory effect on the activity of the enzyme.  
Polymethylated polysaccharides (PMPSs) are complex intracellular polysaccharides, which 
are exclusive to mycobacteria and closely related species. PMPSs include methylglucose 
lipopolysaccharides (MGLPs) and methylmannose polysaccharides (MMPs). MGLPs, which 
are composed of acylated glucose and 6-O-methylglucose units, are found in all 
mycobacterial species, including the slow growing pathogenic M. tuberculosis. On the other 
hand, MMPs are linear polysaccharides that are not found in M. tuberculosis, but are found in 
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non-pathogenic M. smegmatis and other fast growing mycobacteria. Three gene clusters 
(Rv1208-Rv1212c, Rv2418c-Rv2419c and Rv3030-Rv3037c), initially thought to coordinate 
MGLPs biosynthesis, contain several genes that are considered to be essential for                
M. tuberculosis growth. One of the genes Rv3030, encoding for a SAM-dependent 6-O-
methyltransferase, is essential for survival of the bacilli and plays a pivotal role in the 
biosynthesis of MGLPs.  
In the present study, an orthologue of Rv3030 from M. smegmatis has been structurally 
characterised. To overcome a myriad of issues with crystallisation, low resolution and lack of 
reproducibility of the crystals, an alternative approach was taken to determine the structural 
features of the protein by NMR spectroscopy using 15N, 13C labelled protein. The protein has 
the β-sheet topology of the classic Rossmann fold, and exists as a monomer in solution.  
OtsA and Rv3030, essential for survival of M. tuberculosis, represent attractive anti-
tuberculosis drug targets, and this study focuses on understanding structural, biophysical and 
biochemical properties of these targets. This knowledge may then be used to identify lead 
chemical entities that bind to these proteins and modulate their function, providing new 
chemical tools that may be of use in designing antimicrobials for the fight against 
tuberculosis. 
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1.1 The Genus Mycobacterium and Tuberculosis Infection 
The genus Mycobacterium is one of the ancient bacterial genus, surmised to be originated 
150 million years ago (Daniel, 2006). It includes 175 species (as of July 2016, List of 
Prokaryotic Names with Standing in Nomenclature, http://www.bacterio.net/), most of which 
are saprophytes without clinical relevance, but there are number of opportunistic and strict 
pathogens that infect humans and animals (Rastogi et al., 2001).  
Mycobacterial infections trace back to antiquity, impacting humankind and advancements in 
health care research. World’s deadly diseases, tuberculosis and leprosy, caused by                         
M. tuberculosis (M. tb) and M. leprae respectively, have plagued humankind for centuries 
(Palomino et al., 2007). The tubercule bacilli was discovered by Robert Koch on 24th March 
1882, refuting the idea that the disease tuberculosis (TB) was hereditarily acquired or was 
only affecting people of low-social strata living in unhealthy conditions (Hass and Hass, 
1996). 
TB, earlier also known as the white death and the great white plague, was epidemic in 
Europe and America during 18th and 19th centuries, and by the end of 19th century, there was 
also a rise in incidence in India and China (Palomino et al., 2007). Though improvement in 
general public health, and advent of early diagnostic techniques and anti-tuberculosis drugs, 
reduced the burden, the disease was never eradicated, and around 1985, there was upsurge in 
number of TB cases in industrialised countries (Frith, 2014). There has also been emergence 
of infection by opportunistic non-tuberculous mycobacteria inhabiting natural reservoirs, 
which is now being recognized worldwide (Cook, 2010; Falkinham, 2009).  
Mycobacteria are acid-fast, obligatory aerobic actinomycetes, placed within the CNM 
(Corynebacterium-Nocardia-Mycobacterium) complex on the basis of chemotaxonomic 
studies (Lechevalier and Lechevalier, 1970). Mycobacteria form straight or slightly curved, 
non-motile and non-sporulated rods that grow as filaments, have unusually high content of 
guanine and cytosine in its genomic DNA, and a unique lipid rich cell wall composed mainly 
of mycolic acids, that differentiates it from other closely related genera (Palomino et al., 
2007). The species within this genus exhibit pronounced diversity, inhabiting diverse 
biotopes with only a handful of them causing pathogenicity. Slow growing species, like       
M. tuberculosis and M. leprae, are obligatory intracellular pathogens triggering infection in 
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humans and animals; whereas rapid growers, like M. smegmatis, are environmental 
saprophytes and typically non-pathogenic (Palomino et al., 2007). Several species form white 
or cream coloured colonies, but many fast growing species also form orange or bright yellow 
colonies containing carotenoid pigments (Zureck, 1985). In most species, the pigments are 
formed only in dark (scotochromogenic species), but some species form pigments only in 
response to light (photochromogenic species) (Dworkin et al., 2006).  
M. tb poses a great threat to humanity and harbour in one-third of global society, either as the 
carrier of latent infection or as the active disease (Dye, 2009). Tuberculosis is one of the 
leading causes of mortality worldwide due to bacterial infection, and it is estimated that in 
2014, there were 9.6 million new TB cases and 1.5 million deaths, out of which 0.4 million 
were among HIV-positive patients (Global tuberculosis report, WHO, 2015). The disease 
manifests itself primarily in lungs, though cases of extra-pulmonary TB are not uncommon 
(Kaufmann, 2001). The pathogen has evolved mechanistically and modulates expression of 
various metabolism-related genes to inhabit alveolar macrophage, wherein all other microbes 
perish due to microbicidal activity (Hingley-Wilson et al., 2003; Kaufmann, 2001).  
Despite considerable progress in the health care and medical sector, the rapid emergence in 
drug resistant strains of M. tb, and co-epidemics of TB and HIV has exacerbated the effect of 
TB, making it one of the most challenging diseases to control and eradicate (Global 
tuberculosis report, WHO, 2015; Wallis et al., 2016; Zumla et al., 2012). Thus, there is an 
urgent need to develop novel therapeutics for treatment of this insidious disease, which 
requires identification of novel pathways and new drug targets.  
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1.2 Mycobacterial Cellular Envelope  
Mycobacteria has a unique, resilient cell envelope having three distinct layers: an outer coat 
or capsule, a cell wall and an inner plasma membrane (Figure 1.1) (Brennan, 2003). This 
ensemble of free and bound polysaccharides, lipids, proteins and their conjugates confers 
much of the pathogenicity and drug-resistance to mycobacteria, and also modulates the host 
immune response (Hett and Rubin, 2008; Riley, 2006). The outer capsule, and the cell wall 
rich in long chain fatty acids known as mycolic acids (MA), are unique elements of 
mycobacteria that differentiates it from other prokaryotes (Dworkin et al., 2006). The 
composition of MA in the cell wall further individualize mycobacteria from closely related, 
MA containing genera Corynebacterium and Nocardia (Dworkin et al., 2006). 
Deciphering of the M. tb genome along with advancements in analytical techniques has 
helped in better understanding of the basic genetics, biosynthesis and structure of 
mycobacterial cell envelope (Brennan, 2003). 
 
 
 
FIGURE 1.1    The schematic representation mycobacterial cell envelope. 
GL: glycolipids, MA: mycolic acid, AG: arabinogalactan, PG: peptidoglycan (Figure adapted 
from  Maranha et al., 2015; Nobre et al., 2014). 
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1.2.1 The Capsule 
The surface of mycobacteria is a loosely bound structure known as capsule, which differs in 
composition between the pathogenic and the non-pathogenic species of mycobacteria (Hett 
and Rubin, 2008; Sani et al., 2010). The previously debated existence of this layer was 
confirmed when a thick capsule produced by pathogenic mycobacteria was detected in vitro 
by plunge freezing cryo-electron microscopy technique (Ortalo-Magne et al., 1995; Sani et 
al., 2010; Zuber et al., 2008). 97% of capsular matter is composed of polysaccharides and 
proteins, containing miniscule amounts of lipids (PIMs and LAM) as well (Sani et al., 2010).  
Three types of polysaccharides found in the capsule of M. tb are: arabinomannan (AM) 
consisting of a 6-α-D-Man-l mannan core and arabinan termini capped with mannosyl 
residues; a D-mannan composed of α-(1→6)-linked D-mannose units; and a high molecular 
weight α-D-glucan, which is analogous to glycogen (Lemassu and Daffé, 1994; Ortalo-
Magne et al., 1995). The high molecular weight (>100 kDa) α-D-glucan, which is the chief 
constituent of this labile layer amounting to 90% of the polysaccharides, is composed of       
α-(1→4)-linked D-glucose units, branched every five or six residues by oligoglucosides 
(Angala et al., 2014; Lemassu and Daffé, 1994). Some of the enzymes involved in 
biosynthesis of glucan and glycogen, are also involved or have putative function in synthesis 
of methylglucose lipopolysaccharides (MGLPs), an intracellular polysaccharide (described in 
detail in section 1.4), thus suggesting that the capsular α-D-glucan is synthesized in the 
cytoplasm and then transported to the surface by unknown carriers (Kalscheuer et al., 2010; 
Kaur et al., 2009a; Stadthagen et al., 2007).  
These capsular polysaccharides have been implicated in several biological roles, including 
host-pathogen interactions, immunomodulation and immunopathogenesis (Angala et al., 
2014; Kaur et al., 2009a). α-D-glucan has also been propounded to be involved in bacilli 
evasion of the immune system by molecular mimicry (Lemassu and Daffé, 1994). α-D-glucan 
mediates nonopsonic binding of M. tb to complement receptor-3 (CR-3), one of the principal 
phagocytic receptors of monocytes and neutrophils and this CR3-mediated phagocytosis 
promotes intracellular survival by suppressing IL-12 production and diminution of respiratory 
burst (Cywes et al., 1997; Ehlers and Daffé, 1998). However, since most of these studies 
have been elucidated in vitro, pivoting on the purified capsular glucan with cellular models, 
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α-D-glucan may not be accurately pertinent in mycobacterial infections, and warrants further 
investigation to define its role in M. tb pathogenicity and survival (Kaur et al., 2009a).  
1.2.2 The Cell Wall 
Mycobacterial cell wall is a complex, bi-layer structure that forms a stringent permeability 
barrier (Hett and Rubin, 2008). The insoluble core of the cell wall, the mycolyl-
arabinogalactan-peptidoglycan (mAGP) complex, consists of covalently linked peptidoglycan 
(PG), arabinogalactan (AG) and mycolic acids, sequentially extending outwards from the 
plasma membrane (Figure 1.2) (Brennan, 2003; Hett and Rubin, 2008). Also present therein 
are free soluble-lipids, cell-wall proteins, the phosphatidylinositol mannoside (PIM), the 
phthiocerol-containing lipids, lipomannan (LM) and lipoarabinomannan (LAM) (Riley, 
2006). The mycobacterial cell wall has received special attention from the perspective of 
drug-development and diagnostics, with several anti-tubercular agents targeting the 
biosynthesis of ingredients of the cellular envelope.   
Peptidoglycan  
Peptidoglycan (PG) or murein, is an intricate glycopolymer forming a rigid coat outside the 
plasma membrane that allows the bacteria to maintain its shape, resist the effects of osmotic 
pressure and serves as a foundation for other cell wall structures (Kaur et al., 2009a).  The 
glycan backbone is a nexus of alternating units of N-acetylglucosamine and modified 
muramic acid in a linear β-(1,4) linkage, with tetra-peptide side chains that are cross-linked, 
providing auxiliary structural cohesion to the cells (Brennan, 2003). There has been a 
renewed interest in PG synthesis as a promising target for novel chemotherapeutics (Angala 
et al., 2014).  
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Arabinogalactan  
Arabinogalactan (AG) is the major cell-wall polysaccharide of mycobacteria, attached to PG 
by a phosphoryl-N-acetylglucosaminosyl-rhamnosyl linkage (Bhamidi et al., 2008; Brennan, 
2003). It is vital for cell wall integrity and for tethering mycolic acid chains to PG layer 
(Brennan, 2003). AG is an assembly of arabinan and galactan, both in furanose form, with 
approximately 30 galactose residues arranged in an alternating (1→5), (1→6) linkages, and 
arabinan is attached to position 5 of the galactan in (1→5) linkages (Hett and Rubin, 2008). 
The anti-microbial action of ethambutol, a first-line anti-TB drug that inhibits synthesis of 
arabinan domains of LAM and AG, demonstrates the importance of AG in M. tb (Belanger et 
al., 1996; Goude et al., 2009). 
Mycolic Acids  
The outer layer of the mycobacterial cell wall, also referred as the mycomembrane, is 
concocted of C60-C90 α-branched, β-hydroxylated mycolic fatty acids that are covalently 
linked to the arabinogalactan-peptidoglycan layer; and free glycolipids intercalating with 
mycolic acids (MA) (Sani et al., 2010). This highly insoluble network of fatty acids is the 
predominant feature that contributes to low permeability of the cell wall and to the intrinsic 
resistance to drugs (Brennan, 2003; Hett and Rubin, 2008). Essentiality of MA in survival 
and virulence of the bacilli is reflected by the complexity and variability of MA biosynthetic 
pathway, and by the fact that isoniazid, the prime first-line antituberculous drug, targets MA 
biosynthesis (Cantaloube et al., 2011). Intracellular MGLPs form stable 1:1 ratio complexes 
with fatty acyl chains and acyl-CoAs, and regulate the activity of mega-enzyme FAS-I, 
involved in biosynthesis of MA, thus deriving the rationale that fatty acid synthesis as well is 
controlled by the intracellular polysaccharides (Flick and Bloch, 1974; Mendes et al., 2012). 
Glycoconjugates of Cell Wall 
The mycobacterial cell wall contains a high content of lipoglycans and lipoglycoproteins, 
phosphatidyl-myo-inositol mannosides (PIMs), lipomannan (LM) and lipoarabinomannan 
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(LAM) (Kaur et al., 2009a). These ubiquitous molecules amalgamate non-covalently with 
both the inner and outer layers of cell envelope, through their phosphatidyl-myo-inositol (PI) 
moiety (Ortalo-Magne et al., 1995; Pitarque et al., 2008). The PI anchor is conserved in these 
lipoglycans, suggestive of their metabolic relationship, and is heterogenous with variations 
occuring in number, location and nature of fatty acids (Besra and Brennan, 1997; Kaur et al., 
2009a). PIMs may contain one to six mannoses attached to inositol, but the major ones in           
M. tb are PI-dimannosides (Ac1PIM2 and Ac2PIM2) and PI-hexamannosides (Ac1PIM6 and 
Ac2PIM6) (Gilleron et al., 2001, 2003). Structurally, LMs and LAMs are extensions of PIMs. 
In addition to the PI moiety, LAM and LM possess a common linear α-(1,6)-linked mannan 
backbone made of 20-25 Manp residues, occasionally branched at C-2 by single Manp units; 
and in case of LAM, there is an additional arabinan moeity (Chatterjee and Khoo, 1998; 
Chatterjee et al., 1992; Gilleron et al., 2000). These glycoconjugates are involved in 
promoting entry of M. tb inside phagocytes, modulating the immune response, apoptosis and 
regulating phagosome maturation in vitro, but because these studies have been done with 
purified molecules and cellular models, it may not reflect their true significance (Appelmelk 
et al., 2008; Briken et al., 2004; Kaur et al., 2009a; Torrelles et al., 2008). PIMs regulates 
cell division, act as permeablity barrier and maintains the integrity of cell wall (Parish et al., 
1997; Patterson et al., 2003). 
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1.3 Trehalose: From Mycobacterial Perspective 
Trehalose (α-D-glucopyranosyl-(1,1)-α-D-glucopyranoside) is a non-reducing disaccharide, 
abundantly found in plants, insects, yeast, bacteria, fungi and invertebrates (Becker et al., 
1996; Gancedo and Flores, 2004; Grennan, 2007; Strom and Kaasen, 1993; Wright and 
Marshall, 1971). It exhibits unusual stability because of the two linked glucopyranose rings 
occurring at the reducing end of the glycosyl residues (α-carbons), and its glycosidic bond is 
not cleaved by α-glycosidase (Ohtake and Wang, 2011).  
Trehalose carries out divergent roles in different species, and its production is commonly 
related to physiological stresses. The most prevalent effect is its potential to allow 
resurrection of plants from complete desiccation due to its unique water-retention property 
(Ohtake and Wang, 2011). Trehalose is also produced in response to osmotic stress and is 
critical for thermal tolerance in many organisms (Hottiger et al., 1987). In insects, trehalose is 
the major source of energy, and is involved in anoxic tolerance and development (Chen et al., 
2002). Apart from being the energy source and an osmoprotectant in several bacteria as well, 
trehalose has noted structural and functional importance in Mycobacterium tuberculosis. In 
mycobacteria, trehalose is found abundantly in cytosol and cell wall, both as a free 
disaccharide and as glycoconjugate, constituting approximately 1.5-3% of total dry weight of 
cell in M. smegmatis (Elbein, 2003).  
1.3.1 Trehalose Metabolism in Mycobacteria 
It has been widely contemplated that mycobacteria has three pathways for trehalose 
synthesis: OtsAB, TreYZ and TreS (Avonce et al., 2006; Elbein, 2003). Though 
mycobacteria can principally exploit all the three pathways, OtsAB is the dominant pathway 
for trehalose production in M. tb (De Smet et al., 2000; Murphy et al., 2005). Recent studies 
in M. smegmatis have shown that trehalose synthase (TreS) is not the trehalose producing 
pathway, and its overexpression in M. tb decreases the level of trehalose (Miah et al., 2013). 
The multiple trehalose biosynthetic pathways underline its crucial role in the bacteria. 
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OtsA-OtsB Pathway 
This is the most dominant pathway that catalyses production of trehalose from NDP-glucose 
and glucose-6-phosphate by a two-step process. In the first step, OtsA enzyme (trehalose-6-
phosphate synthase, TPS) catalyses the condensation reaction between NDP-glucose and 
glucose-6-phosphate to produce an intermediate, trehalose-6-phosphate, and this 
phosphorylated compound is then dephosphorylated by OtsB enzyme (trehalose-6-phosphate 
phosphatase, TPP) into trehalose (Figure 1.3) (De Smet et al., 2000). 
In M. tuberculosis H37Rv, genes otsA and otsB2 have been demonstrated to be essential for 
growth by saturation transposon mutagenesis, and are required for survival (Griffin et al., 
2011; Sassetti et al., 2003). Trehalose-6-phosphate synthase (OtsA) is encoded by the otsA 
gene (Rv3490), and its mutants showed severe growth defects in vitro and in vivo (Murphy et 
al., 2005). Furthermore, genome analysis of M. tb has identified two open reading frames of 
the otsB gene: otsB1 (Rv2006) and otsB2 (Rv3372), which encode putative trehalose-6-
phosphate phosphatase (Cole et al., 1998; Murphy et al., 2005). otsB1 is part of a regulon, 
which is induced by exposure to hypoxia or to low concentrations of nitric oxide, its product 
has no detectable phosphatase activity, and is associated with non-replicating survival of  the 
bacteria (Edavana et al., 2004; Voskuil et al., 2003). otsB2, the functional homologue, has 
been reported to be strictly essential for growth of the bacilli, and mutation of otsB2 gene 
caused lethality and validated that phosphatase activity of OtsB is carried out only by this 
homologue, and the supply of exogenous trehalose did not reverse the phenotype (Murphy et 
al., 2005). Moreover, OtsB2 was also shown to induce humoral and cellular immune 
responses, and may be a candidate for vaccine development for control of TB disease (Zhang 
et al., 2007).  
TreY-TreZ Pathway 
This pathway, first identified in Rhizobia, Arthrobacter and Sulfolobus acidocaldarius, 
produces trehalose from terminal maltoses in glycogen chains by the activity of products of 
treY and treZ genes (Maruta et al., 1996c, 1996a, 1996b). TreY, a maltooligosyltrehalose 
trehalohydrolase encoded by treY gene, catalyses the rearrangement of the α-(1→4)-linkage 
Chapter-1  General Introduction 
12 
 
of the terminal disaccharide at the reducing end in glycogen into an α-(1→1)-linkage, and 
then the trehalose disaccharide is subsequently hydrolysed by the product of treZ gene, 
maltooligosaccharyltrehalose trehalohydrolase (Figure 1.3) (Woodruff et al., 2004). 
The gene cluster in Mycobacterium tuberculosis has two genes Rv1563c (treY/ glgY) and 
Rv1562c (treZ/glgZ) adjoining, with an additional gene treX/ glgX (Rv1564c) encoding a 
putative glycogen-debranching enzyme, though the function of the latter still remains to be 
validated (Cole et al., 1998; De Smet et al., 2000; Seibold and Eikmanns, 2007). Though this 
pathway is predominant in C. glutamicum (Tzvetkov et al., 2003), genetic inactivation of 
treY/treZ genes has no effect on M. tb growth in vitro (Murphy et al., 2005). In M. leprae, 
treY is a pseudogene, leaving OtsAB the only intact pathway for trehalose production (Cole 
et al., 2001). 
TreS Pathway 
Trehalose production by this pathway initially involved catalysis by the enzyme trehalose 
synthase (TreS), which isomerized the α-(1→4)-linkage of maltose into an α-(1→1)-linkage in 
trehalose, using free maltose as a substrate, unlike TreY (Elbein, 2003). Though it was 
considered one of the pathways for trehalose biosynthesis in mycobacteria, recent genetic 
studies have confuted the role of TreS in synthesis of trehalose from maltose in vivo, and 1H- 
and 19F-NMR analyses confirm that flux through TreS flows from trehalose to α-maltose, and 
overexpression of TreS led to a decrease in trehalose levels (Miah et al., 2013). While knock-
out mutants of treS (Rv0126) in M. tb showed no evident growth impairment compared to 
wild type during initial phase, they did lead to noticeable reduction in the bacterial load 
during late and near time-to death stages of infections in mice, thus indicating TreS could 
have a role only in the late-stage pathogenesis of the disease (Murphy et al., 2005).  
Another function of TreS that has been suggested is the α-amylase activity, wherein the 
enzyme was proposed to catalyse hydrolysis of glycogen with an α-amylase domain (Pan et 
al., 2008). But this was disproved when it was shown that the expected active site residues 
were absent from the acarbose binding site, and this activity in mycobacteria was only 
observed in vitro and at a very low rate, suggestive of a non-physiological role (Caner et al., 
2013). Also, TreS has two different active sites that would explain the lack of α-amylase 
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activity without affecting the observed trehalose-maltose interconverting activity (Pan et al., 
2004). 
Trehalose Catabolism 
M. tb possesses a trehalase-encoding gene (Rv2402), in addition to TreS, that directly 
hydrolyses trehalose, to balance the intracellular levels of trehalose during specific growth 
conditions (Elbein et al., 2010; Pan et al., 2004). Though the importance of trehalase activity 
and hypothetical regulation with TreS-Mak-GlgE pathway (described in section 1.5) in vivo 
remains elusive, these mechanisms can be significant for rapid assemblage of carbon and 
energy reserves in response to stress, or during osmoadaptation, when tight regulation of 
trehalose levels is required (Carroll et al., 2007; Elbein et al., 2010). In M. tb, the trehalase-
encoding gene was not considered essential by saturation transposon mutagenesis which 
hypothetically posits an overlapping function with TreS (Griffin et al., 2011). But 
contrastingly, a trehalase-negative mutant M. smegmatis could not be retrieved, advocating its 
essentiality for growth (Carroll et al., 2007).  
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FIGURE 1.3    Trehalose metabolism in M. tuberculosis.  
Enzymes are indicated in purple. OtsA: trehalose 6-phosphate synthase; OtsB2: trehalose 6-
phosphate phosphatase; TreY: maltooligosyl-trehalose synthase; TreZ: maltooligosyl-trehalose 
trehalohydrolase. (Figure adapted from Carroll et al., 2007; Miah et al., 2013; Woodruff et al., 
2004). 
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1.3.2 Biological Importance of Trehalose in Mycobacteria 
Mycobacterium tuberculosis produces trehalose for an array of tasks, through various 
independent pathways utilising different substrates. In spite of that, OtsAB has been validated 
to be the prime route for generating trehalose, and alternate pathways cannot compensate its 
depletion. Trehalose is a constituent of the mycobacterial cytoplasm and trehalose-containing 
compounds are abundant in mycobacterial cell wall, many of which are species-specific 
(Gautier et al., 1992; Jackson et al., 2007; Nobre et al., 2014).  
Trehalose Mycolates 
Trehalose-containing glycolipids in the cell envelope either protect mycobacteria from harsh 
environmental conditions or act as important virulence factors during pathogen-host 
interactions (Etienne et al., 2009; Harland et al., 2008; Stanley and Cox, 2013; Welsh et al., 
2013). The most prevalent glycolipids are trehalose-6-mycolate (trehalose monomycolate/ 
TMM) and trehalose 6, 6’-dimycolate (TDM) (Figure 1.4 A and B), which play a pivotal 
role in the low permeability and high resistance of mycobacteria to many antibiotics (Ortalo-
Magne et al., 1995). TMM is a ubiquitous metabolite in mycobacteria, implicated as a carrier 
of mycolic acid from the site of synthesis in the cytosol to the acceptor arabinogalactan in the 
cell wall (Dhariwal et al., 1987).  
TDM intercalates with the AG-linked MAs in the outer membrane, and confers to the 
envelope integrity and mediates interactions with the host’s immune system (Nobre et al., 
2014; Welsh et al., 2013). A potent antigenic “cord factor”, derived from trehalose 
dimycolate by modification of its lipid chains, has been associated with virulence of 
pathogenic mycobacteria (S. Glickman, 2008). TDM modifies macrophage gene expression, 
prevents phagosome-lysosome fusion and inhibits phagolysosome acidification that favours 
bacterial survival inside macrophages (Sakamoto et al., 2013). It is also the sole 
mycobacterial constituent that has potent immune-stimulatory activity, which imparts 
granuloma formation, adjuvant activity and tumour regression properties (Lang, 2013; Welsh 
et al., 2013). Recent investigations on the dynamic properties of TDM as a function of 
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temperature indicated that higher rigidity of trehalose mycolates and interaction between 
mycolates was related to the trehalose molecule itself (Migliardo et al., 2015).  
Acyltrehaloses 
M. tb produces a multitude of other different surface-exposed acyltrehaloses, namely the 
sulfatides, diacyltrehaloses (DATs), triacyltrehaloses (TATs) and pentacyltrehaloses (PATs) 
(Figure 1.4 C and D) (Daffé et al., 1988; Lemassu et al., 1991; Muñoz et al., 1997), which 
are complex glycolipids made of trehalose esterified with up to five multiple methyl-
branched long-chain fatty acids (Rousseau et al., 2003). Mycolipenic acids, the major acyl 
substituents found in PAT, TAT and some forms of DAT, have been found in the pathogenic 
M. tb, but not in the avirulent strain M. tuberculosis H37Ra or in the attenuated vaccine strain 
M. bovis BCG (Cason et al., 1956). This is indicative that these moieties play a crucial role in 
virulence of M. tb. These trehalose esters are potent inhibitors of leucocyte migration in vitro 
and DAT inhibits the proliferation of murine T-cells (Saavedra et al., 2001). Moreover, due 
to antigenicity of these fatty acids, they are candidate antigens for the serodiagnosis of TB 
(Besra et al., 1992; Lemassu et al., 1991). Though studies with purified molecules in cellular 
models implicate a significant role of acyltrehaloses in virulence of M. tb, their relevance 
during the natural process of infection remains to be unravelled (Jackson et al., 2007; 
Rousseau et al., 2003). 
Sulfolipid-1  
The outer membrane of M. tb abundantly contains sulfolipid-1 (SL-1), which is a 
tetraacylated trehalose-2-sulfate glycolipid (Figure 1.4 E), and the 50-year long search for its 
biological relevance has attributed in myriad, occasionally conflicting, roles in mycobacteria 
(Goren, 1972; Rousseau et al., 2003). It has been suggested that in cell-culture models, 
purified SL-1 activates and suppresses the production of cytokines and reactive oxygen 
species produced by human leukocytes (Pabst et al., 1988; Zhang et al., 1988). SL-1 are 
lysosmotropic and alter phagosome-lysosome fusion, thereby allowing the bacilli to survive 
inside macrophages (Goren et al., 1976). The levels of SL-1 are directly correlated with 
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virulence, with this sulfated-glycolipid being unique to the M. tb complex (Gangadharam et 
al., 1963). SL-1 in concert with cord factor disrupt mitochondrial oxidative phosphorylation, 
and both trehalose containing glycolipids damage mitochondrial structure and function, 
forming basis of the synergistic toxicity in vivo (Kato and Goren, 1974). Anionic SL-1 also 
regulates the intracellular growth of bacteria in a species-specific fashion, and arbitrates its 
susceptibility to a human cationic antimicrobial peptide LL-37 in vitro (Gilmore et al., 2012; 
Nobre et al., 2014). 
Lipooligosaccharides 
Mycobacterial lipooligosaccharides (LOS) are a distinct class of trehalose-containing 
glycolipids (Figure 1.4 F), composed of oligosaccharide chains linked to trehalose, and 
acylated with polymethylated-branched fatty acid (Etienne et al., 2009). LOS, found in many 
mycobacterial species such as M. kansasii, the Canettii strain of M. tuberculosis,                      
M. marinum, M. gastri, display substantial structural variations in the lipid moiety and the 
glycan core (Daffe et al., 1991; Hunter et al., 1983, 1988). Extensively reported structures of 
LOS from M. marinum reveals that they encompass a string of subspecies, LOS-I to LOS-IV, 
which are sequential intermediates that differ in number of monosaccharide units (Rombouts 
et al., 2009, 2010, 2011). These highly antigenic cell-surface exposed glycolipids have been 
implicated in infection of host macrophages, sliding motility and biofilm formation (Ren et 
al., 2007). LOS are liable to interfere with inception of proinflammatory response, by 
inhibiting the secretion of TNF-ɣ in LPS-stimulated human macrophages in vitro (Alibaud et 
al., 2014).  
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FIGURE 1.4    Structures of trehalose-conjugates in 
                          mycobacteria. 
A. TMM: trehalose monomycolate  
B. TDM: trehalose dimycolate 
C. PAT: pentaacyltrehalose  
D. DAT: diacyltrehalose 
E. SL-1: sulfolipid-1  
F. LOS: lipooigosaccharide (tetrasccharide 
core of LOS from M. kansasii) 
(Figure adapted from Nobre et al., 2014; 
Woodruff et al., 2004). 
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1.4 Methylglucose Lipopolysaccharides 
Mycobacteria produce complex polymethylated polysaccharides (PMPSs) (Berg et al., 2007), 
which were initially isolated in Clinton Ballou’s laboratory from Mycobacterium phlei (Gray 
and Ballou, 1971). These are cytoplasmic lipo-polysaccharides, composed of 10-20 sugar 
units, many of which are partially O-methylated (Jackson and Brennan, 2009). Two types of 
PMPSs found in mycobacteria and closely related species are 3-O-methylmannose 
polysaccharides (MMPs) and 6-O-methylglucose lipopolysaccharides (MGLPs) (Jackson and 
Brennan, 2009; Mendes et al., 2012).   
MMPs are composed of 10-13 units of 3-O-methyl-D-mannoses linked via α-(1→4)-linkages, 
with a single α-(1→4)-linked unmethylated D-mannose present at its non-reducing and an α-
methyl aglycon at the reducing end (Figure 1.5) (Mendes et al., 2012). These are found in 
non-pathogenic, fast-growing species of mycobacteria (Weisman and Ballou, 1984) and 
Streptomyces griseus, though the latter have acetylated molecules (Harris and Gray, 1977). 
MMPs however, have not been observed in M. tb and this indicates that they are probably 
restricted to the fast-growing mycobacterial species, unlike MGLPs (Stadthagen et al., 2007). 
 
 
 
 
 
 
 
FIGURE 1.5    Structure of 3-O methylmannose polysaccharides (MMPs) from M. smegmatis.  
Methyl groups are highlighted in green (Figure adapted from Mendes et al., 2012). 
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MGLPs are polysaccharides of glucose and methylglucose that are esterified with short-chain 
fatty acids (Ferguson and Ballou, 1970). These are a heterogeneous mix of closely related 
polysaccharides, differing in their degree of glycosylation, number of methylation sites, and 
on the nature and frequency of the esterified acyl chains (Tuffal et al., 1995). MGLPs have 
been identified in a few Nocardia species and in M. tuberculosis, M. bovis BCG, M. leprae,                 
M. smegmatis and M. xenopi, and the slow-growing, pathogenic mycobacteria may contain 
only this type of PMPSs (Gray and Ballou, 1971; Jackson and Brennan, 2009; Mendes et al., 
2012). 
1.4.1 Composition and Structure of MGLPs 
The sugar constituents of MGLPs are D-glucose, 6-O-methyl-D-glucose, 3-O-methyl-D- 
glucose and D-glyceric acid; and the lipid components are propionate, isobutyrate, succinate, 
and octanoate (Lee, 1966; Lee and Ballou, 1964).  
 
The main MGLP chain contains an assortment of α-(1→4)-linked glucose units and ten 6-O-
methylglucose units, with two branching glucoses linked via β-(1→3)-linkage to the glucoses 
1 and 3 of the MGLPs main chain (Mendes et al., 2012). A 3-O-methylglucose is present at 
the non-reducing end, whereas, the reducing end is composed of α-D-glucopyranosyl-(1-2)-
D-glyceric acid (glucosylglycerate, GG), which is linked to the first glucose of the main 
MGLP chain via α-(1→6) linkages and form diglucosylglycerate (DGG) (Figure 1.6) 
(Mendes et al., 2012).  
Acetate, propionate and isobutyrate are esterified to the methylglucose units close to the non-
reducing end; and succinate to both the branching glucoses (Keller and Ballou, 1968; Smith 
and Ballou, 1973). Early results by Smith and Ballou showed that in preparations of MGLPs 
from M. phelei, an octanoate moiety was attached to the primary hydroxyl group of the 
glycerate at the reducing end (Smith and Ballou, 1973). However, a recent study has 
redefined the architecture of this end, according to which octanoate is present at the C6-OH 
position of the glucoses of GG and DGG, and not to the glycerate molecule (Figure 1.6) 
(Maranha et al., 2015).   
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FIGURE 1.6    Structure of methylglucose lipopolysaccharides (MGLPs).  
Octanoyl-DGG highlighted by red dashed box, represent new architecture of the reducing end of 
the MGLP chain, based on the recent findings (described in the text). R2 and R3 are acyl groups 
(blue). R2: succinate; R3: acetate, propionate or isobutyrate. Methyl groups are highlighted 
green. (Figure adapted from Maranha et al., 2015; Mendes et al., 2012). 
In solution, MGLPs conform to a helical structure because of the stereotypical constraints 
conferred by α-(1→4) linkages (Jackson and Brennan, 2009; Mendes et al., 2012). Methyl 
groups face inwards to the center of the coil, forming a hydrophobic, cylindrical cavity, 
which allows accommodation of a long-chain fatty acid derivative (acyl-CoA) (Yabusaki et 
al., 1979). GG probably attaches the MGLP chains to the cytoplasmic membrane, and the 
reducing end is distinct from the helical conformation (Smith and Ballou, 1973; Tuffal et al., 
1995). The structure and function of the short-chain fatty acids esterified to MGLPs is yet to 
be unraveled, but it has been suggested that these acyl groups stabilise the conformation of 
the polysaccharide chains, equivalent to the one stimulated during interaction with fatty acids 
(Mendes et al., 2012). 
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1.4.2 Biosynthesis of MGLPs 
Two gene clusters (Rv1208-Rv1213 and Rv3030-Rv3037c) were initially considered to be 
involved in MGLP biosynthesis in M. tb, until recent results indicated at least three more 
clusters (Rv1326c-Rv1327c, Rv2417c-Rv2419c and Rv0126-Rv0127) may be involved in this 
pathway (Figure 1.7, Table 1.1) (Mendes et al., 2012).  
              Rv3030          Rv3031         Rv3032          Rv3033          Rv3034c      Rv3037c        Rv3038c  
  
              Rv1208           Rv1209         Rv1210          Rv1211          Rv1212c   Rv1213   
               GpgS                                   TagA                                    GlgA       GlgC 
                  Rv2417c     Rv2418c      Rv2419c                               
                              OctT            GpgP                                    
                                    
                                   Rv0126          Rv0127 
               TreS              Mak  
                      
                  Rv1326c            Rv1327c 
                   GlgB                   GlgE            
FIGURE 1.7    Gene clusters proposed to be involved in biosynthesis of MGLPs in M. tuberculosis H37Rv. 
Shading is done as follows- green: genes essential for growth of M. tb; red: genes non-essential 
for growth of M. tb; blue: genes with unknown function; yellow: genes with hypothetical 
function (Figure adapted from Maranha et al., 2015; Mendes et al., 2012). 
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Table 1.1    Genes and enzymes involved in MGLP biosynthesis in M. tuberculosis. 
     * GgH enzyme is found only in fast-growing mycobacteria, and not in slow-growing species like  
      M. tuberculosis. 
 
Gene in 
M. tb  H37Rv 
Protein Proposed Function References 
Rv1208 GpgS (Glucosyl-3-
phosphoglycerate synthase) 
Glucosylglycerate 
biosynthesis 
Kaur et al., 2009b 
Rv2419c GpgP (Glucosyl-3-
phosphoglycerate phosphatase) 
Glucosylglycerate 
biosynthesis 
Mendes et al., 2011 
 GgH* (Glucosylglycerate 
hydrolase) 
Glucosylglycerate 
hydrolysis 
Alarico et al., 2014 
 Rv2418c OctT (Octanoyltransferase) Octanoylation of GG and 
DGG 
Maranha et al., 2015 
Rv3031 Putative glycoside hydrolase  Probably DGG biosynthesis  Mendes et al., 2012; 
Stadthagen et al., 2007 
Rv1326c GlgB (Glycogen branching 
enzyme) 
Probably DGG biosynthesis  Garg et al., 2007;  
Mendes et al., 2012 
Rv3032 α-(1→4) glycosyltransferase Glycosylation of the MGLP 
chain 
Stadthagen et al., 2007 
Rv1212c GlgA ( α-(1→4) 
glycosyltransferase) 
Glycosylation of the MGLP 
chain 
Stadthagen et al., 2007; 
Sambou et al., 2008 
Rv3030 Putative SAM-dependant 6-O- 
methyltransferase 
Methylation at 6-O position 
of glucoses in MGLP chain 
Stadthagen et al., 2007 
Rv3037c Putative SAM-dependant 3-O- 
methyltransferase 
Methylation at 3-O position 
of terminal glucose at non-
reducing end of MGLP 
chain 
Stadthagen et al., 2007 
Rv3034c Putative 
acetyltransferase 
Esterification of glucoses of 
MGLP chain  
Stadthagen et al., 2007 
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Kamisango and colleagues proposed a model for the biosynthesis of MGLPs in which 
biosynthesis of the main polysaccharide chain is controlled by synchronized interplay of 
glycosylation, acetylation and methylation reactions, and occurs in a stepwise fashion from 
reducing to non-reducing end through sequential glycosylation-methylation reactions (Figure 
1.8) (Kamisango et al., 1987). However, it is not yet known how the synthesis of the chain is 
terminated (Jackson and Brennan, 2009). 
Two genes, Rv1212c and Rv3032, which encode for α-(1→4) glycosyltransferase, are 
associated with glycosylation and elongation of the MGLP chain in M. tb (Stadthagen et al., 
2007). Knock-out mutants of Rv3032 led to production of low levels of MGLPs, but not 
critically low, and its activity was shown to be partially compensated by Rv1212c, which is 
basically involved in biosynthesis of glycogen and capsular α-glucan (Sambou et al., 2008; 
Stadthagen et al., 2007).  However, the bacilli did not recuperate after double disruption of 
these genes, thus implying that at least one functional gene is required for its survival 
(Sambou et al., 2008; Stadthagen et al., 2007). Rv3032 was also shown to be involved in 
glycogen and capsular α-glucan biosynthetic pathways, though not as extensively as Rv1212c 
(Sambou et al., 2008). It is not yet known which genes are responsible for carrying out the β-
(1→3) glycosyl-branching. 
Ballou and co-workers identified and characterized a soluble protein from extracts of M. phlei 
that methylates at 6-O and 3-O positions of some glucosyl units in MGLPs and partially 
acetylated α-(1-4)-D-gluco-oligosaccharides, using SAM as the methyl group donor for the 
methyltransferase reactions (Ferguson and Ballou, 1970). Methylation at a particular position 
on the sugar moiety is dependent on its degree of acetylation, i.e. methylation occurs only at 
6-O position at low levels of acetylation, whereas high levels of acetylation inhibits 
methylation at 6-O position, and some methylation then occurs at 3-O position (Grellert and 
Ballou, 1972). Methyltransferases involved in MGLP synthesis in M. tb are encoded by the 
genes Rv3030 and Rv3037c (detailed in section 1.4.4) (Stadthagen et al., 2007).  
Tung and Ballou demonstrated that the acylation of the MGLP chain is carried out by a 
membrane-associated acyltransferase that catalyzes the transfer of acetyl, propionyl, 
isobutyryl, octanoyl and succinyl groups from their respective acyl-CoA derivatives, though 
at different rates (Tung and Ballou, 1973). This advocates possibility of more than one 
acyltransferase involved in synthesis. Nevertheless, a novel acyltransferase in mycobacteria 
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has been identified, an octonoyltransferase- OctT (Rv2418c) that transfers an octanoate 
moiety to the C6-OH position of glucose of GG and DGG (Maranha et al., 2015). It has been 
also proposed that if the same octanoylation of GG at C6-OH position occurs in vivo, it can 
restrain the synthesis of MGLP chain, as this is the point where the second glucose of DGG 
attaches, and subsequently the chain is progressed (Maranha et al., 2015; Stadthagen et al., 
2007). 
During nitrogen deficiency, GG gets accumulated, and when the nitrogen levels are 
replenished, GG is hydrolyzed by GG hydrolase (GgH), an enzyme present only in the fast-
growing species, to produce glucose and glycrate, and which possibly regulate the MGLP 
biosynthesis in rapidly-growing mycobacteria (Alarico et al., 2014).  
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FIGURE 1.8    Proposed pathway for biosynthesis of MGLPs.  
Question marks represent probable gene function. Dashed arrows represent hypothetical steps in 
biogenesis. →glycosylations (blue) are responsible for elongation of the MGLP main 
chain whereas (1→3) glycosylations (red) add branching glucoses. GT: glycosyltransferase; 
MeT: methyltransferase (maroon); AcT: acyltransferase (green); R2 and R3 are acyl groups 
(green) and methyl groups are in maroon. 3-PGA: D-3-phosphoglyceric acid;                                   
SAM: S-adenosylmethionine; SAH: S-adenosylhomocysteine; GpgS: glucosyl-3-
phosphoglycerate synthase; GpgP: glucosyl-3-phosphoglycerate phosphatase;                                
GgH: glucosylglycerate hydrolase (found only in fast-growing mycobacteria);                               
OctT: octanoyltransferase; DggS: diglucosylglycerate synthase; TreS: trehalose synthase;         
Mak: maltokinase; GlgE: maltosyltransferase. (Figure adapted from Alarico et al., 2014; 
Maranha et al., 2015; Mendes et al., 2012). 
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1.4.3 Biological Role of MGLPs 
The majority of in vitro studies to decipher the physiological functions of MGLPs were 
performed in Konrad Bloch’s laboratory (Flick and Bloch, 1974; Ilton et al., 1971; Machida 
and Bloch, 1973). A salient feature of PMPSs is their capability to form a stable 1:1 ratio 
complex with fatty-acyl and acyl-CoA of lengths ranging from C16 to C22, and shortening or 
lengthening of the fatty-acyl chains notably lowers the affinity of interaction and never 
reaches a 1:1 molar ratio (Machida and Bloch, 1973). They help in sequestering the newly 
synthesized products of fatty acid synthase-I (FAS-I) and regulate the activity rate of the 
mycobacterial FAS-I complex by alleviating product inhibition and allowing continuous 
synthesis of acyl-CoAs (Bloch, 1977; Machida and Bloch, 1973). These polysaccharides 
significantly decrease the Km of FAS-I for acyl- CoA substrates, thus enabling synthesis at 
low substrate concentrations, and a higher enzyme turnover (Flick and Bloch, 1974; Ilton et 
al., 1971; Machida and Bloch, 1973).  
PMPSs prevent metabolism disruption due to fatty acid accumulation, as free fatty-acid 
chains (C16-C22) inhibit activity and inactivate several enzymes (Kawaguchi and Bloch, 1974; 
Yabusaki et al., 1979). Mycobacterial PMPSs can also serve as fatty acid carriers (Mendes et 
al., 2012; Yabusaki et al., 1979) and safeguard the long chain acyl-CoAs from degradation by 
the action of cytoplasmic lipolytic enzymes (Yabusaki and Ballou, 1979). 
Mycobacteria adapt to temperature changes by rapidly altering the length, level of saturation 
and chain branching of mycolic acids in the outer membrane (Baba et al., 1989; Stratton et 
al., 2002; Toriyama et al., 1980). It has been hypothesized that MGLPs help mycobacteria in 
thermal adaptation, as a study indicated that the growth rate of M. smegmatis mutants, 
synthesizing very low levels of MGLPs, was severely affected at high temperatures (39-
42°C) (Stadthagen et al., 2007).  
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1.4.4 SAM-Dependent Methyltransferases in MGLP Biosynthesis 
The gene cluster Rv3030-Rv3037c, considered to participate in MGLPs biosynthesis, contains 
two putative SAM-dependent methyltransferase genes, Rv3030 and Rv3037c (Stadthagen et 
al., 2007), belonging to methyltransferase family-11 and methyltransferase family-26, 
respectively (identified by Pfam) (Punta et al., 2012). The former catalyses 6-O-methylation 
of glucoses of MGLP, while the latter is proposed to catalyse 3-O-methylation of the terminal 
glucose at non-reducing end of the MGLP chain (Jackson and Brennan, 2009; Mendes et al., 
2012). Stadthagen and colleagues created the knock-out mutants of Rv3030 orthologue in     
M. smegmatis (earlier annoted as MSMEG2349, now annotated as MSMEG_2350) and found 
that the disruption of this gene severely impaired the growth of the mutant at high 
temperatures (39-42°C) and the mutant completely obliterated the MGLP activity as 
compared with the wild-type (Stadthagen et al., 2007). This indicates that Rv3030 orthologue 
in M. smegmatis play a pivotal role in the biosynthesis of MGLPs. 
An additional SAM dependent methyltransferase gene, Rv3038c, found adjacent to Rv3037c 
(Figure 1.7), is a member of methyltransferase family-11 (identified by Pfam) (Punta et al., 
2012) and contains LysR family signature but shows no similarity to known LysR family 
members (as given in TubercuList database) (Lew et al., 2011).  
Rv3030 and Rv3038c are regarded essential, whereas Rv3037c is non-essential for                         
M. tuberculosis growth by high-density mutagenesis (Griffin et al., 2011; Sassetti et al., 
2003), however, the latter is required for survival of the pathogen in primary murine 
macrophages, as demonstrated by transposon site hybridization (TraSH) in M. tuberculosis 
H37Rv (Rengarajan et al., 2005). These genes are essential, either for growth or survival of 
M. tuberculosis, and are promising drug targets (Griffin et al., 2011; Mendes et al., 2012; 
Rengarajan et al., 2005; Sassetti et al., 2003; Stadthagen et al., 2007). 
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1.5 A Possible Link between Trehalose Metabolism, MGLP Chain   
              Elongation and Biosynthesis of Capsular α-glucan and Glycogen 
Maltose is produced from trehalose in a reaction catalyzed by TreS (Rv0126) (described afore 
in section 1.3.1), which is then phosphorylated by maltokinase (Mak or Pep2, Rv0127) to 
produce maltose-1-phosphate (M1P), the substrate of maltosyltransferase (GlgE, Rv1327c) 
that elongates glycogen chains, and possibly other α-(1→4) glucose polymers such as the 
capsular a-glucan or the intracellular MGLPs (Elbein et al., 2010; Kalscheuer et al., 2010; 
Miah et al., 2013). Gene Rv1326c, encoding for α-(1→6) glycogen branching enzyme 
(GlgB), is present upstream of Rv1327c, and both genes are present in the gene cluster 
involved in glycogen synthesis (Elbein et al., 2010; Kalscheuer et al., 2010). It has been 
hypothesized that GlgB has an involvement in the synthesis of DGG, an early intermediate 
for MGLP chain synthesis (Elbein et al., 2010; Jackson and Brennan, 2009) (section 1.4.2). It 
has been proposed that under normal growth conditions, glycogen would be synthesized by 
the GlgA-GlgB (Rv1212c-Rv1326c) pathway, while during heat-stress, excess trehalose 
would be used for glycogen production via TreS-Mak-GlgE (Elbein et al., 2010). The 
putative connection of the gene clusters Rv0126-Rv0127 and Rv1326c-Rv1327c in the MGLP 
biogenesis, offers a possibility of utilizing trehalose via Tres-Mak-GlgE and glycogen 
biosynthetic genes as alternative routes for biosynthesis and elongation of MGLP chains, 
though it still needs to be experimentally validated (Figure 1.8) (Elbein et al., 2010; Jackson 
and Brennan, 2009; Kalscheuer et al., 2010). 
1.6 Drug Development Against Tuberculosis: Combating the Old 
Enemy 
The research for development of drugs against TB has seen groundbreaking advancements, 
but has faced severe issues and challenges. Despite the success of highly efficacious oral 
four-drug (isoniazid, ethambutol, rifampicin and pyrazinamide) anti-tubercular combinatorial 
treatment, introduced almost 60 years ago, TB continues to strikingly increase the morbidity 
and mortality rates (Ma et al., 2010; Stehr et al., 2014). After the discovery of rifampicin in 
the 1960s, a long period passed without witnessing a new formulation to treat this old enemy, 
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up until last decade wherein several novel treatment options have emerged, now being 
studied in pre-clinical and clinical trials (Mdluli et al., 2015; Sloan et al., 2013; Zumla et al., 
2014; Zuniga et al., 2015). Moreover, drug-resistance of the bacilli and HIV-TB co-pandemic 
has substantially pressurised the healthcare sector, necessiating the need for new and more 
potent treatment regimens.  
The typical first-line treatment against drug-susceptible TB involves combination of 
rifampicin, isoniazid, ethambutol and pyrazinamide given for a minimum period of 6-9 
months, with an ‘intensive phase’ of 4 drugs (rifampicin, isoniazid, pyrazinamide and 
streptomycin or ethambutol) for the first two months, followed by a four month ‘continuation 
phase’ of two drugs (rifampicin and isoniazid) (Figure 1.9, Table 1.2) (Piccaro et al., 2013; 
Zumla et al., 2014). However, the current treatment is long, complex and has severe side-
effects, which leads to non-adherence, and as a consequence, there is a high risk of failure 
and relapse, continuous spread of infection and resistance to the antibiotics (Zumla et al., 
2014). Management of drug resistant TB, multi-drug (MDR-TB) and extreme-drug (XDR-
TB), necessitates further administration of second-line (aminoglycosides, polypeptides, 
fluoroquinolones) and third-line (macrolides, linezolid, thioacetazone) drugs, which prolongs 
the treatment and makes it even more arduous to manage (Table 1.2) (Chan and Iseman, 
2008; Gandhi et al., 2010; Koul et al., 2011; Riccardi et al., 2009; Zumla et al., 2012). The 
problem with present therapy is further augmented by incompatibility of anti-TB drugs, 
particularly rifampicin, with many anti-retroviral drugs, thus, making it inconvenient to use 
for HIV-TB co-infection (Aaron et al., 2004; Breen et al., 2006; Centers for Disease Control 
and Prevention (CDC), 2002; McIlleron et al., 2007; Nannelli et al., 2008).   
Overall, there is a pressing need for development of novel therapeutics that are more potent to 
reduce treatment duration, inhibit new targets to be effective against MDR- and XDR-TB, are 
compatible with anti-retroviral treatment, have no antagonistic drug-drug interactions, and 
have fully assessed safety profile (Wallis et al., 2016; Zumla et al., 2014; Zuniga et al., 
2015). 
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FIGURE 1.9    Chemical structures of current first-line drugs used for treating drug-susceptible TB. 
(cont.) 
Drug 
(Chemical class) 
Year of 
Discovery 
Target Mode of Action References 
First-Line Drugs     
Rifampicin 
(Rifamycin) 
1963 rpoB 
(β-subunit of RNA 
polymerase) 
Inhibition of 
transcription 
(Dickinson and 
Mitchison,1981;  
Węgrzyn et al., 
1998) 
Isoniazid 
(Hydrazide) 
1952 inhA  
(Enoyl-[acyl-carrier-
protein] reductase) 
Inhibition of mycolic 
acid biosynthesis 
(Bollela et al., 
2016; Rozwarski 
et al., 1999) 
Ethambutol 
(Ethylenediamine) 
1961 embA, embB, embC 
(indolylacetylinositol 
arabinosyltransferase) 
Inhibition of 
arabinogalactan and 
LAM biosynthesis 
Goude et al., 2009 
Pyrazinamide 
(Amides) 
1954 pncA 
(Pyrazinamidase, 30s 
ribosomal subunit) 
Inhibits translation, 
trans-translation,  and 
affects the pH balance of 
the cytoplasm 
(Scorpio and 
Zhang, 1996; 
Scorpio et al., 
1997; Sun et al., 
1997) 
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Table 1.2    Current drugs for treatment of tuberculosis.  
      LAM: lipoarabinomannan 
 
Drug 
(Chemical class) 
Year of 
Discovery 
Target Mode of Action References 
Second-Line  
Drugs 
    
Streptomycin 
(Aminoglycoside) 
1944 Ribosomal S12 gene 
and 16S rRNA 
components of 30S 
ribosomal subunit 
Inhibition of protein 
synthesis 
(Finken et al., 
1993; Ruusala 
and Kurland, 
1984) 
Kanamycin 
(Aminoglycoside) 
1957 rrs 
(30S ribosomal 
subunit) 
Inhibition of protein 
synthesis 
(Alangaden et al., 
1998; Sirgel et al., 
2012) 
Amikacin 
(Aminoglycoside) 
1972 rrs 
(30S ribosomal 
subunit) 
Inhibition of protein 
synthesis 
(Alangaden et al., 
1998; Sirgel et al., 
2012) 
Ofloxacin 
(Fluoroquinolone) 
1980 gyrA, gyrB 
(DNA gyrase and 
DNA topoisomerase) 
Inhibition of DNA 
supercoiling 
(Chien et al., 
2016) 
Para-amino 
salicylic acid 
(Salicylic acid  
derivatives) 
1948 folP 
(Dihydropteroate 
synthase) 
Inhibition of thymidylate 
synthase, folate 
biosynthesis and 
interference with iron 
uptake 
(Donald and 
Diacon, 2015) 
Ethionamide 
(Thioamide) 
1961 inhA  
(Enoyl-[acyl-carrier-
protein] reductase) 
Inhibition of mycolic 
acid biosynthesis 
(DeBarber et al., 
2000; Wang et al., 
2007) 
Cylcoserine 
(Amino acid  
analogues) 
1955 ddlA 
(D-alanine racemase 
and ligase) 
Inhibition of 
peptidoglycan 
biosynthesis 
(Bruning et al., 
2011) 
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After a long stagnant phase, the drug-development pipeline for TB has been filled with 
several novel, diverse and promising candidates in the last decade. The chemical entities, 
either the repurposed drugs or new compounds, are at different stages of development, as 
depicted in Figure 1.10, with description of drugs in Figure 1.11 and Table 1.3. There is 
also a huge need for drugs that can kill M. tb in latent phase and treat latent TB infection 
(Santivañez-Veliz et al., 2016; Stuurman et al., 2016).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1.10    TB drug development pipeline. 
Global pipeline of chemical entities being discovered or developed for the treatment of TB (as 
in August 2015). GLP: good laboratory practice; DS-TB: drug-susceptible tuberculosis; MDR-
TB: multidrug-resistant tuberculosis; LTBI: latent tuberculosis infection; InhA: enoyl CoA 
reductase; LeuRS: leucyl-tRNA synthetase. Details of ongoing projects can be found on the 
Working Group on New TB Drugs-Pipeline website.  
* along with Optimized Background Regimen  
(Figure adapted from Global tuberculosis report, WHO, 2015). 
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A. Repurposed Drugs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                   (cont.) 
Gatifloxacin Moxifloxacin 
Fluoroquinolones 
Riminophenazines 
Clofazimine 
Rifamycins 
Rifapentine 
Meropenem Clavulanate 
β-lactams 
Oxazolidinones 
AZD-5847 
Linezolid Sutezolid 
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B.  New Chemical Entities 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1.11     Chemical structures of repurposed and novel TB drugs. 
A. Drugs that are used for treatment of other diseases, now being assessed for treating 
tuberculosis. 
(Figure adapted from Zumla et al., 2013). 
B. Novel drugs developed specifically for treating tuberculosis.  
         (Figure adapted from Stehr et al., 2014). 
 
 
Bedaquiline (TMC-207) 
Diaryquinolones 
Delamanid (OPC-67683) 
PA-824 
Nitroimidazoles 
SQ-109 
Benzothiazinones 
BTZ-043 
Ethylenediamines 
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                (cont.) 
Chemical Class Drugs Properties References 
 Fluoroquinolones  Gatifloxacin 
 Moxifloxacin 
 Target DNA gyrase, and 
inhibits DNA synthesis 
(Nuermberger et al., 
2004; Zumla et al., 
2013) 
Riminophenazines  Clofazimine  Leprosy drug repurposed for 
treating TB 
 Targets the outer membrane 
(Dey et al., 2013; 
Verma et al., 2013) 
 Rifamycins  Rifapentine  Targets β-subunit of RNA 
polymerase, and inhibits 
transcription 
 Longer half-line than 
rifampicin 
(Benator et al., 2002; 
Rosenthal et al., 2007; 
Steingart et al., 2011; 
Sterling et al., 2011) 
 β-lactam 
antibiotics 
 Combination 
of Meropenem 
and 
Clavulanate 
  Clavulanate inhibits activity 
of β-lactamase (BlaC) 
 Meropenem inhibits activity 
of DD-carboxy-peptidase  
 Alter PG biosynthesis 
(De Lorenzo et al., 
2013; Hugonnet et al., 
2009; Kumar et al., 
2012) 
 Oxazolidinones  Linezolid 
 Sutezolid 
(PNU-100480) 
 AZD-5847 
 Target the 23S rRNA in the 
50S ribosomal subunit, and  
inhibit protein synthesis   
(Ashtekar et al., 1991; 
Fortún et al., 2005; 
Sotgiu et al., 2012; 
Wallis et al., 2010, 
2011, 2014) 
 Diarylquinolines  Bedaquiline  Targets the c-subunit of ATP 
synthase, and inhibits energy 
production 
 Equally active against 
dormant and active bacilli 
(Andries et al., 2005; 
Cox and Laessig, 
2014; Diacon et al., 
2009; Huitric et al., 
2010; Koul et al., 
2007, 2008; Pym et 
al., 2016) 
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Table 1.3    Repurposed and novel drugs for treatment of tuberculosis. 
DrpE1: decaprenylphosphoryl-beta-D-ribose 2′-epimerase 
AG     : arabinogalactan    
LAM  : lipoarabinomannan  
PG      : peptidoglycan 
 
 
 
Chemical Class Drugs Properties References 
 Benzothiazinones  BTZ-043  Targets the flavoenzyme 
DprE1, and inhibits AG and 
LAM biosynthesis 
 Nanomolar bactericidal 
activity in vitro and ex vivo 
 No antagonism with current 
TB drugs or the candidates 
(Lechartier et al., 
2012; Makarov et al., 
2009; Neres et al., 
2012; Trefzer et al., 
2012) 
 Nitroimidazoles  PA-824  
 Delamanid 
(OPC-67683) 
 Prodrugs, activated by  
F420-deazaflavin-dependent 
nitroreductase (Ddn) 
 PA-824 inhibits mycolic acid 
synthesis and poisons 
respiratory chain 
 Delamanid inhibits mycolic 
acid synthesis and kills 
intracellular bacilli 
(Diacon et al., 2011; 
Gler et al., 2012; 
Manjunatha et al., 
2009, 2006; 
Matsumoto et al., 
2006; Singh et al., 
2008; Skripconoka et 
al., 2013) 
Ethylenediamines  SQ-109  Targets MmpL3, and inhibits 
mycolic acid biosynthesis 
(Heinrich et al., 2015; 
Lee et al., 2003; 
Tahlan et al., 2012) 
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The biology of M. tb that is advantageous for its persistant survival and development of drug-
resistance, coupled with the complexiety of the human disease, imposes several hinderances 
in the drug discovery pathway. Although the anti-TB drug development pipeline has 
witnessed significant progress in the last decade, it is still limited. The treatment of TB is 
based on combinatorial administration of drugs to prevent drug-resistance, and thus, the drugs 
in the pipeline are still being trialled with the existing drugs to shorten or improve the therapy 
time (Zumla et al., 2014). The animal models used for evaluating the lead compounds before 
the clinical trials are not accurate representatives of the pathogenesis of the human disease, 
thereby making it difficult to predict the efficacy of the drug (Young, 2009). Although 
several agents are present in the pipeline, it would take likely another decade to fully develop 
and execute for clinical development. There is a compelling need for new chemical moieties 
as only few drugs in the pipeline are currently in the clinical development phase. 
An alternate approach for the TB therapy is the adjunct immunotherapy or host-directed 
therapy, which directs to strengthen the host immune system, and is being considered as a 
supplement to the drug therapy to shorten the treatment time, prevent re-occurrence of the 
disease, and improve success rate of treating MDR-TB (Uhlin et al., 2012; Wallis et al., 
2016; Zumla et al., 2015a). This is necessary to eliminate the active bacilli or contain the 
infection in latent form, protect the lungs, prevent and repair damage to the organ tissue, and 
avert resistance (Wallis and Hafner, 2015; Zumla et al., 2015b). The adjunct therapy 
includes: immunotherapy with interleukin-2, interferon-ɣ and interleukin-7; cell based 
therapy with mesenchymal stromal cells; drugs used for treatment of other diseases and do 
not target M. tb directly (for instance, metformin that is used for treating diabetes promotes 
macrophage autophagy, anti-cancer drug imatinib affects macrophage function); 
micronutrients like vitamin-D that have immuno-modulatory effects; and therapeutic 
vaccines (Alangari et al., 2011; Rosenzweig et al., 2006; Silva et al., 2016; Uhlin et al., 2012; 
Wallis and Hafner, 2015; Wallis et al., 2016; Zumla et al., 2015b, 2015a).  
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1.7 Objectives and Approaches of the Doctoral Study 
Whilst much improvement has been made in the development of novel therapeutics to treat 
TB, there is a continual need to identify new potential drug targets, and investigate new 
therapeutic agents and treatment regimens, for more effective treatment and management of 
the infection. It is clear from the review of literature above that mycobacterial pathogenesis is 
closely related to its cellular envelope, and that MGLPs and trehalose play a critical role in 
defining the architecture of the cell wall, bacterial growth and survival. Therefore, it is 
imperative to explore these pathways, which offer a multitude of novel and essential enzymes 
that can be targeted to combat the M. tuberculosis infection.  
Design of therapeutics for treatment of a disease relies on understanding the basic molecular 
mechanisms underpinning it. The primary objective of this doctoral study is to gain 
knowledge about the target proteins by their structural and functional characterisation. The 
information gained creates a foundation and may be used to carry out an early-stage drug 
discovery, to identify chemical fragments that bind to proteins and modulate its function, and 
that could be developed into new lead inhibitors for novel anti-TB treatment (Figure 1.12). 
The targets investigated in this study are: Rv3030, Rv3037c and Rv3038c-SAM dependent 
methyltransferases involved in MGLP biogenesis; and OtsA involved in trehalose 
biosynthesis. The rationale behind selection of these targets was to unearth new targets that 
are currently not being investigated for structural and drug discovery studies, and thus, offer a 
novel dimension in targeting the disease mechanistic. Essentiallity of these enzymes, either 
for growth or for survival of the bacilli, and lack of human orthologues, make them attractive 
targets to study. A pre-requisite for structure determination and drug-discovery studies is 
production of tractable amounts of protein, purified to homogeneity. Detailed experimental 
analyses of these targets revealed feasibility of only two targets, Rv3030 and OtsA, which 
will be described in detail in the following chapters. Initial experimental data on the 
remaining targets, Rv3037c and Rv3038c, is presented in the annex. 
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FIGURE 1.12    Objectives and approaches of the doctoral study. 
Organisation of Thesis 
This thesis describes in detail, the work done on the targets OtsA and Rv3030.  
Each corresponding chapter on these targets consists of a summary, an introduction, the 
methodology, results and discussion.  
 Chapters 2 details the work on Target-1: OtsA, trehalose 6-phosphate synthase 
involved in trehalose biosynthesis.  
 Chapters 3 and 4, documents work on Target-2: Rv3030, methyltransferase involved 
in MGLP biogenesis.  
 
Chapter 5 presents final concluding remarks and future perspectives. 
Additional supporting information is present in Appendices I- IV. 
Preliminary experimental data on targets Rv3037c and Rv3038c is presented in Appendix-
V.  
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2.1 Summary 
This chapter focuses on studies of mycobacterial trehalose-6-phosphate synthase, through the 
functional and structural characterisation of the enzyme, which form the basis for a possible 
structure-guided drug discovery campaign for antibacterials targeting the Mycobacterium 
tuberculosis enzyme. As the Mycobacterium tuberculosis enzyme could not be expressed in 
the soluble fraction, other mycobacterial orthologues were investigated. The orthologue from 
Mycobacterium thermoresistibile was expressed in E. coli, and the recombinant enzyme was 
successfully purified and crystallised. The best crystals diffracted to 2.18 Å, and crystallised 
in cubic symmetry. The three-dimensional structures in both apo and ligand-bound states 
were determined. The previously reported structures of OtsA from E. coli are of protein-
ligand complexes (Gibson et al., 2002a, 2004). This work describes the first mycobacterial 
OtsA structure. The apo-structure of M. thermoresistibile OtsA was also the first structure of 
trehalose-6-phophate synthase in the apo-form, although subsequently the apo-enzyme 
structure from B. xenovorans also has been determined (February, 2016). Biochemical 
characterisation showed that the enzyme was able to utilise several glucose-donor substrates, 
like other mycobacterial OtsAs, but displayed highest preference for ADP-glucose, and was 
strictly dependent on glucose-6-phosphate as the acceptor substrate. Moreover, the activity of 
the enzyme was shown to be regulated by feedback inhibition. The donor-substrate bound 
structures of protein also offer a plausible explaination for substrate preference.  
This chapter also focuses on early-stage drug discovery against the mycobacterial OtsA, 
using M. thermoresistibile OtsA as the representative system. Fragment-based approaches 
were used for identification and validation of hits. Preliminary screening of a small-scale 
fragment library by thermal shift assay led to identification of several fragments that bind to 
the enzyme. The top hits among these, were further validated by inhibition assay. However, it 
was not possible to obtain fragment-bound structures with any of the fragments that were 
tested. 
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2.2 Introduction 
Trehalose-6-phosphate synthase (OtsA) is a glycosyltransferase that catalyses the transfer of 
glucose from a nucleotide-glucose donor to an α-anomer of glucose-6-phosphate, the 
acceptor substrate, to form trehalose-6-phosphate. Glycosyltransferases are enzymes that 
catalyse formation of glycosidic bonds using either a nucleotide- or a lipid-dependent sugar 
donor (Varki et al., 2009). During the anomeric reaction, the net stereochemistry of the sugar-
donor substrate can be retained or inverted, and as a result, the mode of catalysis is different 
(Lairson et al., 2008). The inverting glycosyltransferases employ a straightforward single 
substitution SN2 mechanism with an oxocarbenium-ion transition state (Lairson et al., 2008). 
On the other hand, the catalytic mechanism by retaining glycosyltransferases is ambiguous, 
and probably involves a Koshland double-displacement mechanism, as in glycoside 
hydrolases, or an SNi ‘internal return’ process (Lairson et al., 2008). The reaction catalysed 
by OtsA is proposed to proceed through same-face SNi process, with the net retention of the 
stereochemistry of the sugar-donor substrate. In this reaction, the nucleotide-phosphate group 
of the donor leaves and the nucleophile, glucose-6-phosphate, attacks from the same face, 
while the other face of the glucose-donor substrate is guarded by the enzyme. However, it 
remains unclear whether the reaction occurs in a concerted manner, or in a stepwise fashion 
involving formation of a metastable intermediate (Errey et al., 2010; Lee et al., 2011).  
Two structural classes have been identified for nucleotide-dependent enzymes, GT-A and     
GT-B, both of which have the classic Rossmann fold. The enzymes with GT-A fold have two 
adjoining Rossmann domains, whereas the GT-B topology has two flexibly-linked Rossmann 
domains facing each other (Bourne and Henrissat, 2001; Lairson et al., 2008). There is no 
association between the catalytic mechanism and the overall fold, as retaining and inverting 
glycosyltransferases belong to both structural classes (Coutinho et al., 2003). The structures 
of E. coli OtsA revealed that it is the first retaining glycosyltransferase whose structure 
possesses the GT-B topology (Gibson et al., 2002a, 2004). Distinct folds are now evident for 
the soluble domains of the lipid-dependent glycosyltransferases. For example, the lipid-
dependent glycosyltransferase (GT51) synthesising peptidoglycan has a bacteriophage 
lysozyme-like fold, instead of the Rossmann fold (Lovering et al., 2007; Yuan et al., 2007).  
The trehalose-6-phosphate synthase reaction was first demonstrated in the cell-free extracts 
of S. cerevisiae (Cabib and Leloir, 1958), and has been observed in an assorted set of 
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organisms: mycobacteria (Pan et al., 2002, 2004), E. coli (Gibson et al., 2002b),                    
D. discoideum (Roth and Sussman, 1966), silk moths (Murphy and Wyatt, 1965), locusts 
(Candy and Kilby, 1959) and Arabidopsis thaliana (Vogel et al., 2001). Mycobacteria 
produce trehalose through multiple pathways, and trehalose-conjugates play a vital role in 
defining the architecture of the cell wall and the virulence of the bacilli. The prime OtsAB 
pathway for trehalose biosynthesis utilizes trehalose-6-phosphate synthase (Tps/OtsA) and 
trehalose-6-phosphate phosphatase (Tpp/OtsB2) enzymes. In M. tb, the otsA (Rv3490) gene 
encodes for trehalose-6-phosphate synthase, which catalyses the first step of OtsA-OtsB2 
pathway, producing trehalose-6-phosphate from NDP-glucose and glucose-6-phosphate.  
Targeting trehalose biosynthetic pathway is useful for development of novel anti-TB 
therapies. This is evident from the fact that trehalose is important in physiology and virulence 
of M. tb, and is absent in humans. Disruption of trehalose-6-phosphate synthase leads to 
growth impairment or lethality in several organisms, and thus, it is a potent drug target. For 
example, in D. melanogaster, TPS is an insecticidal target because insertion in tps1 gene was 
lethal during early larval stage (Kern et al., 2012); mutants of TPS in C. neoformans and        
C. gattii were attenuated in virulence and thus, it is a fungicidal target (Petzold et al., 2006). 
In M. tb, OtsA mutants show severe impaired growth and a substantial decrease in virulence 
in mouse models (Murphy et al., 2005). This makes OtsA an attractive target to develop 
chemical moieties that can aid in fighting against TB. 
2.3 Basic Principles of Protein Crystallisation and Crystallography, 
and Other Techniques Deployed 
 
2.3.1 Protein Crystallisation and Data Collection 
Protein crystallisation is based on the principle that protein solution of high concentration (in 
mg ml-1) is mixed with precipitant, which reduces protein solubility. When solution becomes 
supersaturated and thermodynamically metastable, spontaneous nucleation occurs and 
crystals may start to form (Figure 2.1). Several crystallisation trials are done with different 
reagents, varying reagent concentrations, pH and temperature, to determine conditions that 
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will yield diffracting crystals. There are several crystallisation techniques, but the most 
common method is vapour diffusion. 
 
 
 
 
 
FIGURE 2.1    Phase diagram of protein crystallisation.  
Drops remain clear when protein and precipitant solution are not mixed in appropriate 
concentrations and are unable to cross the solubility line, or when spontaneous nucleation does 
not occur even though drops are set with protein and precipitant in sufficiently high 
concentrations. If the concentrations are too high, the drops immediately precipitate. When 
drops reach the spontaneous nucleation region, crystal nuclei are formed and crystals grow 
further in the metastable growth region, till they are in equilibrium with the protein solution. 
This is when the crystals reach their final size and the growth terminates. (Figure adapted from 
Rupp, 2009). 
In the vapour diffusion method, protein and crystallisation cocktail are mixed in the desired 
ratio, and then, due to the concentration gradient, water evaporates from the crystallisation 
drop into the reservoir of precipitant. This makes the protein-precipitant solution more 
concentrated, which may lead to supersaturation, nucleation and crystallisation. Vapour 
diffusion is implemented either as hanging- or sitting-drop technique (Figure 2.2). In the 
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hanging-drop method, a protein drop is mixed with crystallisation cocktail in the reservoir 
and placed on siliconized cover slide. The rim of the reservoir is greased; the flipped-over 
cover slide is placed on the well and sealed. On the other hand, in the sitting-drop vapour 
drop technique, the drop sits on a shelf or post. Sitting-drop method can be used with robotic 
setup, whereas hanging- drop method is used for manual setup for small-scale optimisations. 
 
 
 
 
 
FIGURE 2.2    Diagrammatic representation of vapour-diffusion crystallisation techniques.   
                         (Figure adapted from Rupp, 2009). 
It is essential to obtain complex structure of target protein with cofactors, substrates or 
therapeutic lead compounds to understand the dynamics of interactions at atomic level, which 
take place during catalytic mechanism and protein-drug binding. The two chief routes to 
obtain complexes are soaking and co-crystallisation. Soaking is the technique in which the 
ligand is incorporated in the already grown crystal by adding the substance in the mother 
liquor. Co-crystallisation, on the other hand, involves incubation of protein solution with the 
ligand, and then crystallising the mixture together.  
When crystals are grown to a suitable size, they are harvested from the drop along with the 
mother liquor. The harvested crystal is cryoprotected, before flash freezing in liquid N2 and 
mounting it on a diffractometer for data collection. Cryoprotection plays a critical role in 
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protecting the crystals from radiation damage, and also prevents crystallisation of mother 
liquor during rapid cooling, which otherwise can be detrimental to the diffraction quality of 
the crystal. Routinely used cryoprotectants are glycerol, MPD, PEGs, ethylene glycol and 
sucrose. Screening of cryoprotectants is generally required to ensure their suitability for a 
specific protein. The crystals are mounted on the goniometer for X-ray data collection. 
Data collection is the final experimental step before in silico structure determination and 
analysis. Most commonly, the crystal exposed to the X-ray beam is rotated about a single axis 
in small successive increments, and the fraction image is recorded at each rotation increment. 
The intensity of spots of individual images are integrated and actual reflection intensities are 
determined. The quality of crystal is determined by the initial diffraction image, which 
subsequently dictates the remaining strategic data collection process.  
Several texts and reviews can be referred for the detailed understanding of protein 
crystallisation and developments in the field (Benvenuti and Mangani, 2007; Bergfors, 2009; 
Deller et al., 2016; Giegé, 2013; Luft et al., 2007; Rhodes, 2006; Rupp, 2009; Sugahara, 
2014). 
2.3.2 Protein Crystallography 
This section summarises the basic theory of protein crystallography and techniques used in 
this study. Texts providing further detail and the latest developments include the classic text 
Protein Crystallography (Blundell and Johnson, 1976), and more recent monographs 
(Garman, 2014; Nannenga and Gonen, 2014; Ogata et al., 2015; Rhodes, 2006; Rupp, 2009). 
2.3.2.1 Geometric Assembly of Protein Crystals and Space Groups  
 
Protein crystals, which are periodic assemblies of large and flexible macromolecules, are 
necessary for producing X-ray diffraction. A unit cell, the basic repeating building block of a 
crystal, is a combination of unit lattice and molecular motifs. A unit cell is a mathematical 
construct defined by the lengths of three edges: a, b and c, and the angles between them: α, β 
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and ɣ. The asymmetric unit is the smallest part of the unit cell containing the motif that can 
generate the complete unit cell when space group symmetry operations are applied. A crystal 
lattice is the periodic construct, generated by finite repeats of unit cells. It is an imaginary 
three-dimensional grid, consisting of an array of points so arranged that their environments 
are identical.   
There are different types of unit cells and are generally divided into two categories. The first 
category is the primitive unit cell, in which the lattice points are present only at the vertices of 
the unit cell and they do not have any additional internal symmetry. There are six types of 
primitive lattices. The second category is the centered unit cell, which contains additional 
lattice points to those at vertices of the cell. There are three types of centerings: face, body or 
base, which lead to eight centered lattices. These are collectively known as 14 Bravais 
lattices, and belong to one of the seven crystal systems: triclinic, monoclinic, orthorhombic, 
rhombohedral, hexagonal, tetragonal and cubic. A symmetry operation is the operation 
applied to the asymmetric unit to generate its identical copies. A space group provides 
complete description about the symmetry of the unit cell and its contents. It reveals 
information about the lattice type and the symmetry operations used. In total, there are 230 
space groups, of which only 65 are possible for chiral proteins.  
2.3.2.2 Reciprocal Lattice and Diffraction Basics 
 
X-rays are electromagnetic radiations of high energy, which are scattered by interacting with 
the electrons in the molecules. X-rays with energy range of 5000-15000 eV are used for 
diffraction experiments. The diffraction pattern of real space molecules in a crystal is 
represented in a reciprocal space by Fourier transformation. The reciprocal lattice is a 
mathematical construct that describes diffraction events. The position of a reflection in 
reciprocal space is indicated by h, k and l, known as Miller indices. The diffraction of X-rays 
by a crystal can be quantified by Bragg’s Law, which considers the diffracted X-rays as 
reflections from lattice planes.  
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The equation is defined as: 
                                                                                
                                               where,     λ - wavelength  
                                                            dhkl - distance between two lattice planes 
       θ - scattering angle of X-ray beam 
       n - integer 
The structure factor, Fhkl, determines the scattering of X-rays from a crystal in the direction 
hkl, and is a sum of all partial waves emitting from each and every atom of the unit cell. The 
intensity of scattered electromagnetic waves, Ihkl, is proportional to the square of the 
amplitude of the structure factor, and measured as diffraction spots. Fourier transformation of 
experimentally measured structure factor amplitudes along with phases generated from the 
phasing experiments produces electron density of the molecules. This electron density is 
represented in the form of a two-dimensional contour map or a three-dimensional grid, 
known as an electron density map. However, it is not possible to determine the phase of the 
diffracted X-ray directly by measuring its intensity. This means that during the measurement 
process, the phase information is lost, and this leads to the ‘phase problem’. The information 
regarding the phases needs to be separately supplemented, in order to determine the structure 
of the protein.  
2.3.2.3 Experimental Phasing by Molecular Replacement 
 
There are several methods for solving the phase problem. These involve preparation of heavy 
atom derivatives, Se-Met labelling of protein or use of sulphur single-wavelength anomalous 
diffraction and collection of otherwise redundant data (Friedel pairs). However, another 
powerful, important and simple method to obtain initial phases is molecular replacement. 
This technique calculates phases from a known similar structure, generally having sequence 
identity of ~30% of more with the protein whose structure needs to be determined. The 
known protein is called the phasing model or the probe. In this method, the orientation of the 
probe in the unknown structure is determined by the rotation function, and the location of 
properly oriented probe in the unit cell is found by the translation function. Both the functions 
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are Patterson or maximum likelihood based. The phasing model is rotated and translated in 
the unit cell of the sought-after protein structure, until a best fit is obtained between the 
calculated diffraction data from the model and the observed data from the target structure.  
2.3.2.4 Model Building and Refinement 
 
After obtaining an initial model of the protein structure, it is fitted into the experimentally 
observed electron density, either manually or through automated programs. Model 
improvement and refinement is a cyclic process, and with every round, the phases and the 
electron density map improve, so allowing further building of the model and corrections. The 
model rebuilding-refinement cycles are continued until a good fit between observed and 
calculated structure factor amplitudes is obtained, which can be mathematically quantified by 
the residual index (R-value or R-factor). The lower the R-value, the better is the fit between 
the model and the experimental data.  
                                                                        
                                 where,       Rf  - residual index 
    F(i)obs - observed structure factor amplitude 
    F(i)cal  - calculated structure factor amplitude 
2.3.2.5 Structure Validation and Analysis 
 
The structural model generated after sufficient rounds of rebuilding and refinement, is 
subjected to quality checks to determine its plausibility. The Ramachandran plot, which 
indicates how well the structure conforms to the stereo-chemical constraints, is very useful 
for validating the structure. A good model has the majority of residues tightly clustered in the 
favoured regions with minimum outliers, whereas a poor model has many outliers and no 
clustering. The structure is also checked to minimise errors concerning the bond angles and 
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lengths, chirality, dihedral angles, non-bonded atoms, planarity of aromatic rings and crystal 
packing. 
2.3.3 Circular Dichoism 
Circular dichroism (CD) is a method that is used to analyse the secondary structure of a 
protein, by utilizing differential absorption of left- and right-handed circularly polarised light 
produced by the peptide bonds in the polypeptide backbone. Different secondary structure 
elements have characteristic spectra in the far UV regions (Whitmore and Wallace, 2004, 
2008). 
2.3.4 Biochemical Characterisation using Coupled-Enzyme Colorimetric Assay 
Production of trehalose-6-phosphate from NDP-glucose and glucose-6-phosphate, followed 
by the release of NDP, is estimated by measuring continuous oxidation of NADH by a 
coupled-enzyme colorimetric assay. This assay involves detection and quantification of the 
NDP released, when glucose is transferred from NDP–glucose to glucose-6-phosphate, by 
coupled conversion of phosphoenolpyruvate to pyruvate by pyruvate kinase, and of pyruvate 
to lactate by lactate dehydrogenase. In the final reaction, the oxidation of NADH is measured 
spectrophotometrically at 340 nm. 
2.3.5 Isothermal titration calorimetry 
Isothermal titration calorimetry (ITC) is a quantitative technique that can measure the 
thermodynamic properties of protein-ligand interaction. It determines the heat evolved on 
binding of the ligand with its partner and directly measures the binding equilibrium. The 
energetics of binding complement the structural and functional studies, and provide a 
complete detail of the interaction forces (Freyer and Lewis, 2008; Milev, 2013; Pierce et al., 
1999). 
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2.3.6 Thermal Shift Assay 
The stability of protein is influenced by several factors, one of them being ligands that bind to 
them. The thermal stability can either increase or decrease upon ligand binding, and the 
change is monitored by a fluorescent dye (e.g. Sypro Orange). When the protein unfolds at a 
particular temperature, the dye binds to the exposed hydrophobic regions and the signal 
produced is quantified. The change in the melting temperature of the protein in the presence 
and absence of ligands or fragments is used to identify binding (Kranz and Schalk-Hihi, 
2011; Niesen et al., 2007). 
2.3.7 Fragment-Based Drug-Discovery  
Fragment based drug-discovery (FBDD) is a powerful method which relies on structural 
biology and synthetic chemistry (Davies and Hyvönen, 2012). FBDD approach involves 
screening and validation of small molecules, of molecular weight < 300 Da, against the target 
protein, using an assortment of biophysical and structural techniques (Figure 2.3). The hits 
obtained after screening are usually weakly binding to the target in vitro and have low 
affinity. These hits are then elaborated into lead compounds using fragment growing, linking 
or merging techniques to improve their potency (Scott et al., 2012). Fragment elaboration is 
an iterative process, directed by the structure of the target protein with fragments, as well as 
quantitative analysis of binding and biochemical assay to measure efficacy (Doak et al., 
2016; Scott et al., 2012). The first FDA-approved drug developed by fragment based 
approach was Zelboraf (PLX4032) for treatment of late-stage melanoma (Bollag et al., 2010). 
FBDD has the following advantages: 
a. a small fragment library allows exploration of a large region of chemical space. 
b. the hit-rate of screening a fragment library is high,    
c. optimised hits from fragment-screening have high atom-binding efficiency. 
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FIGURE 2.3    Typical process of a fragment-based drug-discovery approach.  
(Figure adapted from Scott et al., 2012).  
2.4 Methodology 
 
2.4.1 Bioinformatic Analysis of the Primary Sequence, Sequence Alignment and 
Prediction of Secondary Structures  
The amino-acid sequences of OtsA (Rv3490) from M. tuberculosis and of its orthologue in     
M. smegmatis (MSMEG_5892) were obtained from the TubercuList database (Lew et al., 
2011) and the SmegmaList database (Kapopoulou et al., 2011) respectively, by searching 
with the gene name. Orthologous proteins in M. thermoresistibile, E. coli, B. xenovorans,                     
C. albicans, N. farcinica, S. cerevisiae, L. aerocolonigenes, S. hygroscopicus,                         
D. melanogaster, C. felis, D. discoideum and A. thaliana were identified by performing a 
protein-BLAST (blastp) (Altschul et al., 1990) search with M. tuberculosis protein sequence. 
Amino-acid sequences were obtained from the National Centre for Biotechnology 
Information (NCBI) database, and were aligned using Clustal Omega (Goujon et al., 2010; 
McWilliam et al., 2013; Sievers et al., 2014). The alignment was analysed and edited using 
Jalview (Waterhouse et al., 2009). Physicochemical properties of proteins were calculated 
using ProtParam (Gasteiger, 2003). Secondary structures and disordered regions of the 
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protein were predicted using PSIpred and DisoPred, respectively (Jones, 1999; Ward et al., 
2004). 
2.4.2 Identification of Structural Orthologues and Surface Conservation Analysis 
 
A distance matrix search for structural homologues was performed using the DALI server 
(http://ekhidna.biocenter.helsinki.fi/dali_server/start) (Holm and Rosenstrom, 2010) to 
identify similar structures in the PDB. The conserved surface regions were identified using 
the ConSurf server (http://consurf.tau.ac.il/2016/) (Ashkenazy et al., 2010; Landau et al., 
2005). 
2.4.3 DNA, Bacterial Strains and Cloning of Mycobacterial otsA Genes 
 
Genomic DNA from M. tuberculosis H37Rv was obtained from ATCC (ATCC25618D-2), 
and M. thermoresistibile (DSMZ 44167) genomic DNA was obtained from the Deutsche 
Sammlung von Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany).             
E. coli DH5α (Invitrogen) and BL21 (DE3) (New England Biolabs) strains were used for 
cloning and protein expression, respectively. 
Dr. Vitor Mendes provided the glycerol BL21 cell stock for the expression clone of                       
M. thermoresistibile OtsA pET-28a SUMO. The gene was cloned into BamHI and HindIII 
restriction sites in the pET-28a SUMO vector that has a cleavable, N-terminus SUMO tag 
and kanamycin resistance marker (obtained from Dr. Clifton Barry III’s laboratory, National 
Institute of Health, Bethesda, USA). 
otsA gene from M. tuberculosis genomic DNA was PCR amplified with the following primer 
pair: 
Forward primer: 5’-ATACCATGGCTCCCTCGGGAGGCCAG-3’  
(containing NcoI restriction site- underlined) 
Reverse primer: 5’- ATTCTCGAGTTAGCCTTGGCCCCTCGGGTG-3’  
(containing XhoI restriction site-underlined) 
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PCR was done with the KOD Hot Start DNA polymerase (Novagen), and the reaction was set 
up according to the manufacturer’s protocol. DNA was denatured at 95°C for 2 min, followed 
by 30 cycles each comprising a 20 sec denaturation step at 95°C, 15 sec annealing step at 
60°C, and 30 sec extension step at 70°C. A final extension step was done at 70°C for 5 min. 
The amplicon generated was cloned in NcoI and XhoI restriction sites of pHAT-4 vector 
(with a cleavble, N-terminus His6 tag and ampicillin resistance marker) (Novagen). The gene 
and vector were digested with NcoI and XhoI restriction enzymes (ThermoScientific) and 
ligated using T4-DNA ligase (New England Biolabs) at room temperature for 10 min. The 
ligation products were transformed in E. coli DH5α competent cells, plated on LB agar-
ampicillin plates, and incubated overnight at 37°C.  Single colonies were randomly picked 
and inoculated in LB media (Melford) with 100 μg/ml ampicillin (Sigma), and grown 
overnight at 37°C, with constant shaking at 220 rpm. Plasmids were isolated and purified 
according to the manufacturer’s protocol (ThermoScientific GeneJet Plasmid Miniprep Kit). 
The integrity of clones was confirmed by sequencing (DNA Sequencing Facility, Department 
of Biochemistry, University of Cambridge, UK), and plasmids were transformed into E. coli 
BL21 (DE3) strain. 
2.4.4 Expression and Purification of Mycobacterial OtsA Proteins 
2.4.4.1 Protein Expression Trial of M. tuberculosis OtsA 
Transformed E. coli BL21 (DE3) cells of M. tb OtsA-His6 were inoculated in 5 ml LB media 
containing 100 μg/ml ampicillin, and grown overnight with constant shaking (220 rpm) at 
37°C. A small scale-up of the culture was done by inoculating 10 ml of fresh LB medium 
containing ampicillin, with 300 μl of the overnight culture. Cells were grown at 37°C till 
OD600 reached 0.8, then cooled to 20°C, induced with 0.5 mM IPTG (Melford) for protein 
expression and grown overnight (14-16 hours) at 20°C with constant shaking. The cells were 
harvested by centrifuging at 6200 x g, 4°C for 10 min. The pellet obtained was suspended in 
1 ml resuspension buffer (50 mM Tris-HCl pH 7.5, 20 mM Imidazole, 500 mM NaCl and 
protease inhibitor cocktail (Roche)) and 10 μg/mL DNase (Sigma) was added. Cells were 
lysed with BugBuster protein extraction reagent (Novagen), at final concentration of 1 X, by 
incubating at room temperature for 10 min, and the lysate was centrifuged (20,000 x g, 4°C 
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for 10 min). The resulting supernatant was bound to the Ni-NTA agarose resin (Qiagen) 
packed in a 1 ml column (prepared in-house), with the help of a bench top centrifuge at 300 x 
g. The resin was washed twice with 500 μl wash buffer (50 mM Tris-HCl pH 7.5, 20 mM 
Imidazole, 500 mM NaCl) by centrifuging the column at 300 x g for 1 minute, and protein 
was eluted in 250 μl elution buffer (50 mM Tris-HCl pH 7.5, 500 mM Imidazole, 500 mM 
NaCl) by centrifuging the column at 950 x g for 1 min. The protein was analysed with SDS-
PAGE. The protein’s identity was confirmed by MALDI fingerprinting (PNAC facility, 
Department of Biochemistry, University of Cambridge, UK). 
2.4.4.2 Expression and Purification of Full-Length Recombinant M. thermoresistibile 
OtsA 
The recombinant orthologous protein of OtsA in M. thermoresistibile with a cleavable, N-
terminus His6-SUMO tag was purified.  
Culture growth and expression: A loop of frozen BL21 cells of the expression clone was 
plated on an LB-agar-kanamycin plate and incubated overnight at 37°C. All the cells were 
collected from the plate and inoculated in 250 ml LB media with 30 μg/ml kanamycin. The 
culture was grown overnight at 37°C, with constant shaking at 220 rpm. The culture was 
scaled up to 6 litres by adding 30 ml of the overnight culture to each 1-litre of fresh LB media 
containing 30 μg/ml kanamycin. Cells were grown at 37°C till OD600 reached 0.75, cooled 
down to 20°C, induced with 0.5 mM IPTG for protein expression, and incubated overnight 
(14-16 hours) at 20°C with constant shaking. 
Cell harvesting and lysis: Cells were harvested by centrifugation (4200 x g, 30 min, 4°C) 
during the late exponential growth phase and the pellet was re-suspended in buffer (20 mM 
Tris-HCl pH 7.5, 20 mM Imidazole, 500 mM NaCl, cocktail of protease inhibitor), and         
10 μg/mL DNase-I and 5 mM MgCl2 were added to the cell suspension. Cells were lysed by 
sonication, followed by centrifugation (30,000 x g, 40 min, 4°C) to remove the cell debris, 
and supernatant was collected (step-1). The pellet was suspended again in buffer (20 mM 
Tris-HCl pH 7.5, 20 mM Imidazole, 500 mM NaCl, 0.2% Triton X-100) and incubated on ice 
for 45 min, to extract any protein from the cellular fraction. The resuspension was centrifuged 
again (30,000 x g, 40 min, 4°C) to remove cell debris, and the supernatant was collected 
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(step-2). Supernatant from both step-1 and step-2 was pooled and filtered using 0.2 μm 
syringe filter.  
Affinity purification: A pre-packed sepharose column (HiTrap IMAC FF, 5 ml, GE 
Healthcare) was charged with 0.1 M NiSO4, according to the manufacturer’s protocol, and 
equilibrated with purification buffers. Supernatant was bound to the column with the help of 
a peristaltic pump at room temperature. The column was washed for 30 CV with wash buffer 
(20 mM Tris-HCl pH 7.5, 20 mM Imidazole, 500 mM NaCl), and 30 ml protein was eluted 
using elution buffer (20 mM Tris-HCl pH 7.5, 500 mM Imidazole, 500 mM NaCl). The 
purity of the protein was determined by SDS-PAGE. Protein concentration was measured at 
280 nm with NanoDrop spectrophotometer. 
Cleavage of the tag and dialysis:  The SUMO tag was subsequently cleaved with Ulp1 
protease, after affinity purification. Ulp1 protease (see appendix-II for purification protocol 
of Ulp1) was added to the eluted protein at a ratio of 1 mg Ulp1 protease to 200 mg protein to 
cleave the His6-SUMO tag. The protein-protease mixture was then dialysed in 20 mM Tris-
HCl pH 7.5, 20 mM Imidazole and 500 mM NaCl buffer, using a 10 kDa MWCO dialysis 
membrane, and incubated overnight at 4°C.  
Gel filtration: The overnight-digested protein was concentrated by centrifuging (4000 x g, 30 
min, 4°C) in 10 kDa MWCO concentrators. The protein was loaded onto a Superdex-200 
column (HiLoad 16/600 Superdex 200 pg, GE Healthcare), pre-equilibrated with 500 mM 
NaCl and 20 mM Tris-HCl pH 7.5. Purification was carried out at room temperature. The 
protein was eluted in 1 ml fractions and the purity of fractions was determined by SDS-
PAGE. The purest fractions were pooled and concentrated by centrifuging (4000 x g, 30 min, 
4°C) in 10 kDa MWCO concentrators. The concentration of NaCl was reduced from 500 mM 
to 350 mM with 20 mM Tris-HCl pH 7.5 buffer. The purity of the protein was assessed with 
SDS-PAGE and the final concentration was determined spectrophotometrically. The protein’s 
identity was confirmed by MALDI fingerprinting (PNAC facility, Department of 
Biochemistry, University of Cambridge, UK). 
 
Chapter-2     Functional and Structural Studies, and Probing the Druggability of M. thermoresistibile   
                     OtsA  
58 
 
2.4.5 Circular Dichroism  
0.5 mg/ml M. thermoresistibile OtsA, dialysed in a buffer of 20 mM sodium phosphate pH 
7.5 and 330 mM NaF, was placed in quartz cuvette with 1 mm path-length. The circular 
dichroism (CD) spectra were recorded on Aviv model 410 spectropolarimeter. A wavelength 
spectrum was recorded from 260 nm to 190 nm, at 1 nm intervals and 3 sec averaging time. A 
control run was performed with the buffer. For the protein sample, the raw data from the 
three measurements were averaged, corrected for the buffer signal, and smoothed. A 
temperature melt spectrum was recorded at a constant wavelength of 222 nm from 25˚C to 
95˚C, at 1˚C interval and 3 sec averaging time. The CD signal is reported in theta machine 
units in millidegrees.  
2.4.6 Biochemical Characterisation of Recombinant M. thermoresistibile OtsA 
The reactions were done at 37 ºC and a typical 100 µl enzyme reaction contained 20 mM 
Tris-HCl pH 7.5, 60 mM NaCl, 0.3 mM NADH, 2.5 mM phosphoenolpyruvate, 0.7 units of 
pyruvate kinase/lactate dehydrogenase, 2.5 µM OtsA and varying concentrations of glucose-
6-phosphate and NDP-glucose to determine the kinetic parameters. All reagents used were 
obtained from Sigma-Aldrich. 
The substrate specificity of the enzyme was examined using ADP-glucose, GDP-glucose and 
UDP-glucose as glucose donors (at a fixed concentration of 2.5 mM); and glucose-6-
phosphate, glucose-1-phosphate and fructose-6-phosphate as glucose acceptors (at fixed 
concentration of 5 mM). The effects of cations and pH were determined by the above 
mentioned coupled-enzyme colorimetric assay, with 100 µl mix containing appropriate 
divalent cation and buffer.  The effects of cations were tested by incubating reaction mixtures 
with chloride salts of Mg2+, Mn2+, Zn2+, Ca2+, Fe2+ and Co2+ (5 mM and 10mM). The pH 
profile was determined in 20 mM acetate buffer at pH 5.0- 5.5, 20 mM MES buffer at pH 6.0-
6.5, 20 mM Tris-HCl buffer at pH 7.0-9.0, and 20 mM CAPS buffer at pH 9.5-10.0. A 
temperature-dependent profile was not studied, as M. thermoresistibile is a thermophile and 
its proteins are too thermostable (Edwards et al., 2012). The effects of trehalose and 
trehalose-6-phosphate as feedback inhibitors of M. thermoresistibile OtsA were tested in the 
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conditions mentioned above with fixed concentrations of glucose-6-phosphate (5 mM) and 
ADP-glucose (2.5 mM).  
All the reactions were done in triplicate in a UV-1800 Shimadzu UV spectrophotometer and 
data were analysed with Prism 5 (GraphPad Software) and Microsoft Excel. 
2.4.7 Crystallisation of M. thermoresistibile OtsA and Data Collection 
 
 
2.4.7.1 Crystallisation of Apo M. thermoresistibile OtsA protein and Data Collection 
Initial crystallisation screening was performed for purified M. thermoresistibile OtsA protein 
using the sitting-drop vapour-diffusion method at 18˚C. The screens used were: classics 
(Qiagen), cryo (Rigaku), PEGs-I, JCSG+ (Molecular Dimensions) and Wizard I & II 
(Rigaku). The protein (0.3 µl) at a concentration of 10 mg/ml was mixed with the well 
solution in two different protein: precipitant ratios of 1:1 and 1:2 using the Phoenix robot (Art 
Robbins Instruments). Initial crystals were obtained in several conditions, of which, a 
condition from the PEGs-I crystallisation screen was optimised further. This condition is 
composed of 40 % PEG-200 and 0.1 M Tris-HCl pH 8.5, with 1:1 protein: precipitant ratio. It 
was further optimised using a 24-well Linbro plate and hanging-drop vapour-diffusion 
method. The grid was prepared manually with different concentrations of PEG-200 (30 %,  
35 %, 40 %, 45 %, 50 %, and 55 %) and 0.1 M Tris-HCl at varying pH (7.5, 8.0, 8.5, and 
9.0). The condition obtained from this grid (35 % PEG-200, 0.1 M Tris-HCl pH 9.0, and 
protein: precipitant =1:1) was optimised using an additive screen HT (Hampton Research), 
and LDAO was found to be the best additive. The additive containing condition was further 
optimised, and the final optimised condition contained 40 % PEG-200, 0.3 % LDAO, with 
2:1 protein: precipitant ratio. The crystal condition contained PEG-200, at a high enough 
concentration for it to act as a cryoprotectant. Thus, the crystals were directly flash frozen in 
liquid nitrogen for data collection. An X-ray diffraction dataset of the crystal was collected at 
I02 beamline of Diamond Light Source synchrotron (DLS, Oxford, UK).  
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2.4.7.2 Soaking and Co-Crystallisation of M. thermoresistibile OtsA with Substrates 
and Products 
The ligand-bound structures of M. thermoresistibile OtsA were obtained by soaking the apo-
crystals with ligands (ADP-glucose, UDP-glucose, GDP-glucose, trehalose and trehalose-6-
phosphate) in the optimised crystal condition using the hanging-drop vapour-diffusion 
method. Crystals were then transferred to a 2 μl drop of reservoir solution containing 10 mM 
of ligand and incubated for 18-20 hours. The crystals were directly flash frozen in liquid 
nitrogen for data collection. 
The ternary complex of M. thermoresistibile OtsA with ADP and glucose-6-phosphate (G6P) 
was obtained by co-crystallising the protein with 5 mM ADP and 5 mM G6P. An initial 
screening was done using the screens: classics, JCSG+, Wizard I & II, and Wizard III & IV. 
Best crystals were obtained from the JCSG+ screen, in the condition containing 0.3 M 
magnesium formate dehydrate and 0.1 M Bis-Tris-HCl pH 5.5. Crystals were cryoprotected 
by soaking them briefly in a solution containing the mother liquor and 25% ethylene glycol, 
and were flash frozen in liquid nitrogen for data collection. 
The binary complex of M. thermoresistibile OtsA-ADP was obtained by co-crystallising the 
protein with 5mM ADP. Initial screening was done using the screens: classics (Qiagen), 
JCSG+ (Molecular dimensions), Wizard I&II (Rigaku), and Wizard III&IV (Rigaku). The 
initial crystals were obtained from the Wizard I&II screen, in the condition containing 1.2 M 
ammonium sulphate and 0.1 M HEPES pH 7.5. This was further optimised by using an 
additive screen HT, and 2, 5-hexanediol was found to be the best additive. Crystals were 
cryoprotected by soaking them briefly in a solution containing the mother liquor and 25% 
ethylene glycol, and were flash frozen in liquid nitrogen for data collection. 
The X-ray diffraction datasets of the soaked-crystals and co-crystals were collected at I03, 
I04, and I04-1 beamlines of Diamond Light Source synchrotron, Oxford, UK. The 
interactions between ligands and protein were calculated using Arpeggio 
(http://structure.bioc.cam.ac.uk/arpeggio).  
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2.4.8 Structure Solution and Refinement of OtsA Datasets 
 
The diffraction datasets were processed using MOSFLM (Battye et al., 2011) and reduced 
using AIMLESS (Evans and Murshudov, 2013), both tools from the CCP4 suite (Winn et al., 
2011). The resulting integrated and scaled file was used for molecular replacement to 
determine initial phases using PHASER (McCoy et al., 2007) from the PHENIX software 
package (Adams et al., 2010). The structure of E. coli OtsA (PDB entry: 1UQU) was used as 
the phasing model. The model was built building with Coot (Emsley et al., 2010), and 
refinement was performed in REFMAC 5 (Murshudov et al., 1997) of the CCP4 suite or 
PHENIX (Adams et al., 2010), as well as manually. The structure was validated using Coot, 
and REFMAC 5 or PHENIX. The figures were prepared with Pymol (The PyMOL Molecular 
Graphics System, Version 1.8 Schrödinger, LLC.) and UCSF Chimera (Pettersen et al., 
2004). 
2.4.9 Isothermal Titration Calorimetry  
 
The thermodynamics of the binding between M. thermoresistibile OtsA and ligands (ADP-
glucose, UDP-glucose, GDP-glucose, glucose-6-phosphate) was characterised using a 
Microcal ITC200 titration calorimeter at 25ºC. Protein at concentration of 100 µM in 20 mM 
Tris-HCl pH 7.5, 330 mM NaCl was used for all titrations. 1 mM ligands were injected in      
2 µl aliquots, and 18 injections with 120 sec spacing were done. Data were analysed by 
fitting a simple single-site model using Origin software (Microcal). 
 
 
 
2.4.10 Fluorescence-Based Thermal Shift Assay 
 
The initial screening of a fragment library (kindly provided by Prof. Abell’s group, 
Department of Chemistry, University of Cambridge) against M. thermoresistibile OtsA was 
carried out using a fluorescence-based thermal shift assay. The assay was performed in a 96-
well plate format, using a CFX Connect real-time PCR machine (Bio-Rad). Each 25 µl well 
contained 20 μM protein, 100 mM HEPES pH 7.5, 350 mM NaCl, 5X Sypro Orange 
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fluorescence dye (Invitrogen) and 5 mM fragments. Fragments were dissolved in 100% 
DMSO. 5 mM ADP-glucose and 5% DMSO were used as the positive and negative controls 
respectively.                  
The fragment library was also screened in the presence of ADP. The reaction mixture was the 
same as mentioned above, but contained 5 mM ADP in addition. For this screening, 5 mM 
ADP-glucose and 5 mM ADP were used as the positive and negative controls respectively. 
The thermal scan was recorded for each sample from 25°C to 95°C, at 0.5°C increments. The 
fluorescence was measured every 30 sec. The best binders were selected on the basis of ΔTm 
and the shape of the melting curve. The data were analysed using an in-house Microsoft 
Office Excel macro.  
2.4.11 Soaking and Co-crystallisation with Fragment Hits 
 
To obtain the fragment-bound structures of M. thermoresistibile OtsA, the apo-crystals 
produced using the hanging-drop vapour-diffusion method were soaked in the optimised 
crystal condition containing the fragments. Crystals were then transferred to a 2 μl drop of 
reservoir solution containing different concentrations of ligand (20 mM, 50 mM, 100 mM 
dissolved in 100% DMSO) and incubated for 14-16 hours. The crystals were directly flash 
frozen in liquid nitrogen for data collection. 
To obtain strutures bound with the fragments hits obtained from the thermal shift screening of 
the enzyme along with ADP, M. thermoresistibile OtsA was co-crystallised with 5 mM ADP 
and each of 5 the fragments at a concentration of 5 mM. Initial screening was done using the 
screens: wizard I&II, wizard III&IV and JCSG+. Crystals were obtained in several 
conditions, but the following conditions were common for all the fragments tested: 
1. JCSG+ screen, solution C9 (0.1 M Sodium/potassium phosphate pH 6.2, 25 % 1,2-
Propandiol 10 % Glycerol) 
2. Wizard I&II screen, solution A2 (10% 2-propanol, 100 mM HEPES pH 7.5, 200 mM 
Sodium chloride) 
3. Wizard I&II screen, solution B1 (1.26 mM Ammonium sulfate, 100 mM Sodium 
cacodylate pH 6.5) 
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4. Wizard III&IV screen, solution E3 (100 mM Bis-TRIS pH 5.5, 200 mM Ammonium 
sulfate) 
 
Crystals of protein with fragment(s) and ADP were also obtained in the condition where the 
protein was co-crystallised with ADP and G6P (condition containing 0.3 M magnesium 
formate dehydrate and 0.1 M Bis-TRIS pH 5.5). Different cryoprotectants were used (30% 
glycerol, 25% ethylene glycol, 30% PEG-400, 25% MPD, 1:1 Paratone-N: Paraffin). Crystals 
were cryoprotected by soaking them briefly in a solution containing the mother liquor and the 
cryo-protectant, and were flash frozen in liquid nitrogen for data collection. 
All the datasets were collected in beamlines I03 and I04 of Diamond Light Synchrotron 
(Oxford, UK). 
2.4.12 Inhibition Assays  
 
The inhibition assay was performed, as described in section 2.4.6, with varying 
concentrations of the fragments. The value of IC50 was calculated from the dose-response 
curve for each fragment.  
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2.5 Results 
 
2.5.1 Alignment and Analysis of OtsA Sequences 
 
OtsA is found in diverse species, such as bacteria, fungi, insects, plants. Based on the BLAST 
analysis of M. tuberculosis OtsA protein sequence, it exhibits homology to OtsA proteins in 
different prokaryotes and eukaryotes, including M. thermoresistibile (80% identity),                    
M. smegmatis (79% identity), E. coli (34% identity), B. xenovorans (35% identity),               
C. albicans (37% identity), N. farcinica (77% identity), S. cerevisiae (37% identity),              
L. aerocolonigenes (69% identity), S. hygroscopicus (64% identity), D. melanogaster (35% 
identity), C. felis (36% identity), D. discoideum (37% identity) and A. thaliana (36% 
identity). The sequences were aligned using Clustal Omega, and the predicted secondary 
structure elements of M. thermoresistibile OtsA were mapped onto the alignment.  
The residues of the catalytic site of E. coli OtsA, determined from the crystal structure of the 
protein complexed with UDP and glucose-6-phosphate (PDB ID: 1GZ5) (Gibson et al., 
2002a), were marked. The alignment shows that in OtsA enzyme from all these species, 
despite sharing limited sequence similarity, the residues of the catalytic site of E. coli OtsA 
are conserved, with the exception of Phe339 (Figure 2.4). In E. coli OtsA, this residue 
confers the specificity for the uracil moiety (Gibson et al., 2002a).  
The loop between Arg9 and Gly22 of E. coli OtsA is catalytically important, and is the 
shortest among the other OtsA sequences (Gibson et al., 2002a, 2004). The enzyme from       
B. xenovorans also has a short loop like that of the E. coli enzyme. In other organisms, 
including mycobacteria, there is an insertion of 8-9 residues in this loop. 
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FIGURE 2.4    Sequence alignment of OtsA sequences from different organisms.   
Amino-acid sequence alignment of OtsA in bacteria, fungi, insects and plants. Sequence 
alignment is annotated with predicted secondary structural features of M. thermoresistibile OtsA 
(orange tube: α- helix; green arrow: β-strand; purple curvy line: disordered region). The catalytic 
site loop is shaded grey. Conserved residues of the substrate-binding pocket of E. coli OtsA 
(Gibson et al., 2002a) are highlighted maroon. Other residues are shaded according to the degree 
of conservation. The unconserved residue, Phe339, of the catalytic pocket of E. coli OtsA and 
the corresponding residues in other species in the alignment are marked with a black star.  
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2.5.2 Expression Trial of M. tuberculosis OtsA 
 
An expression trial of N-terminal His6-tagged M. tuberculosis OtsA showed that the protein 
was expressed in the insoluble fraction. A strong band of His6-tagged M. tuberculosis OtsA 
observed around 58 kDa was seen in the pellet fraction (Figure 2.5).  
 
  
 
 
 
 
 
 
 
 
FIGURE 2.5    Expression trial of His6 -tagged M. tuberculosis OtsA. 
Expression trial of His6-tagged protein on Ni-sepharose column. MW of the tagged protein- 58 
kDa. Orange arrow: tagged protein in the pellet fraction.  
(MWM: molecular weight marker, L: cellular lysate, S: supernatant, P: pellet, FT: flow through, 
Pr: tagged protein). 
 
The results of expression trials done by Dr. Vitor Mendes indicated that SUMO-tagged              
M. thermoresistibile OtsA was present in the soluble fraction, whereas the SUMO-tagged        
M. tuberculosis protein was mostly insoluble and found in inclusion bodies (Dr. Vitor 
Mendes, personal communication). Thus, the SUMO-tagged orthologous protein from                                  
M. thermoresistibile was expressed and purified. 
 
           MWM    L      S      P     FT    Pr                            
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2.5.3 Expression and Purification of the Full-Length Recombinant  
M. thermoresistibile OtsA 
 
The full-length orthologous protein was expressed with a cleavable N-terminus SUMO tag in 
E. coli. The initial affinity purification indicated that protein was expressed in both soluble 
and pellet fractions. Further, the protein from the cellular fraction was extracted by a very 
mild detergent treatment step during affinity purification, which increased the overall yield 
by almost 30%. The SUMO tag cleaved by the Ulp1 protease was separated, and the protein 
was further purified by gel filtration. High-levels of protein, purified to homogeneity, were 
produced. MALDI fingerprinting confirmed that a strong band observed at 58 kDa was of the 
full-length M. thermoresistibile OtsA, and a low molecular weight band was the degradation 
product of the full-length protein (Figure 2.6). The trace from the gel-filtration run indicated 
that the tag-less protein behaved as a tetramer in the solution. The purified orthologous 
protein was used for subsequent structural studies, biochemical and biophysical assays.  
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FIGURE 2.6    Expression and purification of M. thermoresistibile OtsA. 
A. Metal affinity purification of SUMO tagged protein on Ni-sepharose column and cleavage of 
SUMO tag by UlpI protease. MW of the protein- 54.5 kDa, MW of SUMO tag-13.8 kDa, MW 
of the tagged protein-68.3 kDa. Green circle: tag-less protein after Ulp1 cleavage, orange circle: 
SUMO tag.  
(MWM: molecular weight marker, S1: supernatant from soluble fraction, TP: Triton X-100 
treated pellet, S2: supernatant after detergent treatment, P: pellet, FT: flow through, P1 to P2: 
tagged protein, CP: protein cleaved with Ulp1 protease) 
B. Gel filtration of the cleaved protein on Superdex-200 column. Maroon arrow represents the 
degradation band of the full-length protein. 
(MWM: molecular weight marker, F1 to F6: tag-less protein fractions)     
C. The gel filtration profile. The protein eluted at around 65 ml. 
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2.5.4 Analysis of the Secondary Structure and Thermodynamic Stability by 
Circular Dichroism 
 
A circular dichroism (CD) experiment was conducted on M. thermoresistibile OtsA to 
identify any detrimental effect of the mild detergent treatment on the protein structure. The 
far-UV CD spectrum showed that the protein was folded, and was a mix of α-helices and β-
strands (Figure 2.7 A). The thermal stability of M. thermoresistibile OtsA was examined by 
measuring ellipticity over the temperature range of 25-95˚C. This was important in 
determining whether the protein had any unfolded intermediates due to the mild detergent 
treatment during purification. The protein displayed a monophasic, steep melting curve, 
indicating absence of any intermediates. The unfolding of the protein occurred over a narrow 
temperature range between 64˚C and 73˚C (Figure 2.7 B).  
 
 
 
 
 
 
 
 
 
FIGURE 2.7    The circular dichroism spectra of full-length M. thermoresistibile OtsA. 
A. Wavelength scan indicates that the protein is folded with a combination of α-helices and β-
strands.  
B. Thermal profile shows a narrow range for the melting temperature.  
 
 
 
 
 
 
 
 
 
 
A. B. 
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2.5.5 Properties of M. thermoresistibile OtsA, Substrate-Preference and Regulation 
of Enzyme Activity by Feedback-Inhibition  
 
M. tuberculosis OtsA and M. thermoresistibile OtsA belong to glucosyltransferase family-20 
of the CAZy classification (Carbohydrate Active Enzymes database, www.cazy.org) 
(Campbell et al., 1997; Lombard et al., 2014). The kinetic parameters for M. thermoresistible 
OtsA were determined with Km values of 0.17 ± 0.03 mM for ADP-glucose, and of 0.23 ± 
0.04 mM for glucose-6-phosphate (Table 2.1, Figure 2.8).  
 
TABLE 2.1    Kinetic parameters for M. thermoresistibile OtsA obtained in this study. 
         (Km: Michaelis Menton constant, kcat: turnover number, kcat/Km: catalytic efficiency) 
  
FIGURE 2.8    Kinetics of M. thermoresistibile OtsA with ADP-glucose and glucose-6-phosphate.  
 
SUBSTRATE Km (mM) kcat (s-1) kcat/Km (M-1s-1) 
ADP-Glucose 0.17 ± 0.03 1.75 ± 0.08 10300 ± 2600 
Glucose-6P 0.23 ± 0.04 4.22 ± 0.23 18300 ± 5700 
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The activity of recombinant M. thermoresistibile OtsA was not dependent on divalent cations. 
There was no substantial difference in the activity of the enzyme upon adding Mg2+, Mn2+, 
Zn2+, Ca2+, Fe2+ and Co2+. However, the activity was slightly higher with Mg2+ and Mn2+ than 
other tested divalent cations (Figure 2.9 A). The effect of pH was also tested on the activity 
of the enzyme. M. thermoresistibile OtsA was active between the pH 5.0 and 10.0 at 37˚C, 
exhibiting maximum activity between pH 7.0-8.5 (Figure 2.9 B).  
 
 
 
 
FIGURE 2.9    Effect of divalent ions (A) and pH (B) on the activity of M. thermoresistibile OtsA.  
M. thermoresistibile OtsA used ADP-glucose, GDP-glucose and UDP-glucose as glucose 
donors with decreasing preference, and had strict specificity towards glucose-6-phosphate as 
the glucose acceptor (Figure 2.10), in conformity with what has been reported previously for 
M. tuberculosis OtsA (Asención Diez et al., 2015; Pan et al., 2002). The ITC data further 
established the preference of ADP-glucose over other glucose donors. Binding of ADP-
glucose was determined in the tested conditions with an observable Kd of 21.88 µM ± 2.00 
µM. The complexation of ADP-glucose with M. thermoresistibile OtsA was endothermic 
(positive peaks in the ITC output) (Figure 2.11). The association was characterised by an 
unfavorable enthalpy change (ΔH°= +6002 cal/mol) and a positive entropy change (ΔS= 
+41.5 cal/mol/deg) (values of thermodynamic properties are shown in an inset in the figure 
2.11). Other glucose donors, including GDP-glucose and UDP-glucose, and the glucose 
acceptor G6P, showed no observable heat of binding in the tested conditions. 
B. A. 
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FIGURE 2.10    Substrate preference of M. thermoresistibile OtsA. 
The enzyme showed highest preference for ADP- glucose as its substrate for glucose donor 
(left graph), and had strict preference for glucose-6-phosphate as the acceptor (right graph). 
 
 
 
 
 
 
  
 
 
 
 
 
 
FIGURE 2.11    Isothermal titration calorimetry profile of M. thermoresistibile OtsA with ADP-glucose. 
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It was also shown that the enzyme activity was regulated by both trehalose-6-phosphate, 
which is the reaction product, and trehalose, the pathway product, thus indicating feedback 
inhibition of the enzyme activity. Trehalose-6-phosphate inhibited the enzyme activity by 
approximately 40% at 2 mM, whereas trehalose had a more prominent inhibitory effect with 
almost 50% inhibition at 1 mM (Figure 2.12).  
 
FIGURE 2.12    Feedback inhibition of M. thermoresistibile OtsA by trehalose and trehalose-6-phosphate.    
Enzyme activity was inhibited by 50% at 1 mM trehalose (left graph) and by 40% at 2 mM 
trehalose-6-phosphate (right graph). 
2.5.6 Overall Structure of Apo, Full-Length M. thermoresistibile OtsA  
 
The crystals of M. thermoresistibile OtsA diffracted to 2.18 Å resolution (Figure 2.13) and 
belonged to F4132 space group, with two protomers per asymmetric unit (Figure 2.14 A). 
Superposition of the two protomers with BATON showed that the RMSD between them was 
0.182 Å. The unit cell parameters were a = b = c = 337.5 Å; α = β = ɣ = 90˚. The Matthew’s 
coefficient was calculated to be 2.45, and the protein crystals had 49.79 % solvent content. 
The final protein structure was modelled for residues 7-23, 33-323 and 331-477 as the density 
was not visible for the remaining residues. The data collection and refinement statistics for 
apo-enzyme crystals are detailed in Table 2.2. Each protomer of M. thermoresistibile OtsA 
consists of two domains having the classic Rossmann-fold, and the catalytic site is situated 
between the two domains (Figure 2.14 B). The N-terminal domain consists of residues 1-247 
and 462-486, which constitute a core of 7 parallel β-strands with an antiparallel β-strand on 
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either side, and 8 α-helixes, of which one helix is made of the endmost residues of the C-
terminal domain. The C-terminal domain, spanning the residues 248-461, is made of 6 
parallel β-stands intercalated with 9 α-helixes. The last helix of this domain has a kink and 
extends towards the N-terminal domain (Figure 2.15 A and B). The apo-protein (and in 
bound state with many ligands, described in section 2.5.7) adopts an open conformation. The 
N-terminal domain has the highest values for atomic temperature factors, which indicats that 
this domain is more dynamic (Figure 2.16). This is concomitant with the movement of α1 
helix during the conformational changes of the enzyme essential for its catalytic activity 
(described in detail in section 2.5.8). 
 
 
 
 
 
 
 
 
 
FIGURE 2.13    Apo-enzyme crystals and diffraction pattern of full-length M. thermoresistibile OtsA 
A. Cubic crystals of M. thermoresistibile OtsA. 
B. X-ray diffraction pattern of the crystals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. B. 
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Table 2.2    Data collection and refinement parameters of apo M. thermoresistibile OtsA structure. 
*Parameters in parenthesis are for the highest resolution shell 
DLS: Diamond Light Source, Oxford, UK 
 
 
 Apo M. thermoresistibile OtsA 
Data collection*  
Beamline  Diamond Light Source, I02 
Space group F4132 
Cell parameters:  
                             a/ b/ c  (Å) 337.47/ 337.47/ 337.47 
                             α/ β/ ɣ  (˚) 90/90/90 
Resolution range (Å) 50.88 – 2.18 (2.24 – 2.18) 
No. of reflections:  
                             Observed 1980805 (67062) 
                             Unique 85478 (6222) 
Completeness (%) 100 (99.9) 
Rmeas 0.109 (0.742) 
I/ σ (I) 26.4 (4.1) 
Refinement  
Refinement program REFMAC 5 
Resolution 50.88 – 2.18 
 No. of reflections 84195 
Rwork/Rfree (%) 18.96/20.63 
R.M.S. Deviations:  
                                 Bonds [Å] 0.007 
                                 Angles [˚] 1.056 
 Ramachandran Plot:  
                                    Favored [%] 98.3 
                                    Outliers [%] 0 
B- factors (Å):  
                            Protein atoms 33.8 
                            Solvent 42.6 
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FIGURE 2.14    The crystal structure of apo, full-length M. thermoresistibile OtsA. 
A. Cartoon representation of the homodimer in the asymmetric unit. The dimer is rotated 180˚ 
and represented in molecular surface to show the relative positioning of active sites of the 
protomers in the dimer. 
B. Surface representation of the protein structure, showing two-domain architecture of the 
protein. The catalytic pocket is coloured in orange. Only one protomer is shown. 
B. 
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FIGURE 2.16    Crystallographic B-factor distribution in apo, full-length M. thermoresistibile OtsA. 
Cartoon representation of the structure colored by the B-factor (Debye-Waller or temperature 
factor). B-factor values are shown with colors ranging from red (high fluctuations) to green 
(low fluctuations). N-terminal domain has the highest B-factor value, particularly the α1 helix, 
indicating high flexibilty of this domain. Only one protomer is shown. 
 
 
 
The surface conservation analysis of M. thermoresistibile OtsA showed that the catalytic 
core, at the interface of N- and C-terminal domains of the enzyme, was conserved. This was 
expected as it confers to the trehalose-6-phosphate synthase activity, and is under stronger 
evolutionary pressure. However, a few residues, Leu319, Thr 321, Arg361 and Val 363, of 
the catalytic binding site of the enzyme, particularly the donor-site (described in section 
2.5.7) do not show strong evolutionary conservation, and are of particular interest (Figure 
2.17). This probably accounts for the relaxed preference that OtsAs exhibit for the 
nitrogenous bases of the nucleotide donor-substrate. 
Apart from the catalytic core, there were conserved residues at the dimerisation and 
tetramerisation interfaces, detailed in the following section. 
 
α1 
N-terminal domain C-terminal domain 
Chapter-2     Functional and Structural Studies, and Probing the Druggability of M. thermoresistibile   
                     OtsA  
80 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2.17    Conservation analysis of M. thermoresistibile OtsA. 
The sequence conservation pattern of M. thermoresistibile OtsA, obtained using the Consurf 
server, shown in two views related by a 180° rotation. The conserved and variable residues, 
presented as space-filled model, are colored from the least conserved (turquoise) through 
intermediately conserved positions (white) to the most conserved residues (burgundy). The 
unconserved residues at the donor-subtrated site of the catalytic pocket are labelled.  
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Quaternary Structure of M. thermoresistibile OtsA 
M. thermoresistibile OtsA forms a tetrameric assembly in the crystal-structure (Figure 2.18 
A).  The asymmetric unit contains two protomers that are related by a two-fold axis to form a 
homo-dimer (Figure 2.18 A). The two protomers interact through a large dimerisation 
interface, with residues residing mainly on α5 and α7, and loops between α2- α3, α5- α6, β6- 
α5, α7-β8, β13-α13, β14-α14 and β15-α15 (Figure 2.18 B and C). Many interfacial residues 
are conserved, notably, Phe171, Glu175, Pro181, Arg213, Arg384, Phe410, Asn 424 and 
Pro425. Further, a dimer is formed between each such dimer related by a two-fold axis to 
form a homo-tetrameric assembly (Figure 2.18 A). The two dimers contact through α11 and 
the loop between α11-β12 (Figure 2.18 D and E). This interface contains a few invariant 
residues: Arg334, Gly342, Asn345 and Gly346. 
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FIGURE 2.18    Tetrameric assembly of apo M. thermoresistibile OtsA. 
A. Cartoon representation of M. thermoresistibile OtsA dimer in the asymmetric unit along the 
two-fold rotation axis. 90˚ rotated view displays the entire tetrameric assembly of the protein, 
along the twofold rotation axis. 
B. Side view of M. thermoresistibile OtsA tetramer in cartoon representation, showing the 
dimerisation interface between the protomers, highlighted in green. Same dimerisation 
interface is observed between the protomers 3 and 4. 
C. Molecular surface representation of B. 
D. Front view of M. thermoresistibile OtsA tetramer in cartoon representation, displaying the 
tetramer interface between the homo-dimers, highlighted in maroon.  
E. Molecular surface representation of D. 
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2.5.7 The Donor Site of M. thermoresistibile OtsA: Binding of Glucose-Donor 
    Substrates 
 
Ligand-bound structures of M. thermoresistibile OtsA were determined for glucose-donor 
substrates: ADP-glucose, GDP-glucose and UDP-glucose, by soaking the apo-crystals with 
these ligands. For clarity, only one protomer of the protein-ligand complex is shown in the 
figures. The structure with inactive nucleotide-substrate, ADP, was obtained by co-
crystallisation, and had one protomer in the asymmetric unit. The data collection and 
refinement statistics for ligand-bound crystals are detailed in Table 2.3.  
Table 2.3    Data collection and refinement parameters of glucose-donor substrates bound  
                    M. thermoresistibile OtsA structures. 
*Parameters in the parenthesis are for highest resolution shell 
DLS: Diamond Light Source, Oxford, UK 
 ADP-glucose GDP-glucose UDP-glucose ADP 
Data collection*     
Beamline DLS, I04 DLS, I04 DLS, I04 DLS, I04-1 
Space group F4132 F4132 F4132 I4122 
Cell parameters:     
a/ b/ c  (Å) 337.55/337.55/337.55 337.03/337.03/337.03 337.10/337.10/337.10 129/129/209.7 
α/ β/ ɣ  (˚) 90/90/90 90/90/90 90/90/90 90/90/90 
Resolution range (Å) 
76.38-2.19 
(2.24-2.19) 
56.97-2.29 
(2.54-2.29) 
40.88-4.94 
(5.11-4.94) 
109.91-1.88 
(1.93-1.88) 
No. of reflections:     
Observed 2769099 (89607) 2633027 (95731) 2377933 (91426) 888152 (514347) 
Unique 109260 (6624) 111391 (8113) 120145 (11638) 71808 (5243) 
Completeness (%) 99.9 (99.8) 100 (100) 100 (99.9) 99.9 (99.8) 
Rmeas 0.121 (0.843) 0.069 (0.679) 0.085 (0.691) 0.083 (2.304) 
I/ σ (I) 36.2 (4.8) 37.7 (4.0) 23.7 (3.1) 20.3 (2.1) 
Refinement     
Refinement program REFMAC 5 REFMAC 5 REFMAC 5 PHENIX 
Resolution 76.38-2.19 56.97-2.29 40.88-4.94 48.74-1.88 
No. of reflections 108882 111227 119745 71544 
Rwork/Rfree 17.72/19.51 17.88/21.03 19.41/22.76 21.89/23.44 
R.M.S. Deviations:     
Bonds [Å] 0.009 0.008 0.012 0.009 
Angles [˚] 1.049 1.053 1.087 1.037 
Ramachandran Plot:     
Favored [%] 98.4 97.7 98.1 98.5 
Outliers [%] 0 0 0 0 
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The prime interactions of the glucose-donor substrates are with the C-terminal domain. The 
side chain contacts are made with Arg286, Lys291, Arg365, Asp385 and Glu393; and the 
backbone contacts are made with the absolutely conserved residues Gly386, Met387, Asn388 
and Leu389. The interaction of the donor substrate with the N-terminal domain is mediated 
by His168 and His199. The hydroxyl-groups of the ribose-ring coordinate with the amide 
group of Arg365 and carbonyl groups of Glu393. The phosphate groups interact with the 
amide groups of Arg286, Lys291 and Leu389. The glucose-ring interacts with amide groups 
of His168, His199, Gly386, Met387 and Asn388; and carbonyl group of Asp385 (Figure 
2.19 and Figure 2.20). The protein adopts an open conformation in all the observed 
structures with the donor-groups. 
The adenine moiety of ADP-glucose occupies a deep, buried position of the catalytic site. 
The primary amine of the adenine moiety contacts with the carbonyl groups of Leu319 and 
Arg361, and N1 interacts with the amide group of Val363. The adenine rings also make π- 
interactions with side-chains of Val284, Thr321 and Leu386 (Figure 2.19).  
GDP-glucose is the next preferred substrate. The carbonyl-oxygen of the guanine-ring 
interacts with carbonyl and amide groups Val363. The N1 interacts with the amide group of 
carbonyl group of Val363, and the N7 bonds with carbonyl group of Thr321. It is probably 
not possible for the guanine moiety to occupy the same position as the adenine, due to steric 
clash of the primary amine group of the guanine-ring with the carbonyl group of Val363 
(Figure 2.20). 
It was not possible to observe electron density of UDP-glucose in the structure due to low 
resolution of the crystals, and various attempts to obtain the UDP-glucose bound structure 
were fruitless.  
The interactions ADP made with the protein were essentially similar to those made by the 
adenine ring, ribose sugar and phosphate groups of its activated glucose-donor (Figure 2.21). 
In the binary structure of M. thermoresistibile OtsA with ADP, the enzyme adopts an open 
conformation, and the primary amine of the adenine moiety was buried deep in the catalytic 
pocket, similar to what has been observed with binary structure of the enzyme with activated 
nucleotide donor, ADP-glucose.   
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FIGURE 2.19    Structure of M. thermoresistibile OtsA bound with ADP-glucose. 
A. The observed electron density (blue mesh) for ADP-glucose (ADPG) in the catalytic site of 
the enzyme, shown for both the protomers in the asymmetric unit, in the same oritentation. 
The catalytic site residues are coloured green, but are not annotated for clarity. These are in the 
same orientation as in (B). The map shown is a 2Fo-Fc map, contoured at 1 σ. 
B. Interaction of ADP-glucose with residues of the catalytic site of the protein. Bond lengths are 
shown in Å. 
C. Surface representation of the catalytic site bound with ADP-glucose.  
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FIGURE 2.20    Structure of M. thermoresistibile OtsA bound with GDP-glucose. 
A. The observed electron density (blue mesh) for GDP-glucose (GDPG) in the catalytic site of the 
enzyme, shown for both the protomers in the asymmetric unit, in the same oritentation. The 
catalytic site residues are coloured green, but are not annotated for clarity. These are in the 
same orientation as in (C). The map shown is a 2Fo-Fc map, contoured at 1 σ. 
B. Surface representation of the catalytic site bound with GDP-glucose.  
C. Interaction of GDP-glucose with residues of the catalytic site of the protein. Bond lengths are 
shown in Å. 
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FIGURE 2.21    Structure of M. thermoresistibile OtsA bound with ADP. 
A. The observed electron density (blue mesh) showing ADP at the catalytic site of the enzyme. 
The catalytic site residues are coloured green and annoted. The map shown is a 2Fo-Fc map, 
contoured at 1.5 σ. 
B. Surface representation of the catalytic site bound with GDP-glucose.  
C. Interaction of ADP with residues of the catalytic site of the protein. Bond lengths are shown in 
Å. 
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2.5.8 The Acceptor Site: Binding of Glucose-6-Phosphate and Conformational  
Changes Contributing to the Catalytic Mechanism of M. thermoresistibile      
OtsA 
 
The structure of M. thermoresistibile OtsA with the acceptor substrate was determined by co-
crystallizing the protein with glucose-6-phosphate (G6P) (glucose-acceptor substrate) and 
ADP (inactive donor-substrate). There was one protomer in the asymmetric unit. The data 
collection and refinement statistics for co-crystals are detailed in Table 2.4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.4    Data collection and refinement parameters of ADP-G6P bound ternary  
     M. thermoresistibile OtsA structure. 
*Parameters in the parenthesis are for highest resolution shell 
 
 DLS: Diamond Light Source, Oxford, UK 
 ADP and G6P 
Data collection*  
Beamline DLS, I03 
Space group P6222 
Cell parameters:  
a/ b/ c  (Å) 105.16/105.16/159.83 
α/ β/ ɣ  (˚) 90/90/120 
Resolution range (Å) 79.92-2.14 (2.20-2.14) 
No. of reflections:  
Observed 488670 (17177) 
Unique 29296 (2005) 
Completeness (%) 100 (99.6) 
Rmeas 0.087 (1.238) 
I/ σ (I) 23.5 (2.2) 
Refinement  
Refinement program PHENIX 
Resolution 79.92-2.14 
No. of reflections 28793 
Rwork/Rfree 16.1/18.36 
R.M.S. Deviations:  
Bonds [Å] 0.006 
Angles [˚] 1.034 
Ramachandran Plot:  
Favored [%] 98.8 
Outliers [%] 0 
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The structure of M. thermoresistibile OtsA bound with ADP and G6P adopts a closed 
conformation. The interaction of the acceptor substrate, glucose-6-phosphate (G6P), is 
predominantly with the N-terminus domain through the residues Arg18, Tyr90, Asp144 and 
Gln146. The interaction with the C-terminus domain is through Arg324. The phosphate group 
bonds with Pro37, the amide groups of Arg18 and Arg324, and the carbonyl group of Tyr90. 
The hydroxyls of the glucose-ring coordinate with the carbonyl group of Asp144 and the 
amide group of Gln146. The glucose-donor substrate also establishes new contacts when the 
protein adopts a closed conformation, apart from the interactions it makes with the protein in 
the open conformation. These are interactions of the distal phosphate group with Arg18, 
Gly38 and Gly39, hydroxyl-group of the ribose-ring with the side chain of Thr42, and of the 
proximal phosphate group with Val390 (Figure 2.22 A).  
The ternary structure adopts the closed conformation, which is markedly different from the 
apo- or donor-substrate bound structures in the open-conformation (Figure 2.23). The 
binding of G6P to the protein, along with the activated donor substrate or its nucleotide, 
caused the closure of the catalytic site, due to movement of α1 helix that contains the highly 
conserved Gly-Gly-Lue motif. Domain closure upon the binding of the acceptor substrate has 
also been observed for E. coli OtsA complexed with glucose-6-phosphate and UDP-glucose 
(Gibson et al., 2002a). Binding of ADP alone is not able to mediate domain closure, and the 
protein remains in the open conformation, as observed for its activated donor, ADP-glucose 
(Figures 2.19 and 2.21). 
Moreover, in the OtsA:ADP:G6P ternary structure, the catalytically important loop between 
Arg18 and Gly39 forms a more organised β-hairpin motif that forms a part of 11-strand β-
sheet at the N-terminal domain, as against the 9-strand β-sheet at the N-terminal domain in 
the apo-structure (Figure 2.23).  
The residue Gly39 is completely conserved and is most probably involved in the catalytic 
activity (Gibson et al., 2002a). It lies on the edge of the α1 helix, and forms an interaction 
with the glucose-bound-phosphate of the donor substrate when the catalytic site closes. 
Thereby, a conformational change in the protein structure is essential for its catalytic activity. 
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FIGURE 2.22    Ternary structure of M. thermoresistibile OtsA bound with ADP and glucose-6-  
             phosphate. 
A. Interactions of ADP and G6P with residues of the catalytic site of the protein. Bond lengths 
are shown in Å. 
B. The observed electron density (blue mesh) for ADP and G6P at the catalytic centre of the 
enzyme. The β-hairpin motif and the interacting residues are not shown for clarity. The map 
shown is a 2Fo-Fc map, contoured at 1.5 σ. 
C. Surface representation of the catalytic site bound with ADP and G6P. It shows the catalytic 
pocket in the closed conformation and the deep burial of the adenine moiety in the catalytic 
pocket.  
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A.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
Open conformation 
Closed conformation 
FIGURE 2.23    Conformational states of  
                            M. thermoresistibile OtsA. 
A. Superposition of the structure 
of apo-protein in open 
conformation (teal) and OtsA-
ADP-G6P ternary structure in 
closed conformation (green). 
The yellow arrow represents 
the direction of movement of 
α1 helix during the 
conformational change. The β-
hairpin motif is marked by a 
dashed box. 
B. Surface representation of the 
protein structure in the open 
conformation (top) and in the 
closed conformation (bottom). 
(Active site is highlighted in 
yellow.) 
N-terminal domain C-terminal domain 
β- hairpin 
motif in the ternary 
structure 
α1 
αα
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α1 
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2.5.9 M. thermoresistibile OtsA Structures with the Products: Trehalose-6-
Phosphate and Trehalose 
 
Ligand-bound structures of M. thermoresistibile OtsA were determined for the feedback 
inhibitors, trehalose-6-phosphate and trehalose, by soaking the apo-crystals with these 
ligands. The data collection and refinement statistics for ligand-bound crystals are detailed in 
Table 2.5. For clarity, only one protomer of the protein-ligand complex is shown in the 
figures. Trehalose-6-phosphate (T6P) and trehalose interact with both the N-terminal and C-
terminal domains.  
The phosphate group of T6P interacts with Tyr90, Tyr145, Gln146 and Arg324, similar to the 
interactions made by the phosphate group of G6P. The distal glucose-ring of T6P makes 
connection with the conserved residues His168, His199, Asp385, Gly386, Met387 and 
Asn388 (Figure 2.24). Trehalose occupies the same position as the T6P. The distal glucose 
ring of trehalose makes the same contacts that the glucose-ring of T6P makes. The proximal 
glucose-ring of trehalose makes contact with the side-chain of Arg286 (Figure 2.25). 
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Table 2.5    Data collection and refinement parameters of trehalose-6-phosphate and trehalose bound  
                    M. thermoresistibile OtsA structures. 
*Parameters in the parenthesis are for highest resolution shell 
DLS: Diamond Light Source, Oxford, UK 
 
 
 
 
 Trehalose-6-Phosphate Trehalose  
Data collection*   
Beamline  DLS, I04 DLS, I04 
Space group F4132 F4132 
Cell parameters:   
                             a/ b/ c  (Å) 338.05/ 338.05/ 338.05 337.76/ 337.76/ 337.76 
                             α/ β/ ɣ  (˚) 90/ 90/ 90 90/ 90/ 90 
Resolution range (Å) 37.8 – 2.09 ( 2.14 – 2.09) 57.09 – 1.97 (2.02 - 1.97) 
No. of reflections:   
                             Observed 2462332 (124512) 2688985 (91722) 
                             Unique 97253 (7096) 115412 (8307) 
Completeness (%) 100 (100) 99.9 (99.2) 
Rmeas 0.073 (0.707) 0.064 (0.692) 
I/ σ (I) 34.2 (4.6) 37.2 (3.6) 
Refinement   
Refinement program REFMAC 5 REFMAC 5 
Resolution   
 No. of reflections 96980 115378 
Rwork/Rfree 16.42/17.96 18.22/20.37 
R.M.S. Deviations:   
                                 Bonds [Å] 0.010 0.008 
                                 Angles [˚] 1.035 1.041 
 Ramachandran Plot:   
                                    Favored [%] 98.6 97.2 
                                   Outliers [%] 0 0 
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FIGURE 2.24    Structure of M. thermoresistibile OtsA bound with trehalose-6-phosphate. 
A. The observed electron density (blue mesh) for trehalose-6-phosphate (T6P) in the catalytic site 
of the enzyme, shown for both the protomers in the asymmetric unit, in the same oritentation. 
The catalytic site residues are coloured green and annoted. The map shown is a 2Fo-Fc map, 
contoured at 1 σ. 
B. Interactions of trehalose-6-phosphate with residues of the catalytic site of the protein. Bond 
lengths are shown in Å.  
C. Surface representation of the catalytic site bound with trehalose-6-phosphate. 
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FIGURE 2.25    Structure of M. thermoresistibile OtsA bound with trehalose. 
A. The observed electron density (blue mesh) for trehalose in the catalytic site of the enzyme, 
shown for both the protomers in the asymmetric unit, in the same oritentation. The catalytic 
site residues are coloured green and annoted. The map shown is a 2Fo-Fc map, contoured at 
1 σ. 
B. Interactions of trehalose with residues of the catalytic site of the protein. Bond lengths are 
shown in Å. 
C. Surface representation of the catalytic site with trehalose bound. 
2.5.10 Comparison of Structure of Mycobacterial OtsA with Other Trehalose-6-
Phosphate Synthases 
 
A DALI search for identification of structural homologues of M. thermoresistibile OtsA gave 
the recently characterised (February, 2016) trehalose 6-phosphate synthase from 
Burkholderia xenovorans (PDB ID: 5HXA) as the top hit (Z-score =47.9), followed by          
E. coli OtsA structures bound with UDP-2-fluro-glucose (PDB ID: 1UQT, Z-score =47.5), 
and with UDP-glucose (PDB ID: 1UQU, Z-score= 47.4).  
M. thermoresistibile OtsA shares 34% sequence identity with E. coli and 35% identity with 
B. xenovorans. The structural alignment of mycobacterial OtsA with these OtsA structures 
shows that the overall structural fold is similar, quintessential of GT-B glycosyltransferases 
(Figure 2.26). The structural alignment between mycobacterial OtsA and E. coli OtsA (PDB 
C. 
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ID: 1UQU) resulted in RMSD of 1.55 Å over 415 residues, whereas the structural alignment 
between mycobacterial OtsA and B. xenovorans OtsA (PDB ID: 5HXA) resulted in RMSD of 
1.45 Å over 418 residues. The comparative analysis shows that mycobacterial OtsA has 
insertions in two loops. The first insertion is of 8 residues in the catalytic site loop between 
Arg18 and Gly39. The second insertion is also of 8 residues in the loop between Asn218 and 
Glu232. 
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(Catalytical site loop) 
Insertion-2 
(cont.) 
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FIGURE 2.26    Comparison of structures of M. thermoresistibile OtsA with those of other OtsA proteins. 
A. Sequence alignment of M. thermoresistibile OtsA with E. coli and B. xenovorans OtsA, 
showing the insertions in M. thermoresistibile OtsA. Residues of catalytic site of M. 
thermoresistibile OtsA are marked with circles (yellow: acceptor substrate site, green: donor 
substrate site). 
B. Superposition of structures of M. thermoresistibile OtsA (teal) and E. coli OtsA (PDB ID: 
1UQU) (pink) in open conformation.  
C. Superposition of structures of M. thermoresistibile OtsA (teal) and B. xenovorans OtsA (PDB 
ID: 5HXA) (golden) in open conformation. 
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Comparison of the Ternary Structures in the Closed-Conformation 
The ternary complexes of M. thermoresistibile OtsA:ADP:G6P, and E. coli OtsA:UDP:G6P 
(PDB ID: 1GZ5) adopt a closed conformation. Superposition of these structures showed that 
the α1 helix of M. thermoresistibile OtsA fully overlaps with the helix of E. coli OtsA, and 
the conformational change is restricted to the N-terminus acceptor-domain. In                      
M. thermoresistibile OtsA, the catalytic-site loop having an insertion, forms an organised β- 
hairpin motif in the ternary structure, which is not observed in E. coli OtsA ternary structure 
(Figure 2.27).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
α1 
α1* 
β- Hairpin  
Motif 
FIGURE 2.27    Comparison of structures of  
M. thermoresistibile OtsA with  
E. coli OtsA in closed conformation. 
Superposition of structures of            
M. thermoresistibile OtsA (blue) and 
E. coli OtsA (PDB ID: 1GZ5) 
(yellow) in closed conformation, 
showing ligand-gated movement of α1 
helix in both the structures, necessary 
for catalytic activity.                        
(α1: M. thermoresistibile helix;       
α1*: E. coli helix). Ligands not shown 
in the structures for the sake of clarity.  
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Comparison of the Nucleotide Binding Site 
The donor-substrate bound structures of M. thermoresistibile and E. coli OtsA adopt an open 
conformation. In both the enzymes, the residues interacting with the glucose rings and 
phosphate groups of the NDP-glucoses are mostly conserved. The ribose, phosphate and 
glucose moieties of ADP-glucose or GDP-glucose in the catalytic pocket of                                      
M. thermoresistibile OtsA are respectively superimposable onto the ribose, phosphate and 
glucose moieties of UDP-glucose in the catalytic pocket of E. coli OtsA. However, the 
position occupied by different nitrogenous bases and the interactions they make with the 
enzyme from respective species are different (Figure 2.28 A).  
Gibson and colleagues have shown that in the binary E. coli OtsA:UDP-glucose structure, O4 
and N3 of the uracil moiety make contact with hydrophobic Phe339, and because there are no 
interactions with O2, it is possible to model guanine in place of uracil (Gibson et al., 2002a). 
On the other hand, structures of M. thermoresistibile OtsA with the donor substrates 
described in this chapter show that the adenine or guanine moiety of ADP-glucose or GDP-
glucose respectively, interact with multiple residues: Val 284, Leu319, Thr321, Arg361, 
Val363 and Leu368 (Figure 2.28 B).  
The comparison of the catalytic pocket of E. coli and M. thermoresistibile OtsA reveals that 
the divergent substrate preferences may be attributed to several amino-acid substitutions. The 
preference for ADP-glucose by M. thermoresistibile OtsA (instead of uracil by E. coli OtsA) 
is most likely due to the substitution of Ile295 and Phe339 in E. coli OtsA by Leu319 and 
Val363 respectively in M. thermoresistibile OtsA. In both M. thermoresistibile and E. coli 
OtsA, Leu319 and Ile295 respectively occupy a similar position on a loop in proximity to the 
adjacent protomer; and Val363 and Phe339 occupy a position on a β-strand. The catalytic site 
in M. thermoresistibile OtsA is enlarged by these substitutions that favour the bicyclic 
adenine moiety, especially its primary amine group, to closely-fit in the pocket (Figure 2.28 
C) and make extensive contacts with the hydrophobic and polar residues surrounding it. This 
is consistent with the high activity of M. thermoresistibile with ADP-glucose. Within                       
M. thermoresistibile OtsA, the positioning of guanine of GDP-glucose at this site would be 
prevented due to possible steric clash of its primary amine with the carbonyl of Val363 
(explained in the section 2.5.7, figure 2.20). 
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R361 
ADPG/ UDPG 
V363/
F339 
R365 
E393/
E369 
D385/
D361 
G386 
M387/
M363 
N388/
N364 L389/
E365 
K291 
R286/
R262 
 
L319 
H168/
H154 
 
H199/ 
Q185 
A. 
L368 
V284 
T321 
B. 
M. thermoresistibile OtsA 
R361 
V363 
Protomer-3 
Protomer-2 
L368 
T321 
L319 
V284 
Protomer-2 
Protomer-1 
F339 
Q337 
ADPG 
UDPG 
E. coli OtsA 
L344 
P297 
V260 
I295 
(cont.) 
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FIGURE 2.28    Comparison of the nucleotide-donor binding sites of M. thermoresistibile OtsA with E. coli 
OtsA. 
B. Superposition of activated nucleotide donor site of M. thermoresistibile OtsA (green) and       
E. coli OtsA (Gibson et al., 2004; PDB ID: 1UQU) (yellow). Note the differences in the 
position of the nitrogenous bases. Only one protomer is shown for each protein. The 
interacting residues of M. thermoresistibile OtsA are labelled in green, wherase those of         
E. coli OtsA are labelled in black. 
C. Orthoscopic view of the activated nucleotide donor sites of M. thermoresistibile OtsA and      
E. coli OtsA in the same orientation, focusing on the interactions made by the nitrogenous 
bases. The adjacent protomer is shown in the molecular surface representation. 
D. Activated nucleotide donor sites of M. thermoresistibile OtsA (lime green) and E. coli OtsA 
(golden) in cartoon representation (top) and molecular surface representation (bottom), 
superposed to shown the differences made by the amino-acid substitutions. L319 and V363 of 
M. thermoresistibile OtsA are coloured magenta, and I295 and F339 of E. coli OtsA are 
coloured teal. Note the deepening of the catalytic pocket of M. thermoresistibile OtsA by the 
substitutions, marked by arrows. 
(ADPG: ADP-glucose, UDPG: UDP-glucose) 
ADPG/ 
UDPG 
V363/
F339 
L319/ 
I295 
L319/
I295 
V363/
F339 
ADPG/ 
UDPG 
C. 
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2.5.11 Fragment-Based Drug Discovery Against M. thermoresistibile OtsA  
 
2.5.11.1 Fluorescence-Based Thermal Shift Assay as a High Throughput Preliminary 
Screening Method for Fragment Hits 
The preliminary screening of the fragment library was carried out using a fluorescence-based 
thermal shift assay. A fragment is considered a hit, if upon its binding, the melting 
temperature of the enzyme is altered. If the binding of a fragment increases the melting 
temperature of the enzyme, then it is known as a positive hit; and conversely, if the melting 
temperature is reduced, then the fragment is known as a negative hit (Scott et al., 2012).  
The effect of DMSO on the stability of M. thermoresistibile OtsA was assessed prior to the 
fragment screening, as the fragments were dissolved in DMSO. The average melting 
temperature of the enzyme was determined in the absence and presence of DMSO, and was 
observed to be 63.50 ± 0˚C and 61.75 ± 0.30˚C, respectively. This indicated that DMSO had 
a modest destabilisation effect on the enzyme stability. The binding of ADP-glucose 
(dissolved in DMSO) to the enzyme, had a pronounced effect on the thermal stability of 
enzyme, and increased its melting temperature by 19.20 ± 0.25 ˚C, whereas, ADP (dissolved 
in DMSO) gave a minimal positive shift of +1˚C. A total of 960 fragments were tested and 
two types of screening processes were carried out for identification of hits against                 
M. thermoresistibile OtsA.  
In type-1 screening, the fragment library was screened against the enzyme in the apo-state, i.e 
in the absence of any other ligand. The melting temperature of protein in the presence of 
DMSO (61.75 ± 0.30˚C), and that with ADP-glucose (80.88 ± 0.25˚C) were used as negative 
and positive controls, respectively. A fragment was considered as a hit from type-1 screen, 
when its binding to the enzyme caused a change in the melting point by ± 1.5°C, compared 
with the negative control. This cut-off value was five-times the value of the standard 
deviation of the measured melting point of the negative control.  
The majority of hits from this screening process were negative, and had a destabilisation 
effect on the protein. This may possibily be due the terameric organisation of the enzyme, 
which gets disrupted upon binding of certain fragments, and result in negative shifts. A total 
of 15 fragments were identified as positive hits, giving a hit rate of 1.56%. The chemical 
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structures and value of ΔTm of these positive hits, along with representative thermal profiles 
are presented in Figure 2.29. 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 F14.  
Ethyl-5-methylisoxazole-3-
carboxylate 
ΔTm= +1.75˚C 
F3.  
3-Pyridinylboronic acid 
ΔTm= +15.38˚C 
F10.  
3,4-Dimethoxybenzene 
sulfonamide 
ΔTm= +1.75˚C 
F11.  
2-Phenylimidazole 
ΔTm= +1.75˚C 
F13.  
2-Amino-8-quinolinol 
ΔTm= +1.75˚C 
F12.  
2-(4-Methyl-5-thiazolyl) 
ethyl acetate 
ΔTm= +1.75˚C 
F5.  
Benzo[b]thiophene-2-
propionic acid 
ΔTm= +11.13˚C 
F2.  
6,8-dichloro-2-oxo-2H-
chromene-3-carboxylic acid 
ΔTm= +15.5˚C 
F6.  
2-bromo-1-(3-thienyl)-1-
ethanone 
ΔTm= +11˚C 
F4.  
4-Hydroxy-6-(trifluoromethyl)- 
3-quinolinecarboxylic acid 
ΔTm= +15.13˚C 
F9.  
5-(4-Trifluoromethoxyphenyl)-
nicotinic acid 
ΔTm= +6.63˚C 
F1.  
Ethyl 5-(trifluoromethoxy) 
indole-2-carboxylate 
ΔTm= +16˚C 
F8.  
6-(3-chlorophenoxy) pyridine-
2-carboxylic acid 
ΔTm= +7.5˚C 
F15.  
5-Aminoindole  
ΔTm= +1.38˚C (cont.) 
F7.  
5-(3,4-Dichlorophenyl) 
nicotinic acid 
ΔTm= +9.5˚C 
A.  
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FIGURE 2.29    Fragment hits from type-1 (in the absence of ADP) screening of the fragment library    
   using thermal shift assay.  
A. Chemical structures and corresponding ΔTm values of the fragment hits. 
B. Representative thermal shift profiles of some fragment hits. 
The structural analyses of M. thermoresistibile OtsA demonstrated that the enzyme exhibits 
different conformational states. This structural knowledge was exploited, and formed the 
rationale for screening the fragment library in the presence of ADP, to identify the fragments 
that were able to modulate the conformational change. In this type-2 screening process, the 
same principles were applied and analysis was done as for the type-1 screening. The melting 
point of the enzyme in presence of ADP (62.50 ± 0˚C) was taken as the negative control, and 
that of protein with ADP-glucose (81.50 ± 0.70˚C) served as the positive reference. The cut-
off value for classification of fragments as a hit was ±1˚C. The majority of hits from the type-
2 screening were negative, as observed for type-1 screen. From this screening, 7 fragments 
were classified as hits (hit rate=0.73%), and the maximum value of positive ΔTm observed 
was +15˚C. The chemical structures and value of ΔTm of these 7 positive hits are given in 
Figure 2.30. 
B. 
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FIGURE 2.30    Fragment hits from type-2 (in the presence of ADP) screening of the fragment library        
                            using thermal shift assay. 
The screening of the same fragment library in presence and absence of ADP resulted in 
identification of different fragment molecules that gave positive shifts. However, one 
fragmen, 5-Aminoindole, was found to be a common hit from both the screening types. The 
ΔTm was observed to be 1.38˚C when type-1 screening method was used. In presence of 
ADP in the type-2 screening method, the ΔTm was slightly increased to 2.5˚C.  
2.5.11.2 Inhibition of Trehalose-6-Phosphate Synthase Activity of M. thermoresistibile 
OtsA  
To test the in vitro effects of the hits identified on the activity of the protein, an inhibition 
screen was performed. Dose response curves were produced for the top hits from both the 
screening types, and half maximal inhibitory concentrations (IC50) were determined (Table 
2.6). Representative dose-response curves are shown in Figure 2.31. 
F6. 
6-hydroxy-2,3-
dihydrobenzo[b]furan-3-one 
ΔTm= +1.5˚C 
F4. 
5-Aminoindole 
ΔTm= +2.5˚C 
F2. 
5-(2-thienyl) nicotinic acid 
ΔTm= +14C 
F3. 
Methyl 4-amino-
3-iodobenzoate 
ΔTm= +3.88˚C 
F1. 
1-{2-[4-
(trifluoromethyl)phenyl]-1,3-
thiazol-4-yl}ethan-1-one 
ΔTm= +15˚C 
F5. 
7-aminothieno[2,3-b] 
pyrazine-6-carboxylic acid 
ΔTm= +2˚C 
F7. 
5-Hydroxy-L-tryptophan 
ΔTm= +1.25˚C 
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Table 2.6    Summary of IC50 values of top hits against M. thermoresistibile OtsA.  
Fragment hits tested from both type-1 and type-2 screening by thermal shift assay.   
 
 
 
 
 
 
 
 
FIGURE 2.31    Inhibition of trehalose-6-phosphate synthase activity of M. thermoresistibile OtsA by    
                            fragments. 
                           Representative examples of dose-response curves of F7 from type-1 screen, and F1 and F2      
                           from type-2 screen of thermal shift assay.   
2.5.11.3 Fragment-Bound Structures 
M. thermoresistibile OtsA crystals were soaked or the protein was co-crystallised along with 
the fragments, in order to obtain fragment-complexed structures of the enzyme. However, no 
attemps were successful. 
Fragment Number IC50 Value (µM) 
F2 (Type-2) 500 
F5 (Type-2) 1000 
F4 (Type-2) 650 
F1 (Type-2)       800 
F7 (Type-1) 624 
F8 (Type-1) 870 
F9 (Type-1) 650 
F1 (Type-1) 720 
F4 (Type-1) 530 
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2.6 Discussion 
 
Trehalose plays a pivotal role in mycobacteria and is a constituent of numerous structural 
components of the mycobacterial cell wall. The reactions involved in synthesis of trehalose-
6-phosphate and trehalose are essential in the physiology of the bacteria. In this chapter, I 
describe the successful structural and functional characterisation of the mycobacterial OtsA 
enzyme. The analysis and alignments reported in this chapter show that OtsA from                        
M. tuberculosis has 80% sequence identity with its orthologue from M. thermoresistibile, 
with full conservation of the catalytic site, which makes it an ideal surrogate model for 
structural and functional investigation. The recombinant enzyme from M. thermoresistibile 
was expressed reasonably in the soluble fraction, however, a mild detergent treatment was 
required to extract the protein from pellet in order to improve the yield. There was no 
apparent precipitation and instability of the protein, and the CD spectra demonstrated that 
protein was folded and thermally stable. The protein was functionally active and maintained 
its structural integrity.  
The structures of M. thermoresistibile OtsA exhibit the typical GT-B fold of 
glycosyltransferases with two core Rossmann-fold domains. The overall structural fold is 
surprisingly identical to OtsA enzymes from E. coli and B. xenovorans, despite their low 
sequence identity, and also to VldE and ValL, the pseudo-glycosyltransferases involved in 
validamycin-A synthesis (Cavalier et al., 2012; Gibson et al., 2002a; Zheng et al., 2012). A 
significant difference lies in the catalytically important loop between Arg18 and Gly39 of           
M. thermoresistibile OtsA. It has been reported that the catalytic site loop of E. coli OtsA 
does not contain any insertion and represent the shortest loop in GT-20 family of 
glycosyltransferases, as compared to other members, wherein there are insertions of 8-9 
residues (Gibson et al., 2004). Mycobacterial OtsA also has an insertion of 8-residues in this 
loop. However, the electron density was not visible for this insertion in any of the structures 
described in this work, which indicates that it is highly flexible.  
There is a significant difference between M. thermoresistibile OtsA structures in ‘open’ 
conformation (observed for apo, donor-substrate bound and products-bound structures) and 
the ADP-G6P complex structure in ‘closed’ conformation. In M. thermoresistibile 
OtsA:ADP:G6P ternary structure, the acceptor binding site undergoes a structural and 
conformational change upon ligand-binding. There is a cross talk due to interactions of 
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ligands with the residues of the adjacent domain, which mediates movement of α1 helix and 
closes the catalytic site. Thereby, the enzyme adopts a ‘closed’ conformation that is important 
for its catalytic activity. Also, the catalytically important loop between Arg18 and Gly39, 
which is adjacent to α1 helix, forms a more organised β-hairpin motif in this ternary complex. 
It is possible that this loop folds differently in the apo-form, and the binding of ligands in the 
catalytic site drives it to fold in an ordered fashion. The substrate-gated conformational and 
structural changes has also been observed for other GT-B glycosyltransferases, such as in 
UDP:E. coli OtsA, Trehalose:ValL and UDP:T4 phage β-glucosyltransferase complexes 
(Gibson et al., 2004; Moréra et al., 2001; Zheng et al., 2012).  
OtsA enzyme from different organisms can utilise multiple nucleotide donors, with different 
proclivity (Gibson et al., 2002b; Killick, 1979; Pan et al., 2002; Silva et al., 2005). To 
exemplify, E. coli OtsA prefers UDP-glucose (Gibson et al., 2002b) whereas the M. tb OtsA 
has high specificity for ADP-glucose (Pan et al., 2002). Utilisation of UDP-glucose by               
M. smegmatis OtsA is greatly stimulated by heparin (Lapp et al., 1971). In this study, I 
demonstrated that M. thermoresistibile OtsA, like the enzymes from M. tuberculosis and           
M. smegmatis, is capable of using different glucose-donors, but has a strong preference for 
ADP-glucose. This is a conclusive evidence that mycobacterial OtsA catalyses the production 
of trehalose-6-phosphate from any nucleotide diphosphoglucose derivatives. The donor-
substrate bound structures of M. thermoresistibile OtsA provide a platform to understand the 
possible structural mechanistics that underlay substrate preferences. The preference for ADP-
glucose by M. thermoresistibile OtsA can be attributed to its nucleotide-binding pocket, 
which is enlarged and deepened, as compared to E. coli OtsA, due to substitution of residues 
in the hydrophobic core of the catalytic site (particularly, Ile295 and Phe339 in E. coli for 
Leu319 and Val363 in M. thermoresistibile OtsA). This allows the adenine moiety to fit 
perfectly, with its primary amine occupying the deep, buried spot in the catalytic pocket of                                       
M. thermoresistibile OtsA. Although Gibson and colleagues proposed that it is possible to 
model GDP is place of UDP in E. coli OtsA structure (Gibson et al., 2002a), the structure of 
M. thermoresistibile OtsA bound with GDP-glucose shows that it is not feasible for the 
guanine moiety to occupy the deep buried position, like the adenine moiety, due to steric 
clashes. This was positively confirmed by the biochemical data, which demonstrated GDP-
glucose was the second preferred substrate after ADP-glucose, and the thermodynamics of 
binding determined by ITC. The latter showed that in the tested conditions, heat of binding 
was observed only for ADP-glucose and not for any other NDP-glucose donor (GDP- or 
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UDP-glucose). Furthermore, conservation analysis also revealed that residues of the binding 
site interacting primarily with the nitrogenous base of the NDP-glucose donor are not 
conserved. This further support the possibility of diverse substrate preferences contributed 
due to amino-acid substitutions.   
The enzyme activity was independent of the divalent ions and the pH profile showed that the 
maximal activity was between the pH 7.0-8.5. The enzyme also exhibited a feedback 
mechanism, in which the activity of the recombinant TPS was reduced not only by trehalose-
6-phosphate, but also by trehalose to a relatively greater extent.  
The structural-functional analyses in this chapter demonstrate the suitability of                                          
M. thermoresistibile as a representative system. E. coli OtsA does not exhibit the properties 
necessary for a useful surrogate for TB drug discovery because it shares low sequence 
identity with M. tuberculosis OtsA (34%) and there are differences in regions important for 
the enzyme mechanism (Gibson et al., 2002b, 2004). Thus, the definition of a structure that is 
more closely similar to the M. tb enzyme was an essential pre-requisite for structure-guided 
drug discovery.  
This chapter also reports on the preliminary data to probe the druggability of                                    
M. thermoresistibile OtsA, for identification of hit fragments that could then be developed 
into specific inhibitors. The initial screening of a fragment library was done using a high-
throughput thermal shift assay. This resulted in identification of 15 fragments that bind in the 
absence of ADP and 7 fragments that bind in the presence of ADP, and have a stabilisation 
effect, as indicated by the increase in the melting point of the enzyme upon the binding of the 
fragments. Attempts were made to obtain structures of the enzyme bound with hits, but these 
were not fruitful. The hits were validated by an in vitro inhibition assay. Top fragments hits 
were shown to have an inhibitory effect the trehalose-6-phosphate synthase activity of the 
enzyme, with an IC50 value in the range of 0.5-1 mM. This serves as the start-point for a 
potential drug-discovery campaign against mycobacterial OtsA.  
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3.1 Summary 
 
Another target that was investigated in this study was Rv3030, a SAM-dependent 
methyltransferase in MGLP biosynthesis. The primary aim for this target was to define the 
structure of this enzyme, as there are no available structures of Rv3030 or its closely related 
orthologues in the database. This chapter describes the initial analyses of the amino-acid 
sequences of the protein and its orthologues in order to understand the residue conservation 
and the domain architecture, and a homology model of the protein structure. The design of 
constructs of full-length and truncated proteins and purification of proteins is also described, 
followed by crystallisation trials. Notwithstanding, crystallisation proved challenging. The 
success rate of obtaining well diffracting crystals suitable for structure determination studies 
was very poor, even though many trials were carried out under different conditions, with full-
length and truncated proteins. Only one condition yielded crystals of the full-length 
orthologous protein from M. smegmatis, which took a very long time to grow, diffracted only 
to very low resolution and had low reproducibility. The understanding of structural properties 
of this 6-O-methyltansferase was complemented by circular dichroism, and analytical 
ultracentrifugation, which indicated that protein was folded, monomeric and globular in 
nature.  
3.2 Introduction 
 
S-adenosyl-L-methionine (also known as SAM or AdoMet) is a ubiquitous nucleoside 
involved in many biochemical processes such as transmethylation, transsulphuration, and 
aminopropylation (Parveen and Cornell, 2011). SAM serves as an important co-factor for 
methylation of biologically active molecules, such as proteins, lipids, polysaccharides, DNA 
and RNA that is catalysed by SAM-dependent methyltransferases (SAM-MTs), and S-
adenosyl-L-homocysteine (SAH) is yielded as the byproduct (Kozbial and Mushegian, 2005). 
Methylations at oxygen (O-methylation), carbon (C-methylation) and nitrogen (N-
methylation) are vital in all organisms. SAM-MTs play a pivitol role in many cellular 
processes, such as biosynthesis, protein repair, detoxification, signal transduction, 
metabolism, chromatin regulation, and nucleic acid processing (Martin and McMillan, 2002; 
Schubert et al., 2003). Five different structural classes that have been identified for SAM-
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MTs based on the structure of their catalytic domains are the Rossmann-fold (Class-I), TIM 
barrel (Class-II), tetrapyrrole methylase (Class-III), SPOUT (Class-IV) and SET domain 
(Class-V) (Schubert et al., 2003).  
The majority of SAM-MTs belong to Class-I, the typical α/β Rossmann fold. In this 
arrangement, there are seven β-strands arranged in the order 3214576, forming a planar, 
central β-sheet (Figure 3.1). The β-strands alternate with six α-helices in the polypeptide, 
three arranged on each side of the β-sheet (Martin and McMillan, 2002). The N-terminal β-
strand is in the middle of the sheet and the seventh strand is antiparallel to all other strands 
(Kozbial and Mushegian, 2005). Most of SAM-MTs comply with this design, although 
occasionally the addition of an extra helix or β-hairpin, or deletion of one or both of β-strands 
6 and 7 are observed (Bujnicki, 2000; Martin and McMillan, 2002).  
 
 
 
 
  
 
  
 
FIGURE 3.1    Schematic representation of the Rossmann fold topology of SAM-MTs.  
Helices are shown as blue rectangles, strands as green arrows. SAM and substrate binding 
regions are shown. (Figure adapted from Martin and McMillan, 2002).          
The residues of the SAM-binding site are not conserved, but the co-factor occupies the same 
position of the structural fold in the enzyme and adopts same conformation (Martin and 
McMillan, 2002; Schubert et al., 2003). The SAM-binding region is formed by strands 1, 2 
and 3, the N-terminal part of the β-sheet, and there are only two conserved motifs in the 
C 
4 
SAM SUBSTRATE 
3 2 1 5 6 
N 
7 
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SAM-binding site of Class-I SAM-MTs (Martin and McMillan, 2002). Motif-I is the 
consensus sequence ‘GxGxG’ at the end of β1 strand that is considered to be characteristic of 
the SAM-binding site and is used to bind the adenosyl moiety of SAM (Schubert et al., 
2003). Motif II is a strongly conserved acidic residue present at the C-terminus of β2 strand 
that forms hydrogen bonds with both the ribose hydroxyls of SAM (Schubert et al., 2003). 
The substrate-binding region is formed by the C-terminal part of the β-sheet (Martin and 
McMillan, 2002). 
Methyltransferases of a particular structural class share high similarity of the structural fold, 
but it does not indicate conservation of the amino-acid sequence, and the sequence identity 
can be as low as 10% (Cheng and Roberts, 2001). Nevertheless, the mode of catalysis is 
conserved and methyltransferases catalyse direct transfer of methyl group to the substrate via 
an SN2-substitution mechanism (Horowitz et al., 2013).  
M. tb proteome has 121 methyltranferases that are involved in an array of cellular process 
(Grover et al., 2016). Of these, Rv3030 is an essential SAM-dependent methyltransferase 
involved in MGLP biosynthesis in M. tb that carries out methylation of glucoses of the 
MGLP chain at 6-O position. 6-O-methyl-D-glucose was first identified in Mycobacterium 
phlei (Lee and Ballou, 1964). The methyltransferase activity was described in M. phlei by 
Ferguson and Ballou, which was shown to transfer methyl groups from SAM to 6-O position 
of D-glucose in the oligosaccharides (Ferguson and Ballou, 1970). Later, a study by Grellert 
and Ballou demonstrated that for the methyltransferase activity to occur, the substrate needs 
to be partially acetylated, and provided evidence that the degree of acylation controls the 
positioning of O-methylation (Grellert and Ballou, 1972).  
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3.3 Basic Principles of Techniques Deployed 
 
3.3.1 Sedimentation-Velocity Analytical Ultra-Centrifugation (SV-AUC) 
This technique is used for quantitatively characterising the molecules in a solution. It 
provides useful information about sample homogeneity, size, hydrodynamic shape of 
molecules and association state, using first principles (Schuck, 2016).  
3.3.2 Ligand-Based Nuclear Magnetic Resonance 
Ligand based NMR techniques, saturation-transfer difference (STD) and Carr-Purcell-
Meiboom-Gill (CPMG), are important for screening ligands or small-chemical moieties that 
bind to protein. Signal intensities are observed for free and ligand-bound states. STD-NMR is 
based upon nuclear Overhauser effect (NOE), in which the saturation is transferred from 
protein to the bound ligand through spin diffusion. Two spectra are recorded, an ‘on-
resonance’ spectrum in which there is selective protein saturation and the magnetisation 
transfer to the bound ligand is measured, and an ‘off-resonance’ spectrum in which there is 
no protein saturation and thus, no magnetisation is transferred to the ligand. A difference 
spectrum is produced and intensities are observed only for the ligands that receive 
magnetisation transfer from the protein (Meyer et al., 2004; Viegas et al., 2011). A CPMG 
experiment is based on the relaxation properties of the molecules. Protein molecules have 
slow relaxation rate whereas ligands have faster relaxation times. When a ligand binds to the 
protein, there is a decrease in intensity of the measured signal because of the decrease of free 
molecules in solution that contribute to signal intensity. 
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3.4 Methodology 
 
3.4.1 Bioinformatic Analysis of the Primary Sequence, Sequence Alignment and  
                Prediction of Secondary Structures          
               
The full-length protein sequence of Rv3030 from M. tuberculosis was obtained from the 
TubercuList database (http://tuberculist.epfl.ch/) (Lew et al., 2011), and the sequence of its 
orthologue in M. smegmatis (MSMEG_2350) from the SmegmaList database (http:// 
mycobrowser.epfl.ch/smegmalist.html) (Kapopoulou et al., 2011) by searching with the gene 
name. The orthologous proteins in M. thermoresistibile, M. leprae, M. marinum,                    
M. abscessus, M. ulcerans and N. farcinica were identified by performing a protein-BLAST 
(blastp) search (http://blast.ncbi.nlm.nih.gov/Blast.cgi) (Altschul et al., 1990) with the          
M. tuberculosis protein sequence. The amino-acid sequences were obtained from National 
Centre for Biotechnology Information (NCBI) database (http://www.ncbi.nlm.nih.gov), and 
sequences were aligned using Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/) 
(Goujon et al., 2010; Sievers et al., 2014). The alignment was analysed and edited using 
Jalview (Waterhouse et al., 2009). The methyltransferase family and domain alignment 
coordinates were identified with Pfam (http://pfam.sanger.ac.uk) (Punta et al., 2012). The 
secondary structures of the protein were predicted using PSIpred 
(http://bioinf.cs.ucl.ac.uk/psipred/) (Jones, 1999). 
3.4.2 Protein Homology Modelling of Full-Length Orthologue of Rv3030 from  
    M. smegmatis 
A homology model of full-length protein of orthologue of Rv3030 in M. smegmatis was built 
using ModSuite (http://mordred.bioc.cam.ac.uk/modsuite), which encompasses BATON 
(based on Comparer), FUGUEALI and MODELLER (developed by Dr. Bernardo Ochoa, 
currently for the internal use of Blundell group members only). The templates for model 
building were identified using FUGUE (http://tardis.nibio.go.jp/fugue/prfsearch.html) (Shi et 
al., 2001) and the NCBI protein-BLAST. The protein sequences and PDB files of these 
templates were collected from the RCSB-Protein Data Bank (PDB) (http://www.rcsb.org) 
(Rose et al., 2013) by searching with their respective PDB IDs. The templates were first 
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structurally aligned to each other with help of BATON, and then a sequence-structure 
alignment of the query protein sequence with previously aligned templates was done with 
FUGUEALI. The final model of the protein was generated using MODELLER (Sali and 
Blundell, 1993). Dr. David Ascher and Dr. Bernardo Ochoa helped in in silico modelling of 
the protein structure. 
3.4.3 DNA, Bacterial Strains, Cloning and Expression Trials of Rv3030 and its  
                Orthologues  
 
Genomic DNA from M. tuberculosis H37Rv was obtained from ATCC (ATCC25618D-2),      
M. thermoresistibile (DSMZ 44167) DNA was obtained from the Deutsche Sammlung von 
Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany), and the genomic 
DNA from M. smegmatis strain mc2 155 was obtained from Dr. Nuno Empadinhas 
(University of Coimbra, Portugal). E. coli DH5α (Invitrogen) and BL21 (DE3) (New England 
Biolabs) strains were used for cloning and protein expression, respectively. 
Dr. Vitor Mendes did the cloning and expression trials of full-length Rv3030 and its 
orthologues from M. smegmatis and M. thermoresistibile, and provided the BL21 glycerol 
cell stock of the expression clone. Rv3030 and its orthologue in M. smegmatis were cloned in 
BamHI and HindIII restriction sites in pET-28a SUMO vector. Rv3030 orthologue in                  
M. thermoresistibile was cloned in NcoI and EcoRI restriction sites in pHAT-5 vector, 
containing a C-terminal, non-cleavable His6 tag and ampicillin resistance marker (obtained 
from Dr. Hyvönen’s group, Department of Biochemistry, University of Cambridge) (Peränen 
et al., 1996). 
Genes with truncations of varying lengths at N-terminus of full-length orthologue of Rv3030 
from M. smegmatis, were cloned into BamHI and HindIII restriction sites in pET-28a SUMO 
vector. Details of constructs are given in Table 3.1.  
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TABLE 3.1    Details of constructs and primers used for cloning and expression of truncated orthologues 
         of Rv3030 from M. smegmatis.   
 3030Msmg refers to the orthologue of Rv3030 from M. smegmatis. Restriction enzymes (BamHI       
 in forward primer and HindIII in reverse primer) are underlined. 
PCR was done as described in the section 2.4.3, but with 15 sec annealing step at 58°C, and 
20 sec extension step at 70°C. The amplicons generated and the vector were digested with the 
BamHI and HindIII restriction enzymes (ThermoScientific), and ligated using T4 DNA ligase 
(New England Biolabs) at room temperature for 10 min. The ligation products were 
transformed in E. coli DH5α competent cells, plated on LB agar-kanamycin plates, and 
incubated overnight at 37°C.  Single colonies were randomly picked and inoculated in LB 
media (Melford) with 30 μg/ml kanamycin (Sigma), and grown overnight at 37°C, with 
constant shaking at 220 rpm. Plasmids were isolated and purified according to the 
manufacturer’s protocol (ThermoScientific GeneJet Plasmid Miniprep Kit). The integrity of 
clones was confirmed by sequencing (DNA Sequencing Facility, Department of 
Biochemistry, University of Cambridge, UK), and plasmids were transformed into E. coli 
BL21 (DE3) strain. 
CONSTRUCT DESCRIPTION PRIMER SEQUENCE (5'-3') 
-4N 3030Msmg 
pET-28a SUMO 
4 residues truncated 
from the N-terminus 
Forward- ATAGGATCCGATAACGCCCTTCCTTCGGC 
Reverse- ATTAAGCTTTCATGGCCGCACTGCTATCG 
-8N 3030Msmg 
pET-28a SUMO 
8 residues truncated 
from the N-terminus 
Forward- ATAGGATCCCCTTCGGCTTTACCCCTCAC 
Reverse- ATTAAGCTTTCATGGCCGCACTGCTATCG 
-14N 3030Msmg 
pET-28a SUMO 
14 residues truncated 
from the N-terminus 
Forward- ATAGGATCCACCGGCGAGCGGACCATCCC 
Reverse- ATTAAGCTTTCATGGCCGCACTGCTATCGCC 
-15N 3030Msmg 
pET-28a SUMO 
15 residues truncated 
from the N-terminus 
Forward- ATAGGATCCGGCGAGCGGACCATCCCGG 
Reverse-  ATTAAGCTTTCATGGCCGCACTGCTATCGCC 
-17N 3030Msmg 
pET-28a SUMO 
17 residues truncated 
from the N-terminus 
Forward- ATAGGATCCCGGACCATCCCGGGCCTGG 
Reverse- ATTAAGCTTTCATGGCCGCACTGCTATCGCC 
-24N 3030Msmg 
pET-28a SUMO 
24 residues truncated 
from the N-terminus 
Forward- ATAGGATCCGAGGAGAACTACTGGTTCCG 
Reverse- ATTAAGCTTTCATGGCCGCACTGCTATCG 
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Expression trials of truncated constructs were done as described in the section 2.4.4.1, but 
kanamycin was used as the selection marker at final concentration of 30 μg/ml. The proteins’ 
identity was confirmed by MALDI fingerprinting (PNAC facility, Department of 
Biochemistry, University of Cambridge, UK). 
3.4.4 Expression and Purification of Recombinant Orthologues of Rv3030  
 
3.4.4.1 Expression and Purification of Recombinant Full-Length Orthologue of 
Rv3030 from M. smegmatis 
The recombinant orthologous protein of Rv3030 from M. smegmatis, with a cleavable, N-
terminal His6-SUMO tag was purified from the soluble fraction. 
Culture growth and expression: A loop of frozen BL21 cells of the expression clone was 
plated on LB-agar-kanamycin plate and incubated overnight at 37°C. All the cells were 
collected from the plate and inoculated in 100 ml LB media with 30 μg/ml kanamycin. The 
culture was grown overnight at 37°C, with constant shaking at 220 rpm. The culture was 
scaled up to 2 litres by adding 30 ml of the overnight culture in each 1-litre fresh LB media 
with kanamycin. Cells were grown at 37°C till OD600 reached 0.8, cooled down to 20°C, and 
induced with 0.5 mM IPTG for protein expression, and grown overnight (14-16 hours) at 
20°C with constant shaking. 
Cell harvesting and lysis: Cells were harvested by centrifugation (4200 x g, 30 min, 4°C) and 
the pellet was suspended in buffer (50 mM Tris-HCl pH 7.5, 20 mM Imidazole, 500 mM 
NaCl, cocktail of protease inhibitor (Roche)) and, 10 μg/mL DNase-I (Sigma) and 5 mM 
MgCl2 were added to the cell suspension. The cells were lysed by passing them through 
Emulsiflex (GlenCreston) four times, followed by centrifugation (23,500 x g, 30 min, 4°C) to 
remove cell debris. The supernatant was collected and filtered using 0.2 μm syringe filter 
(Sartorius Stedim). 
Affinity purification: A pre-packed sepharose column (HiTrap IMAC FF, 5 ml, GE 
Healthcare) was charged with 0.1 M NiSO4, according to the manufacturer’s protocol, and 
equilibrated with purification buffers. Supernatant was bound to the column with the help of 
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a peristaltic pump at room temperature. The column was washed for 30 column volume (CV) 
with wash buffer (50 mM Tris-HCl pH 7.5, 20 mM Imidazole, 500 mM NaCl), and 20 ml 
protein was eluted with elution buffer (50 mM Tris-HCl pH 7.5, 500 mM Imidazole, 500 mM 
NaCl). The purity of the protein was determined by SDS-PAGE.  
Cleavage of tag, dialysis and reverse binding: The SUMO tag was subsequently cleaved with 
Ulp1 protease, after affinity purification. Ulp1 protease was added to the eluted protein at a 
ratio of 1 mg Ulp1 protease to 200 mg protein, to cleave the His6-SUMO tag. The protein-
protease mixture was then dialysed in the dialysis buffer (20 mM Tris-HCl pH 7.5, 20 mM 
Imidazole and 500 mM NaCl), using 10 kDa MWCO dialysis membrane (Spectrum Labs), 
and incubated overnight at 4°C. The digested protein was bound to the Ni-sepharose column 
to separate the tag-less protein from the tag. This is known as reverse binding, where the 
His6-SUMO tag and Ulp1 protease bound to Ni-sepharose column while the tag-less target 
protein flowed through. Flow through containing target protein was collected and 
concentrated by centrifuging (4500 x g, 30 min, 4°C) in 10 kDa MWCO concentrators. 
Gel filtration: The protein was loaded onto a Superdex-200 column (HiLoad 16/600 
Superdex 200 pg, GE Healthcare), pre-equilibrated with 100 mM NaCl and 20 mM Tris-HCl 
pH 7.5. Purification was done at room temperature. Protein was eluted in 1 ml fractions and 
the purity of fractions was determined by SDS-PAGE. The purest fractions were pooled and 
concentrated by centrifuging (4500 x g, 30 min, 4°C) in 10 kDa MWCO concentrators. The 
purity of the protein was assessed with SDS-PAGE and the final protein concentration was 
measured at 280 nm with NanoDrop spectrophotometer (Labtech, UK). 
N.B.    Another batch of full-length recombinant orthologous protein of Rv3030 from                             
M. smegmatis was purified but the fusion tag was not cleaved. 
3.4.4.2 Expression and Purification of Recombinant Full-length Orthologue of 
Rv3030 from M. thermoresistibile 
 
The full-length recombinant orthologue of Rv3030 from M. thermoresistibile, with C-
terminus, non-cleavable His6 tag was expressed and purified from the soluble fraction. The 
protocol for expression and purification described in the section 3.4.4.1 was used with some 
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modifications. 100 μg/ml ampicillin was used as the selection antibiotic. There was no tag 
cleavage and the protein was dialysed overnight in 100 mM NaCl and 20 mM Tris-HCl pH 
7.5 buffer. Gel filtration was done as described but at 4°C. 
3.4.4.3 Expression and Purification of Recombinant Truncated Orthologues of 
Rv3030 from M. smegmatis 
 
The truncated recombinant orthologues of Rv3030 from M. smegmatis, with N-terminus, 
cleavable His6-SUMO tag were expressed and purified from the soluble fraction. The 
protocol for expression and purification was as described in the section 3.4.4.1.  
3.4.5 Crystallisation of Orthologues of Rv3030  
 
3.4.5.1 Crystallisation Screening of Full-Length Orthologue of Rv3030 from  
M. thermoresistibile 
 
Initial crystallisation screening was performed for the full-length orthologue of Rv3030 from         
M. thermoresistibile with C-terminal His6 tag, using a sitting-drop vapour-diffusion method 
at 18˚C. The screens used were: classics, pH clear-I (Qiagen), PEGs-I (Qiagen) and wizard 
I&II. 0.3 µl protein at concentrations of 10 mg/ml and 20 mg/ml, was respectively mixed 
with the well solution in two different protein: precipitant ratios of 1:1 and 1:2 using the 
Phoenix robot.  
3.4.5.2 Crystallisation Screening of Full-Length Untagged Orthologue of Rv3030 
from M. smegmatis 
 
A. Initial crystallisation screening: This was done as described in section 3.4.5.1, but the 
protein only at concentration of 20.5 mg/ml was used. 
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B. Co-crystallisation with SAM and SAH: Protein (at 20 mg/ml) was incubated with 2 
mM SAM and 2 mM SAH, in separate reactions, on ice for 30 minutes. Initial 
crystallisation screening was done as described in section 3.4.5.1. 
 
C. Co-crystallisation with MgCl2: Protein (at 10 mg/ml) was incubated with 10 mM 
MgCl2 at room temperature for 30 minutes. The screens used were: classics, pH clear-I, 
pH clear-II (Qiagen), PEGs-I, PEGs-II (Qiagen), cryo (Qiagen), MPD (Qiagen) and 
wizard I&II. 0.2 µl protein-MgCl2 mixture was mixed with the well solution in two 
different protein: precipitant ratios of 1:1 and 1:2 using the Phoenix robot. 
  
D. Limited proteolysis: Limited proteolysis of the full-length protein was performed using 
JBS Floppy Choppy kit (Jena Biosciences). Pre-screening was done to identify the 
suitable protease, according to manufacture’s protocol. An additional, time-dependent 
activity of protease was done with same protocol, except that the incubation times were 
30 minutes, 1 hour and 2 hours. After determining the suitable protease, the 
concentration required and the time for digestion (in this case: chymotrypsin, 1 μg of 
protease for 100 μg protein, digestion for 2 hours); protease and protein were incubated 
at room temperature for 2 hours. The reaction was stopped by adding 1 mM PMSF. 
Initial crystallisation screening with the digested protein was done. The screens used 
were: classics, pH clear-I, pH clear-II, PEGs-I, PEGs-II, cryo, MPD and wizard I & II. 
0.2 µl digested protein was mixed with the well solution in a ratio of 1:1 using the 
Phoenix robot. 
 
E. Optimisation of phase separation condition: A phase separation condition (4M sodium 
formate) identified from the initial screening of full-length protein was optimised, using 
the hanging-drop vapour-diffusion method, as follows: 
1. A grid was prepared for different concentrations of protein (12, 25, 30 and 50 mg/ml) 
and sodium formate (0.5, 1, 2, 3, 4 and 5 M) using a 24-well Linbro plate (Molecular 
Dimensions). 
2. A grid was set with different concentrations of sodium formate (0.5, 1.0, 2.0, 3.0, 4.0, 
5.0 M), 0.1 M Tris-HCl buffer at varying pH values (7.0, 7.5, 8.0, 8.5), but with 
constant NaCl concentration (0.2 M). Protein at 10 mg/ml concentration was used for 
crystallisation. 
3. A grid was set with the same conditions in (2) except that NaCl was not added. 
Chapter-3                    Bioinformatic Analysis, Expression, Purification and Crystallisation of Rv3030 
127 
 
F. Optimization of crystallisation condition: The condition: 4 M sodium formate, 0.1 M 
Tris-HCl pH 8.5, 0.2 M NaCl, where crystals were formed, was further optimised using 
the hanging-drop vapour-diffusion method, as follows: 
1. Reproducibility of the crystal condition: A grid was set with different concentrations 
of sodium formate (2.0, 2.5, 3.0, 3.5, 4.0, 4.5 M), 0.1 M Tris-HCl buffer at varying 
pH values (7.5, 8.0, 8.5, 9.0), but with constant NaCl concentration (0.2 M). Protein at 
10 mg/ml concentration was used for crystallisation. 
2. Streak seeding: The same condition where crystals were obtained was set up. Drops 
(of protein and precipitant at 1:1 ratio) were seeded with previously formed crystals 
using a cat whisker at different time points: immediately, 1 hour, 3 hours, 5 hours, 1 
day, 2 days, 3 days and 1 week after setting drop. 
3. Additive screening: Additives were added to the condition in which crystals were 
obtained. Additive screen HT from Hampton Research was used. 
4. A grid was set with concentrations of sodium formate at narrow differences (3.90, 
3.95, 4.00, 4.05, 4.10, 4.15 M), 0.1 M Tris-HCl buffer at varying pH (7.5, 8.0, 8.5, 
9.0), but with constant NaCl concentration (0.2 M). Protein at 10 mg/ml concentration 
was used for crystallisation. 
5. Matrix seeding (in the same condition where crystals were previously obtained): A 
seed stock of crystals was prepared by fishing out all crystals along with the mother 
liquor and pooling them together in a vial, containing a bead (Hampton Research). 
Crystals were crushed by vortexing in intervals for 15minutes. Drops (1 μl protein +   
1 μl precipitant + 0.2 μl seeds) were set using Oryx robot (Douglas Instruments). 
6. A grid was set with different protein concentrations (2, 3.5, 5, 6.5, 8, and 9.5 mg/ml) 
and different protein: precipitant ratios (1:1, 1:2, 1:3, and 1:4) in the same condition 
where low diffracting crystals were previously obtained.  
7. Screening different salts: A grid was set with different concentrations of sodium 
formate (2.0, 2.5, 3.0, 3.5, 4.0, 4.5 M), different salts (sodium chloride, sodium 
citrate, sodium formate, sodium acetate, Na/K tartrate, ammonium acetate, 
ammonium chloride, sodium melonate) (0.2 M), but with 0.1 M Tris-HCl buffer pH 
8.0. Protein at 10 mg/ml concentration was used for crystallisation. 
 
G. Matrix seeding using Classics screen: The seed stock was diluted 5 times with the 
mother liquor, and was used for seeding and screening new crystal conditions, using the 
sitting-drop vapour-diffusion method. 
Chapter-3                    Bioinformatic Analysis, Expression, Purification and Crystallisation of Rv3030 
128 
 
H. Co-crystallisation with SAM and maltohexaose in crystal condition: Protein (at 5 
mg/ml and 10 mg/ml) was incubated with 2 mM SAM and 2 mM maltohexaose, in 
separate reactions, on ice for 30 minutes before setting crystallisation in the condition: 4 
M sodium formate, 0.1 M Tris-HCl pH 8.5 and 0.2 M NaCl. For each protein 
concentration and each ligand, different protein: precipitant ratios were set (1:1, 1:2, and 
1:3). Crystallisation was performed using the hanging-drop vapour-diffusion method. 
 
 
3.4.5.3 Crystallisation Screening of Full-Length Tagged Orthologue of Rv3030 from 
M. smegmatis 
 
Initial screening trials were done with the tagged protein as stated in section 3.4.5.1, but the 
protein only at concentration of 12 mg/ml was used. 
3.4.5.4 Crystallisation Screening of Truncated Orthologues of Rv3030 from 
M. smegmatis 
 
A. Initial screening trials: These were done as described in section 3.4.5.1, and each of the 
truncated protein, at a concentration of 20.5 mg/ml, was screened. 
 
B. Crystallisation of truncated proteins in the condition where full-length protein 
crystallised:  A grid was set where conditions with concentrations of sodium formate at 
narrow differences (3.90, 3.95, 4.00, 4.05, 4.10, 4.15 M), 0.1M Tris-HCl buffer at 
varying pH (7.5, 8.0, 8.5, 9.0), but with constant NaCl concentration (0.2 M) were 
screened. Crystallisation was set for each of the truncated protein (at 10 mg/ml 
concentration). 
 
C. Optimisation of microcrystalline condition for a truncated protein (17 residues 
truncated at N-terminus): The condition (1.8 M ammonium sulphate, 0.1 M MES pH 
6.5, 0.01 M CoCl2, 10 mg/ml protein) where microcrystals were formed was further 
optimised, using the hanging-drop vapour-diffusion method, as follows: 
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1. A grid was set with different concentrations of ammonium sulfate (0.9, 1.2, 1.5, 1.8, 
2.1, 2.4 M), 0.1 M MES buffer at varying pH values (5.5, 6.0, 6.5), 0.1 M HEPES 
buffer at varying pH values (7.0, 7.5), 0.1 M Tris-HCl buffer at varying pH values 
(7.5, 8.0, 8.5), and with constant CoCl2 concentration (0.01 M). Protein at 10 mg/ml 
concentration was used for crystallisation. 
2. Additive screening: Additives were added to the condition in which crystals were 
obtained. Additive screen from Hampton Research was used. 
3. A grid was set with different concentrations of ammonium sulfate (0.9, 1.2, 1.5, 1.8, 
2.1, 2.4 M), and different buffers (0.1 M Na/K PO4  pH 6.0, 0.1 M Bis-Tris-HCl pH 
6.0, 0.1 M MES pH 6.5, 0.1 M MOPS pH 6.5, 0.1 M ADA pH 6.5,  and 0.1 M Tris-
HCl pH 7.0), and with constant CoCl2 concentration (0.01 M). Protein at 10 mg/ml 
concentration was used for crystallisation. 
 
D. Optimisation of phase separation condition for a truncated protein (17 residues 
truncated at N-terminus): The condition (1.8 M ammonium sulphate, 0.1 M MES pH 
6.5, 0.01 M CoCl2, 0.5% PVP-K15, 10 mg/ml protein) where there was a phase 
separation was further optimised, using the hanging-drop vapour-diffusion method. A 
grid was set with different concentrations of ammonium sulphate (0.9, 1.2, 1.5, 1.8, 2.1, 
2.4 M), 0.1 M MES buffer at varying pH values (5.5, 6.0, 6.5), 0.1 M HEPES buffer at 
varying pH values (7.0, 7.5), 0.1 M Tris-HCl buffer at varying pH values (7.5, 8.0, 8.5), 
and with constant CoCl2 concentration (0.01 M) and PVP-K15 (0.5%). Protein at 10 
mg/ml concentration was used for crystallisation. 
 
 
3.4.6 X-ray Data Collection and Processing 
 
The crystals of full-length orthologue of Rv3030 from M. smegmatis were first checked in-
house with the X-ray diffractometer (ICARUS). Crystals were cryoprotected by soaking them 
briefly in a solution containing the mother liquor and 15% MPD, and were flash frozen in 
liquid nitrogen for data collection. An X-ray diffraction dataset of the crystal was collected at 
I03 beamline of Diamond Light Source synchrotron (DLS, Oxford, UK). Data were 
processed with MOSFLM (MRC, Laboratory of Molecular Biology, Cambridge, UK) (Battye 
et al., 2011).  
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3.4.7 Circular Dichroism of Orthologue of Rv3030 from M. smegmatis 
 
The full-length orthologue of Rv3030 from M. smegmatis at 0.25 mg/ml, in a buffer of          
20 mM sodium phosphate pH 7.5 and 50 mM NaF, was placed in quartz cuvette with 1 mm 
path-length (Hellma). A wavelength scan was recorded for the sample on the Aviv model 410 
spectropolarimeter from 260 nm to 190 nm, with 1 nm increments and 3 sec averaging time. 
A control run was performed with the buffer. For the buffer, the raw data from three 
measurements were averaged. For the protein sample, the raw data from three measurements 
were averaged, corrected for the buffer signal, and smoothed. The CD signal was reported in 
theta machine units (in millidegrees). It was converted into mean residual ellipticity (MRE 
[θ], in degree cm2 dmol-1 residue-1), using the following equations: 
                                          MRE = (MRW x millidegrees) / 10 x d x c 
                                 where,     d- path length of the cuvette in cm  
                                                 c- concentration in mg/ml 
                                         MRW- mean residual weight 
                                        MRW= molecular mass/ (N – 1) 
                                 where,    N- number of amino acids 
The data was deconvoluted using CDSSTR programme on the DichroWeb 
(http://dichroweb.cryst.bbk.ac.uk/) (Whitmore and Wallace, 2004).  
3.4.8 Sedimentation Velocity-Analytical Ultracentrifugation of Orthologue of 
Rv3030 from M. smegmatis 
 
The full-length protein was dialysed overnight in 50 mM NaCl, 20 mM sodium phosphate pH 
6.5 buffer. Sedimentation velocity-analytical ultracentrifugation (SV-AUC) was performed 
with an XL-1 analytical ultracentrifuge (Beckman Optima), with double-sector charcoal filled 
EPON cells, and AN60Ti rotor. The concentration of protein used was 1.2 mg/ml. The buffer 
Chapter-3                    Bioinformatic Analysis, Expression, Purification and Crystallisation of Rv3030 
131 
 
in which protein was dialysed was used as the reference. The samples were spun at a speed of 
50,000 g at 20˚C. Independent measurements were made using both the UV absorbance and 
interference optical systems. A total of 300 scans were recorded at 280 nm. The data were 
analysed using SEDFIT software (Schuck, 2000).  
3.4.9 Ligand-Based NMR  
The 1H-CPMG experiment spectrum was recorded at 298 K on Bruker AvanceIII AV600 
spectrometer equipped with HCNF probe and actively shielded z-gradients. Samples (600 μl) 
containing 1 mM SAM and 10% D2O, in the presence and absence of 10 μM protein, were 
prepared in 50 mM NaCl and 20 mM sodium phosphate pH 6.5 buffer. Samples were placed 
in 3 mm NMR tubes for data acquisition. The resulting spectra were analysed with Bruker 
TopSpin software. 
 
 
3.4.10 Isothermal Titration Calorimetry 
 
The thermodynamics of the binding between the full-length orthologue of Rv3030 from                   
M. smegmatis and its co-factor, SAM, was characterised using a Microcal ITC200 titration 
calorimeter (Microcal) at 25 ºC. Protein at concentration of 50 µM in 20 mM Tris-HCl pH 
7.5, 100 mM NaCl was used for all titrations. 0.5 mM co-factors were injected in 2 µl 
aliquots. A total of 18 injections with 140 sec spacing was done. The injections were further 
continued to achieve saturation, by re-filling the syringe with the titrant, while keeping the 
cell untouched. Data were concatenated and analysed by fitting a simple single-site model 
using Origin software (Microcal). 
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3.5 Results 
3.5.1 Sequence Alignment and Analysis of Rv3030 and its Orthologues 
MGLPs are found in mycobacteria and closely related species in Nocardia and 
Corynebacterium. The BLAST analysis of M. tuberculosis Rv3030 protein sequence shows 
that it has orthologues in closely related species in Mycobacteria and Nocardia, including           
M. thermoresistibile (69% identity), M. smegmatis (MSMEG_2350 (74% identity), M. leprae 
(77% identity), M. marinum (69% identity), M abscessus (70% identity), M. ulcerans (79% 
identity) and N. farcinica (64% identity). The sequences were aligned using Clustal Omega, 
and the predicted secondary structure elements of Rv3030 orthologue from M. smegmatis 
were mapped on the alignment (Figure 3.2). 
The sequence alignment of Rv3030 with its orthologues showed that protein is well 
conserved in the mycobacterial and the closely related Nocardia species. The residues in the 
methyltransferase domain are highly conserved and span about one-third of the protein. The 
alignment coordinates of this domain in Rv3030 and its orthologues from M. smegmatis and          
M. thermoresistibile, as obtained from the Pfam database, are given in Table 3.2. The well-
conserved acidic residue, glutamic acid, and the consensus sequence GxGxG (x is any 
residue) of motif-I, and the conserved acidic residue of motif-II are pesent.  
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FIGURE 3.2    Sequence alignment of Rv3030 and its orthologues. 
The sequence alignment, produced by Clustal Omega, shows that the protein is highly conserved 
between all the species. Predicted secondary structural features are illustrated as- α- helix: 
yellow tube; β-strand: red arrow. Motif-I of SAM-MTs, containing the well-conserved acidic 
residue (glutamic acid) and the consensus sequence “GxGxG”, is marked with a black box. 
Motif-II, the conserved acidic residue Asp (D), is marked with a maroon box. Alignment 
coloured according to conservation. 
TABLE 3.2    Alignment coordinates of the methyltransferase domain in Rv3030 and its orthologues. 
 As given in the Pfam database. 
PROTEIN 
METHYLTRANSFERASE DOMAIN ALIGNMENT 
COORDINATES (RESIDUE RANGE) 
Rv3030 66-157 
Rv3030 orthologue from M. smegmatis 50-141 
Rv3030 orthologue from M. thermoresistibile 56-147 
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3.5.2 Homology Model of Full-Length Orthologue of Rv3030 from M. smegmatis 
A homology model was generated for the full-length, untagged orthologue of Rv3030 from    
M. smegmatis. This helped in understanding the overall structural properties of the protein, 
and formed the basis for preparation of different constructs for expression, purification and 
structure determination. The templates used for building model were methyltransferase 
proteins with structures available in PDB (PDB ID of templates-2GS9, 3EGE, 1VL5, 3CCF, 
3CC8) (Table 3.3).  
 
TABLE 3.3    Structural templates used for homology modelling of orthologue of Rv3030 from 
                        M. smegmatis. 
The model showed that the protein had one domain, with centre of it spanned by a β-sheet, 
typical of the Rossmann fold topology of SAM-MTs. An important feature observed was that 
a few residues at the N-terminus of the protein were unstructured (Figure 3.3).    
 
 
 
 
 
 
PDB ID PROTEIN ORGANISM 
2GS9_A 
 
Hypothetical protein TT1324 Thermus thermophilus HB8 
3EGE_A 
 
Putative methyltransferase from antibiotic 
biosynthesis pathway (YP_324569.1) 
Anabaena variabilis ATCC 
29413 
1VL5_B Putative methyltransferase (BH2331) Bacillus halodurans C-125 
3CCF_B 
 
Putative methyltransferase (YP_321342.1) Anabaena variabilis ATCC 
29413 
3CC8_A Putative methyltransferase (bce_1332) Bacillus cereus ATCC 
10987 
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                                10        20        30        40        50   
3CCF        (  19 )                  kh--sf----------vw--qygedLlqlLn--pqp 
3EGE        (  12 )                   s--qtr---------vpDirIVnaIinlLn--lpk 
1VL5        (  28 )                   g---------------sd---lakLmqIAa--lkg 
2GS9        (   2 )                  dpfaslaeayeawygtplGayViaeeeraLkgLlPp 
3CC8        (  19 )                                      avnpnLlkhIk---ke 
3030M.smg               MGDPDNALPSALPLTGERTIPGLAEENYWFRRHEVVYQRLAHRCAG---- 
                                                            aaaaaaa       
 
                                60        70        80        90        100  
3CCF        (  39 )    gefILDLGCgtGqlTekIaqsgAeVlGTdnaatmIekArqn-----yphl 
3EGE        (  34 )    gsvIADIgAgtGgySvaLAnqgLfVyAVepsivmrqqavv------hpqV 
1VL5        (  43 )    neeVLDVaTggGhvAnaFApfVkkVVAFdltedilkvArafIegnghqqV 
2GS9        (  38 )    gesLLEVgAgTGyWLrrLpYp--qkvGVepseaMlavGrrrA-----peA 
3CC8        (  32 )    wkeVLDIgCssGalGaaIkengTrVSGIeafpeaAeqAk--------ekL 
3030M.smg              -RDVLEAGCGEGYGADLIADVARRVIGLDYDEATVAHVRAR-----YPRV 
                         bbbbb     aaaaaa     bbbbb   aaaaaaaa            
 
                                110       120       130       140       150  
3CCF        (  84 )    -hFdvadAr--nFrvd-kpLdAVFSnamLhwvkepeaAIasIhqaLksGg 
3EGE        (  78 )    -ewftgyAe--nLaLpdksVdGVISIlaIhhfshlekSFqeMqrIIrdgt 
1VL5        (  93 )    -eyvqgdAe--qMpFtderFhIVTCriaAhhfpnPasFVseAyrVLkkgg 
2GS9        (  81 )    -tWvrawGe--aLpfpgesFdVVLLFttLEfvedverVLleArrVLrpgg 
3CC8        (  74 )    dhVvlgdIetmdMpYeeeqFdCVIFgdvLEhlfdPwaVIekVkpyIkqng 
3030M.smg              DIRHGNLAE---LPLPDASVDVVVNFQVIEHLWDQAQFVSECFRVLRPGG 
                        bbb               bbbbbbb  333   aaaaaaaaaaabbbbb 
 
                                160       170       180       190       200  
3CCF        ( 130 )    -rFVAeFGGkgNIkyIleaLynaLetlgihnPqalnpWyfPsigeYvniL 
3EGE        ( 125 )    -IVLLTfDIrlA-qrI--WLydYFpFL-we--dal-rf-lp-ldeQinlL 
1VL5        ( 140 )    qLLLVDnSApe--ndafDvfYnyVekerdy--sHh-rA-wk-ksdWlkmL 
2GS9        ( 128 )    ALVVGVlEa-lS---pWAalyrrlGekgvl-pwaqArF-la-redLkall 
3CC8        ( 124 )    -vILASIpNvsH-IsVlapllagnwtyteygLldkthirfFtfneMlrMF 
3030M.smg              VFLVSTP-------------NRITFSPGRDTPLNPFHTRELNAAELTELL 
                        bbbbbb        aaaaaa   aa                aaaaaaaa 
 
                                210       220       230       240       250  
3CCF        ( 179 )    ekq-gFdVtyaalf---nrpttla-----egefGManWIqmfAsaFLvgL 
3EGE        ( 165 )    qenTkrrVeaipflLphdLsDlFaAAAWrrpelYlkaeVragIssFal-a 
1VL5        ( 183 )    eea-gFeleelhcf---hk--tfi----------FedWCdrm------nv 
2GS9        ( 171 )    g---pPeaegeAVfL--ap--eah-------------------------- 
3CC8        ( 172 )    lkA-GYsiskvdrvy---v-----------------d-hkmy-------- 
3030M.smg              ETA-GFEVEDTLGVFHGAGLAELDA---RHGGSIIEAQVQRAVADAPW-- 
                       aa    bbbbbb                                       
 
                                260       270       280       290       300  
3CCF        ( 220 )    tpdqqvqLirkVeatLq-----dkLyh-q--------esWtAdyrrIrIv 
3EGE        ( 214 )    nqdlvekGlelLtadlnngeWirky--gei---hh-lqeIdIGyrFIyTt 
1VL5        ( 211 )    ttekkqeLSdfIkskpt--eyyqkF---kIvvedgrVysFrgesILMkAr 
2GS9        ( 188 )    -ppyeeadlagrra------------------------gnrPALYLGrWr 
3CC8        ( 192 )    -eplIeelygickkyrl-g------sgfma---eT---vVfqYIIeAeks 
3030M.smg              DEQLLADVAAVRTDDFDLTPAAERDIDDSLDLVAIAVRP----------- 
                        aaaaaaaaaaaa                          b   bbbbbb  
                             
3CCF        ( 256 )    Sikaq 
3EGE        ( 258 )    -l    
1VL5        ( 256 )    kpt   
2GS9                         
3CC8        ( 228 )    ql    
3030M.smg             ----- 
Solvent inaccessible    UPPER CASE X  hydrogen bond to main chain amide  bold x                           
Solvent accessible  lowercase  x  hydrogen bond to main chain carbonyl underline x 
α-helix   red  x  310 helix    maroon x 
β-strand                    blue  x  positive phi   italic x    
A. 
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FIGURE 3.3    Homology model of three-dimensional structure of full-length orthologue of Rv3030 from  
            M. smegmatis. 
A. Structural alignment of sequences of target protein and templates (produced by FUGUEALI). A 
part of N-terminus of target protein (highlighted in yellow) does not align to any secondary 
structure element. The methyltransferase domain of all the proteins aligns fairly well. 
(3030M.smg refers to Rv3030 orthologue from M. smegmatis). 
B. Model of the target protein. Unstructured strand at the N-terminus of protein (corresponding to 
the yellow highlighted part in the structural alignment above) is coloured yellow. 
 
 
 
 
 
B. 
N
 
C 
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3.5.3 Full-length Orthologue of Rv3030 from M. thermoresistibile 
3.5.3.1 Expression and Purification 
 
The expression trials indicated that SUMO-tagged M. tuberculosis protein was insoluble and 
found in inclusion bodies (Dr. Vitor Mendes, personal communication). Thus, orthologues 
from M. thermoresistibile and M. smegmatis were expressed and purified. 
The expression of the orthologous M. thermoresistibile gene in E. coli resulted in high-level 
production of recombinant protein fused with non-cleavable His6 tag at its C-terminus. A 
strong band was seen at 33 kDa. The gel filtration profile showed that the recombinant His6-
tagged protein behaved as a monomer in solution. The protein obtained was pure enough, as 
seen on the gel, for crystallisation experiments (Figure 3.4). 
3.5.3.2 Crystallisation Trials  
 
The tagged M. thermoresistibile orthologous protein was screened against approximately 
1600 crystallisation conditions at two different concentrations of protein, 10 mg/ml and        
20 mg/ml. Heavy precipitation was observed in the majority of conditions, with clear drops in 
a few conditions. However, no phase separation or crystals were observed. 
Since there was no crystallisation lead with the orthologue of Rv3030 from                                       
M. thermoresistibile, the possibility of obtaining crystals from the M. smegmatis orthologue 
was explored. 
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FIGURE 3.4   Expression and purification of C-terminus His6-tagged orthologue of Rv3030 from  
M. thermoresistibile. 
A. Metal affinity purification of His tagged protein on Ni-sepharose column. (MWM: molecular 
weight marker, P1 and P2: tagged protein, FT: flow through, S: supernatant, L: cellular lysate) 
B. Gel filtration of fusion protein on Superdex-200 column. (MWM: molecular weight marker, F1 
to F8: protein fractions) 
C. The gel filtration profile. 
 
 
3.5.4 Full-length Orthologue of Rv3030 from M. smegmatis 
 
3.5.4.1 Expression and Purification of the Full-Length Orthologue of Rv3030 from  
M. smegmatis (with subsequent tag cleavage) 
 
The 42 kDa recombinant protein with cleavable SUMO tag at its N-terminus was purified by 
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      MWM  F1  F2  F3   F4    F5   F6   F7   F8                                                                                              MWM     S     FT    P1    P2     P3               MWM     1           2         3 
affinity chromatography and the tag was subsequently cleaved. The trace from the gel 
filtration run showed that the tag-less protein behaved as a monomer in the solution (Figure 
3.5).  
 
 
 
 
 
 
 
 
 
 
FIGURE 3.5    Expression and purification of full-length orthologue of Rv3030 from M. smegmatis (with   
                          subsequent tag cleavage). 
A. Metal affinity purification of SUMO tagged protein on Ni-sepharose column. A strong band 
seen at MW higher than that of the protein corresponds to the SUMO-tagged protein. (MW of 
protein- 28.1 kDa, MW of SUMO tag- 13.8 kDa, total MW of tagged protein- 42 kDa).  
(MWM: molecular weight marker, S: supernatant, FT: flow through, P1 to P3: tagged protein) 
B. Cleavage of SUMO tag by UlpI protease and reverse binding on Ni-sepharose column.  
(1: tagged protein, 2: tag less protein obtained in the flow through, 3: SUMO tag). 
C. Gel filtration of tag-less protein on Superdex-200 column. (MWM: molecular weight marker, F1 
to F8: protein fractions).     
D. The gel filtration profile. 
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3.5.4.2 Crystallisation of Full-Length, Untagged Orthologue of Rv3030 from 
M. smegmatis 
 
400 conditions were initially screened with untagged protein at a concentration of 20 mg/ml. 
Heavy precipitation was observed in the majority of the conditions. However, a phase 
separation was observed in the condition containing 4 M sodium formate, and the UV trace 
confirmed the solution with protein was separated (Figure 3.6).  
   
 
 
 
 
                                                                       
FIGURE 3.6    Phase separation of full-length, untagged orthologue of Rv3030 in M. smegmatis. 
A. Phase separation in the condition containing 4 M sodium formate. 
B. UV image of the same condition confirming separation of protein phase.  
 
 
 
 
The above condition was optimised further to obtain crystals, by creating a pH gradient and 
concentration gradient of sodium formate, with constant NaCl concentration. Protein at a 
concentration of 10 mg/ml was used for optimisation. The crystals were formed in the 
condition containing 4 M sodium formate, 0.2 M NaCl and 0.1 M Tris-HCl pH 8.5. Later, 
crystals were formed at other pH values but at same sodium formate and NaCl concentrations 
(4 M and 0.2 M, respectively). Thus, crystal growth was independent of pH, but strictly 
required 4 M sodium formate (Figure 3.7). However, the crystal condition was not 
reproducible, and the crystals took very long time to grow (approx. two months). The crystals 
diffracted to low resolution of 6 Å, which made them not suitable for high-resolution 
structure determination and fragment-based drug-discovery. 
A.                                                                         B. 
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FIGURE 3.7    Crystals of full-length, untagged orthologue of Rv3030 from M. smegmatis.  
Crystals in condition containing 4 M Sodium formate, 0.2 M NaCl and 0.1 M Tris-HCl at 
different pH. Crystal formation was invariant of pH. However, the condition was not 
reproducible and diffracted poorly. 
The processed X-ray diffraction dataset showed that crystals belonged to the space group I4 
and the unit cell dimensions were: 
a=b=114.2 Å; c=268.7 Å 
α=β=γ=90° 
However, it was not possible to solve the structure by molecular replacement due to lack of a 
suitable probe. Other phasing techniques, such as using isomorphous replacement by 
preparing heavy-metal derivatives were not possible due to lack of reproducibility of crystals. 
Also, seleno-methionine labelling was not feasible because of presence of only one 
methionine residue in the protein. 
An array of conditions was trialled with full-length orthologues in order to improve the 
resolution of crystals obtained and to identify new crystallisation conditions. These included: 
setting crystallization experiments with the tagged protein, co-crystallisation of untagged 
protein with active substrate (SAM) and substrate analogues (SAH, maltohexaose), co-
crystallisation of untagged protein with Mg2+, limited proteolysis, additive screening, 
screening with different salts, streak seeding and matrix seeding. However, all the attempts 
were unsuccessful. 
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3.5.4.3 Expression and Purification of the Full-Length Orthologue of Rv3030 from  
                M. smegmatis (without subsequent tag cleavage) 
 
High levels of recombinant protein with cleavable SUMO tag at its N-terminus were 
produced. However, SUMO tag was not cleaved by the Ulp1 protease. The gel filtration 
profile showed that the SUMO-tagged protein also behaved as a monomer in solution. A 
single, sharp peak was seen on the trace (Figure 3.8). 
 
 
    
 
                                                             
 
 
 
 
 
 
 
 
 
 
         
 
 
 
FIGURE 3.8    Expression and purification of full-length, SUMO tagged orthologue of Rv3030 from  
                          M. smegmatis. 
A. Metal affinity purification of SUMO tagged protein on Ni-sepharose column. A strong band can 
be seen at a MW higher than that of the protein. (MW of protein- 28.1 kDa, MW of SUMO tag-
13.8 kDa, total MW of tagged protein-42 kDa). (MWM: molecular weight marker, P1 to P2: 
tagged protein, FT: flow through, S: supernatant, L: cellular lysate). 
B. Gel filtration of tagged protein on Superdex-200 column. (MWM: molecular weight marker, F1 
to F5: protein fractions). 
C. The gel filtration profile. 
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3.5.4.4 Crystallisation Trials with Full-Length, Tagged Orthologue of Rv3030 from  
M. smegmatis  
 
Initially, 400 conditions were screened with the tagged-protein at a concentration of 12 
mg/ml. Precipitation was observed in a majority of the conditions but no lead was identified. 
 
3.5.5 Analysis of Secondary Structure by Circular Dichroism 
 
The secondary structure composition of Rv3030 orthologue from M. smegmatis was assessed 
by CD spectroscopy. The UV spectrum showed that full-length protein was folded, and was 
composed of α-helices and β-strands. The data were deconvoluted using the CDSSTR 
programme and fitted at normalized RMSD value of 0.014. The protein contains 31% helical 
content, and a slightly lower β-sheet content of 25% (Figure 3.9). 
 
 
 
 
FIGURE 3.9    The circular dichroism spectrum of full-length orthologue of Rv3030 from M. smegmatis. 
A. Far UV CD spectra of orthologue of Rv3030 from M. smegmatis recorded between 260 and 190 
nm and presented in mean residue ellipticity, MRE ([θ]).  
B. Deconvolution of the data using the CDSSTR program of DichroWeb. 
NRMSD 0.014 
α-helix 31% 
β-sheet 25% 
Turns 20% 
Unordered 26% 
A. B. 
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3.5.6 Determining the Oligomerization State by SV-AUC 
The oligomeric state of full-length orthologue of Rv3030 from M. smegmatis was determined 
by SV-AUC. The data were fitted to a continuous c(S) distribution model, which resulted in a 
sharp, single peak in both the measurements from UV absorption and interference optics 
(Figure 3.10). The estimated molecular weight of the protein from the absorbance scan was 
28.2 kDa; remarkably close to its theoretical monomeric size of 28.1 kDa, and the estimated 
molecular weight from interference optics was 29.1 kDa, which is within 5% of the 
theoretical weight. This indicates that the protein exists as monomer in solution, confirming 
the observation from the gel filtration profile. The frictional ratio calculated from the 
absorbance and interference experiments was 1.27 and 1.32, respectively. This indicates that 
the protein adopts a globular conformation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.10    The SV-AUC 
analysis of full-length orthologue of 
Rv3030 from M. smegmatis. 
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B. 
3.5.7 Characterisation of Ligand Binding to the Full-Length Orthologue of Rv3030 
from M. smegmatis 
The binding of SAM, the methylgroup donor, to this 6-O methytransferase was observed by 
both ligand-NMR and ITC. A decrease in intensity of 1H signal was observed when SAM 
bound to the protein (Figure 3.11 A). The thermodynamics of binding of the co-factor was 
determined, and by fitting the ITC data, Kd was observed to be 41.5 μM ± 3.7 μM. The 
complexation of SAM with this methyltransferase was exothermic (negative peaks in the ITC 
output), with 1:1 stoichiometry (Figure 3.11 B). The association was characterised by a 
favourable enthalpy change and a negative entropy change (values of thermodynamic 
properties are shown in an inset in the figure 3.11) 
 
 
 
 
 
 
FIGURE 3.11    Binding of SAM to the full-  
                            length orthologue of Rv3030      
                            from M. smegmatis. 
A. A CPMG experiment showing 
intensity of SAM in free-state 
(red), and in bound-state with 
the enzyme (blue). The 
decrease in the intensity of the 
signal was observed, which 
confirms binding. 
B. Isothermal titration calorimetry 
profile of SAM binding to the 
enzyme. 
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3.5.8 N-terminus Truncations of Orthologue of Rv3030 from M. smegmatis 
The homology model of the orthologous M. smegmatis protein indicated that some residues 
from the N-terminus of the protein do not align to any secondary structure element. This was 
concordant with the secondary structure prediction results obtained from PSIPred (Figure 
3.2). Therefore, these residues from the unstructured loop at the N-terminus were truncated, 
and this approach was followed so as to readily crystallise and obtain the structure of rest of 
the protein. Six different constructs which had 4, 8, 14, 15, 17, and 24 residues truncated 
respectively, were screened.  
3.5.8.1 Expression and Purification of the Truncated Orthologues of Rv3030 from  
    M. smegmatis 
 
All the constructs with cleavable N-terminus SUMO tag were successfully expressed and 
purified from the soluble fraction with high purity. The fusion tag was subsequently cleaved 
and final polishing was done by gel filtration on Superdex-200 column. The gel-filtration 
profile demonstrated that all the proteins behaved as monomer in solution (Figure 3.12 and 
Figure 3.13). 
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MWM     1            2  
 
 
 
 
 
                                        
 
 
 
 
 
 
 
FIGURE 3.12    Expression and purification of truncated orthologues of Rv3030 from M. smegmatis. 
A. Metal affinity purification of SUMO tagged proteins on Ni-sepharose column. Strong bands 
seen at MW higher than that of the proteins. (MWM: molecular weight marker, L: cellular 
lysate, S: supernatant, FT: flow through, Pr1 to Pr2: tagged proteins). 
B. Cleavage of SUMO tag by UlpI protease and reverse binding on Ni-sepharose column.  
(1: tagged proteins, 2: tag less proteins obtained in the flow through). 
C. Gel filtration of tag-less proteins on Superdex-200 column.  (MWM: molecular weight 
marker, F1 to F8: protein fractions).     
D. Gel filtration profiles. 
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FIGURE 3.13    Expression and purification of truncated orthologues of Rv3030 from M. smegmatis.  
A. Metal affinity purification of SUMO tagged proteins on Ni-sepharose column. Strong bands 
seen at MW higher than that of the proteins. (MWM: molecular weight marker, L: cellular 
lysate, S: supernatant, FT: flow through, Pr1 to Pr2: tagged proteins). 
B. Cleavage of SUMO tag by UlpI protease and reverse binding on Ni-sepharose column.  
(1: tagged proteins, 2: tag less proteins obtained in the flow through). 
C. Gel filtration of tag-less proteins on Superdex-200 column. (MWM: molecular weight marker, 
F1 to F7: protein fractions).     
D. Gel filtration profiles. 
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3.5.8.2 Crystallisation Trials of Truncated Orthologues of Rv3030 from M. smegmatis 
 
Each of the truncated proteins was screened against approximately 600 crystallisation 
conditions, but no phase separation or crystals were observed. However, for one of the 
truncated proteins, which was truncated by 17 residues at its N-terminus, microcrystals were 
formed but in only one condition containing 0.1 M MES pH 6.5, 1.8 M AmSO4, 0.01 M 
cobalt (II) chloride (Figure 3.14 A and B). Further optimisation of this condition by additive 
screening led to identification of a phase separation condition (0.1 M MES pH 6.5, 1.8 M 
AmSO4, 0.01 M cobalt (II) chloride, 0.5% PVP-K15), which was confirmed to be of protein 
by UV imaging (Figure 3.14 C and D). In spite of considerable optimisations carried out, no 
crystals were formed for this truncated construct.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.14    Microcrystals and phase separation of truncated (17 residues from N-terminus)   
                            orthologue of Rv3030 from M. smegmatis. 
A. Microcrystals from initial screening. 
B. UV image of the same condition confirming microcrystals.  
C. Phase separation after optimization of microcrystalline condition. 
D. UV image of the same condition confirming separation of protein phase.  
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3.6 Discussion 
 
Rv3030, a SAM-dependent methyltransferase, carries out methylation at the 6-O position of 
glucoses, which are vital for synthesis of mature MGLP chains. Sequence alignment of 
Rv3030 and its orthologues demonstrated that the enzyme was conserved among the species 
of mycobacteria, thus suggesting that either of the orthologues from M. smegmatis or                            
M. thermoresistibile could be used as a surrogate for structural and drug-discovery studies. 
The three-dimensional structure of the full-length orthologue of Rv3030 from M. smegmatis 
was modelled. This suggested that the protein structure comprises a single domain, with an 
unstructured N-terminus, consistent with the results of in silico prediction of a disordered 
region of the protein 
The results of protein expression and purification show that good quantities of full-length 
soluble proteins, purified to homogeneity, were obtained from both M. smegmatis and                  
M. thermoresistibile. The crystallisation of full-length proteins was carried out. 
Notwithstanding, crystallisation proved challenging, and there was no success in obtaining 
well diffracting crystals suitable for structure determination. In spite of testing and optimising 
a number of conditions, the best crystals produced were of full-length M. smegmatis 
orthologue. However, these were formed in only one condition, took long to form and 
diffracted only to a very low resolution (6Å). Processing of the low-resolution dataset of the 
full-length orthologue of Rv3030 from M. smegmatis showed that the crystals belonged to the 
I4 space group. Attempts to solve the structure were not successful due to several factors. 
Firstly, the absence of the structure of a close orthologue to use as a probe meant that 
molecular replacement could not be used. Secondly, preparation of heavy metal derivatives 
for isomorphous replacement was not feasible, as the crystals could not be reproduced. 
Thirdly, the presence of just one methionine residue in the protein made it unsuitable for 
seleno-methionine labelling for single anomalous diffraction (SAD) phasing. 
The biochemical characterisation had not been possible due to lack of availability of active 
substrate of the enzyme. Further biophysical studies were carried out which revealed that the 
circular dichroism spectrum of the full-length orthologue of Rv3030 from M. smegmatis 
displayed attributes of a folded protein, and SV-AUC data showed that the protein exists as a 
monomer and is globular. These results affirmed that difficulties in crystallisation of the full-
length protein were not because of its incorrect folding. The binding of the co-factor, SAM, 
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to the enzyme, positively supported that the enzyme was folded, as the binding affinity 
observed was biologically relevant.  
Based on the observations from the in silico model of the structure of the Rv3030 orthologue 
from M. smegmatis, a rationale was derived for manipulation of the gene and truncation of 
the disordered region at the N-terminus of the protein, in order to make it amenable for 
crystallisation. Several constructs, with varying degrees of truncation of the unstructured 
region were designed and screened. All the truncated proteins were successfully expressed 
and purified from the soluble fraction, with high purity. However, attempts to crystallise 
these did not give rise to well-formed, high-resolution crystals.  
Although the results of biophysical assays presented in this chapter show that the protein is 
folded, crystallisation of full-length and truncated proteins was very demanding. Henceforth, 
alternative approaches to study the structure of the protein were explored. These included 
nuclear magnetic resonance (NMR) and small-angle X-ray scattering (SAXS), described in 
the next chapter.  
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4.1 Summary 
At the outset of this project, crystallisation was pursued to determine the structure of the 
enzyme. However, as presented in chapter-3, crystallisation was not tractable. Thereby, other 
possibilities were sought to understand the structural features of Rv3030 using its orthologue 
in M. smegmatis as the representative model, and insights were gained from small-angle X-
ray scattering and NMR spectroscopy. The results demonstrated that the enzyme was folded 
and globular, confirming the observations from the biophysical investigation. Further, NMR-
based protein dynamic study revealed that the N-terminus is intrinsically disordered. The 
secondary structure characterisation of protein by NMR showed that the protein had the β-
sheet topology broadly classified as a Rossmann fold. These data provide the first evidence 
about the structural features of this 6-O methyltransferase involved MGLP biosynthesis. 
4.2 Introduction 
Given the central importance of Rv3030 in the survival of M. tb, it is essential to understand 
the structural properties of the methyltransferase, for further elucidation of the catalytic 
mechanism and development of specific inhibitors against this target. Although well-formed 
crystals of full-length orthologue of Rv3030 were obtained, they were not of suitable 
diffraction quality for structure determination. Therefore, a SAXS and NMR-based study to 
determine the structure of the protein was undertaken. 
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4.3 Basic Principles of Small-Angle X-ray Scattering and Nuclear 
Magnetic Resonance 
 
4.3.1 Small-Angle X-Ray Scattering 
Small-angle X-ray scattering (SAXS) is a technique used to study structure and measure 
biophysical parameters of macromolecules in solution. It provides information about the size, 
shape, molecular assembly and conformation of the proteins, other biological molecules and 
complexes. It is relatively a fast and straightforward technique, with no limitation to the 
protein size. The technique also allows quantitative analyses of flexible and disordered 
regions of proteins. Further understanding on the technique can be gained by referring to the 
texts: Graewert and Svergun, 2013; Kikhney and Svergun, 2015; Mertens and Svergun, 2010; 
Petoukhov and Svergun, 2013; Svergun and Koch, 2003. 
The protein solution in quartz capillary is placed in a monochromatic X-ray beam. The 
intensity of scattered X-rays is measured and recorded by an x-ray detector (Figure 4.1).  
 
 
 
 
 
 
 
 
 
 
FIGURE 4.1    Basic principles of a SAXS experiment. 
(s: momentum transfer) (Figure adapted from Kikhney and Svergun, 2015)  
Pure solvent is used as the reference, and the scattering pattern collected for it is subtracted 
from the sample solution. The resulting pattern gives the overall size and shape of the protein. 
Primary X-ray Beam (Intensity = Io) 
Scattered X-ray Beam 
(Intensity = Is) 
Protein 
Sample 
2θ 
X-ray 
Detector 
s =  
Is - I0 
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The protein molecules in the solution are randomly oriented, and thus, the scattering pattern 
is isotropic, and the intensities and amplitudes of scattered beam are spherically averaged.  
The momentum transfer (s) between the primary and scattered X-ray beam is defined as  
                                                                                          
 
        where,    λ – wavelength 
          2θ – scattering angle 
The atomic scattering amplitude, which is the Fourier transformation of the electron density, 
is represented by the following equation: 
                                                                     
 
      where,   ρ(r) – electron density of particle  
            ρs – electron density of solvent 
             r – vector between atoms 
             s – |s| 
SAXS provides valuable information about the characteristics of the protein, including 
molecular weight, maximum dimension (Dmax), and radius of gyration (Rg). Rg provides the 
overall size of the molecule, and for compactly shaped proteins, its value is small.  
By using Guinier approximation, the intensity is defined as: 
                                                                             
The Guinier plot, where the scattering intensity I(s) is plotted against s2, gives information 
about the aggregation of particles in the solution. Lack of linearity is a sign of aggregation or 
repulsive inter-particle interactions. 
The distances between all feasible pairs of atom is represented in form of a histogram, known 
as a distance distribution function, p(r). For a globular protein, the curve is perfectly bell-
shaped, whereas there is an extended tail for an unfolded protein.  
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The following equation helps in calculating Rg from the p(r) function more precisely: 
                                                                             
 
         where,  Dmax – maximum dimension 
SAXS data also provide qualitative identification of the flexible and disordered regions of the 
protein. The Kratky plot (s2I(s) vs. s) is used to identify the folding state and flexible regions. 
The plot is bell-shaped for a folded protein, and in case of unfolded proteins, it exhibits as a 
plateau for a range followed by a constant increase.  
Some beamlines at the synchrotrons allow size-exclusion chromatography to be performed 
just before collecting the SAXS data, which removes unwanted aggregation. This is 
particularly useful to remove noise signals produced because of disproportionate scattering of 
the beam, and consequently affecting the data analysis. 
4.4.2 Nuclear Magnetic Resonance 
 
This section summarises the basic theory of nuclear magnetic resonance, but does not provide 
a substantial coverage on the subject matter, which can be found in a number of texts 
(Kovermann et al., 2016; Kwan et al., 2011; Tengel, 2007; Williamson, 2013; Wüthrich, 
1986, 2001; Zuiderweg, 2002).  
Nuclear magnetic resonance (NMR), discovered by Purcell and Bloch in 1946, is a powerful 
technique to study structure and dynamics of various biomolecules. NMR is complementary 
to X-ray crystallography and allows characterisation of protein dynamics in solution state. 
This is particularly advantageous as the dynamics can be quantified over a large time scale 
and under equilibrium conditions, using multiple probes simultaneously. Solution-state NMR 
offers sample conditions that can be equated to the physiological conditions in the cell. The 
size is, however, the limitation for NMR study, and typically proteins < 300 residues are 
suitable for the structure determination in the absence of costly deuterium-labelling methods. 
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4.3.2.1 Magnetisation and Resonance 
 
NMR is dependent on interaction of nuclear spin of nuclei of atoms with the magnetic field. 
The nuclear spin of nuclei having even number of neutrons and protons is zero, whereas it is 
non-zero for nuclei with odd number of neutrons or protons. Atoms like 1H, 13C, 15N, 19F and 
31P, possess nuclear spin of ½ and are exploited for structure determination. The nuclear spin 
is defined by magnetic quantum number, I, which can have values of + ½ and - ½. These 
values correspond to orientation of nuclei either parallel or anti-parallel to the magnetic field, 
and have different energy states. The parallel orientation has lower energy and is known as 
the α-state; the anti-parallel orientation, on the other hand, has higher energy and is 
designated as the β-state.  
Resonance occurs when a system at a particular energy state is excited with a specific 
frequency, known as the resonant frequency, and this results in transition between the two 
levels having different energies.  
The difference in energy between two levels is defined by the following equation:  
 
                                                                                           
 
           where,  ΔE – energy difference 
               h – Planck’s constant (6.626x10-34 J.s) 
                 – frequency  
The frequency, v, of transition is represented by Larmor equation, and is known as Larmor 
frequency. 
                                                                                           
 
                                                        where,   – gyromagnetic ratio 
                    B – magnetic field  
The bulk magnetisation (M) is defined as a vector sum of the individual nuclear spins in the 
magnetic field.  
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The relationship between magnetisation with the magnetic field is given by: 
                                                                      
 
     where,     M – bulk magnetisation 
           ω – angular Larmor frequency (ω= 2πv) 
At the equilibrium state, the bulk magnetisation is parallel to the static external magnetic field 
(B0, by convention along the z-axis) resulting in the lowest energy state being marginally 
favoured. Classically, if the bulk magnetisation is re-oriented away from this position, it will 
precess around the z-axis at its Larmor frequency. Quantum mechanically, the nuclei transit 
between different energy states when a radio frequency (RF) pulse of energy equal to ΔE is 
applied (i.e. at the resonance frequency). Eventually, the bulk magnetisation gets out of 
phase, due to the effect of T2 relaxation, and returns back to the equilibrium, due to T1 
relaxation. The decay due to T2 relaxation is measured as a fluctuating decline of the 
amplitude of the magnetic waves as a function of time, known as free induction decay (FID). 
Fourier transformation of the FID converts it from a function of time to a function of 
frequency, and the data is represented as an NMR spectrum.  
4.3.2.2 Chemical Shift 
 
The surrounding electrons can marginally alter the magnetic field experienced by the nuclei 
of the same atoms. It is because when external magnetic field is applied, the electrons also 
rotate in their atomic orbitals and produce localized magnetic fields aligned opposite to the 
direction of the magnetic field. As a result, the strength of the local magnetic field and the 
resonant frequency of the nuclei are reduced. This shielding effect of electrons is influenced 
by the chemical environment and is proportional to the magnetic field.  
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Chemical shift is defined as the resonant frequency of a sample nucleus relative to that of a 
reference in the magnetic field, and is expressed in ppm, by the following equation: 
                                                                                    
                                               where,      δ – chemical shift 
        – resonant frequency of sample nucleus 
               ref – resonant frequency of reference 
Generally, the reference used is the resonant frequency of 1H nuclei of tetramethylsilane 
(δTMS= 0 ppm). Proteins have characteristic proton chemical shifts, which helps in the 
identification of various structural groups. 
4.3.2.3 J- Coupling 
 
J-coupling is also known as scalar coupling or indirect spin-spin coupling. In a system of 
covalently bound nuclei, the local magnetic field experienced by a particular spin is not only 
dependent on the surrounding electrons, as in the chemical shift, but is also dependent on the 
spin states of the neighbouring nuclei, arbitrated by electrons through the chemical bonds. 
When an adjacent nuclear spin is parallel to the magnetic field, the local magnetic field is 
increased at the local nucleus. Conversely, it is decreased if the adjacent spin is in an anti-
parallel orientation. The J-coupling is independent of the external magnetic field and is 
mutual, i.e. the same for coupled nuclei.  
This phenomenon splits the NMR signal into multiple lines, depending upon the number of 
surrounding nuclei, which in protein NMR are mostly not helpful. Therefore, the 
heteronuclear spin couplings are decoupled or selectively reduced. However, J-coupling 
provides useful information about dihedral angles and bond lengths that is used for model 
building. The magnitude of coupling, known as the coupling constant J, indicates the 
proximity of the coupled nuclei. As the number of bonds increases, the magnitude generally 
decreases and vice-versa. 
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4.3.2.4 Heteronuclear NOE 
 
The backbone 1H-15N heteronuclear NOE provides information about the motion of the 
individual N-H bond vectors. Those that undergo motion faster than the overall tumbling of 
the molecules (i.e. in the pico-to-nanosecond time scale) show a decreased NOE intensity 
relative to the average observed for the majority of the residues. Thus, for instance, decreased 
values are usually found at both N- and C-terminal ends of the protein (< 0.6), compared with 
ordered regions (0.6-0.9). 
 
 
4.3.2.5 Multi-Dimensional NMR and Resonance Assignment 
 
Multi-dimensional NMR and isotope labelling has enabled determination of macromolecular 
structures of high molecular masses 25 kDa or higher. This is primarily because the 
resolution of the multidimensional spectra is better than the corresponding one-dimensional 
spectra. In the 1-D spectrum, the 1H frequencies are overlapped which makes the assignment 
of resonances unfeasible, whereas in multidimensional spectra, the frequencies are recorded 
in multiple dimensions, thereby the peaks are resolved and assignment of individual peaks is 
possible. Multi-dimensional NMR relies on the transfer of magnetisation between nuclei, 
which allows the relationships between different nuclei to be mapped out. 
The transfer of magnetisation occurs through different methods outlined below: 
a) Through-bond correlation methods, wherein the magnetisation is transferred through J-
coupling between bonded nuclei, either of the same type (homonuclear) or of different 
types (heteronuclear). Homonuclear methods include COSY and TOCSY, whereas 
HSQC is a heteronuclear method. 
b) Through-space correlation methods, which transfer magnetisation between nuclei with 
physical proximity, irrespective of any chemical bond between them. These methods 
are based upon the nuclear Overhauser effect (NOE). 
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2D 1H-15N HSQC Spectrum 
15N-HSQC (heteronuclear single quantum coherence spectroscopy) is a standard 2D 
experiment, which serves as a structural fingerprint and forms an important basis for the 
heteronuclear analysis of protein. It shows correlations between nitrogen and proton nuclei of 
the residues, and the magnetisation is transferred through the J-coupling and often restricted 
to the value of a single bond by setting the transfer time relatively short. One peak for every 
amide spin pair is seen; amine groups are rarely observed due to rapid exchange of the 
proteins with the solvent. An exception to this is proline, which lacks an amide proton. 
Predominantly, backbone amide groups are detected, however, peaks are also produced for 
Trp side-chain Nε-Hε, Asn side-chain Nδ-Hδ2 and Gln side-chain Nε-Hε2. Dependent on 
their exchange properties, peaks for Arg Nε-Hε may also appear, but the chemical shift for 
Nε lies outside the usual spectral range, and so the Nε may appear at a frequency ±1 spectral 
width from the true frequency. This is known as folding or aliasing of the peaks. The same 
effect is observed for Arg Nη-Hη and Lys Nζ-Hζ, when working at low pH. 
The HSQC spectrum provides useful information about the protein folding. When the protein 
is folded, the peaks are well scattered and individual peaks may be resolved. On the contrary, 
disordered proteins produce a spectrum that has a cluster of highly overlapped peaks in the 
central region, which makes the resonance assignment difficult. 15N-HSQC is a major factor 
in analysing the suitability of a protein for NMR structure determination. It is also applicable 
in identification of hot-spots of interactions and, thus, mapping the binding surface in protein-
drug, protein-ligand and protein-protein interaction, by recording the changes in the chemical 
shifts of the residues in apo-state with those in ligand-bound state. This is known as chemical 
shift perturbation mapping.  
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Triple Resonance Experiments in Backbone and Sidechain Assignment 
These experiments are based on bonded connections between 1H, 15N and 13C atoms present 
in the residues. The protein residues contain the basic H-N-Cα-C’ unit, repeated in the 
polypeptide chain, which is exploited for the resonance assignment. Several spectra are 
recorded, which give both intra- and inter-residue connections, and rely on transfer of 
magnetization by J-coupling between N-H, C-C, C-H and C-N bonds. The chemical shift is 
spread across the three dimensions involving both backbone and side-chain H, N and C 
nuclei.  
The information about backbone Cα for the ith and (i-1)th residue is revealed by an HNCA 
spectra, and an HN(CO)CA spectra informs about the (i-1)th residue. In the HNCA 
experiments, the magnetisation is transferred from amide proton to amide nitrogen and then 
to 13Cα atoms of both the ith and (i-1)th residues via N-Cα J-coupling. In the HN(CO)CA 
experiment, the magnetisation transfers through the carbonyl carbon atom, and thus, only the 
peak of 13Cα atom of (i-1)th residue can be observed (Figure 4.2 A and B). The 
magnetisation in both these experiments then returns back to the amide proton, and these are 
known as ‘out and back’ experiments. 
Similarly, a pair of ‘out and back’ experiments, HNCACB and HN(CO)CACB, are recorded 
for Cβ resonances. The HNCACB experiment records 13Cα and 13Cβ peaks for both the ith 
and (i-1)th residues, whereas the HN(CO)CACB experiment detects only the peaks for the (i-
1)th residue. In the HNCACB experiments, the magnetisation is transferred from amide 
proton to amide nitrogen and then to 13Cα and 13Cβ atoms of both the ith and (i-1)th residues.  
In the HN(CO)CACB experiment, the magnetisation transfers through the carbonyl carbon 
atom, and thus, only peaks of 13Cα and 13Cβ atoms of (i-1)th residue can be observed (Figure 
4.2 C and D). 
An HC(CCO)NH experiment can also be used for backbone assignment. In this experiment, 
the magnetisation is transferred from the protons of the sidechain carbons to their 13C atom, 
via isotropic mixing between all the carbons. From here, the magnetisation is transferred, 
through the carbonyl carbon, to the amide nitrogen and amide proton of the (i+1)th residue 
(Figure 4.2 E). The backbone carbonyl is detected through the HNCO spectrum, in which the 
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magnetisation is transferred from amide proton to amide nitrogen and then to the carbonyl 
carbon atom (Figure 4.2 F).  
An interplay of these spectra leads to the sequential identification of residues and backbone 
resonance assignment. However, the sequential assignment is interrupted by the presence of 
proline in the protein sequence, as prolines do not have an amide proton.  
It is also required to assign the side-chains to produce complete set of assignments, essential 
for generating geometric constraints and structural calculations. Typical experiments 
performed for side-chain assignments are HCCH-COSY and HCCH-TOCSY, wherein 
magnetisation transfer occurs via J-coupling and isotropic mixing, respectively. 
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FIGURE 4.2    Triple resonance experiments for backbone resonance assignment. 
The red arrows represent the path of magnetisation transfer. The atoms for which the resonance 
peaks are observed in the spectrum are coloured green.  
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4.4 Methodology 
 
4.4.1 Small Angle X-ray Scattering of the Full-Length Orthologue of Rv3030 in  
M. smegmatis 
The purified protein sample at a concentration of 10 mg/ml in 100 mM NaCl, 20 mM Tris-
HCl pH 7.5 was used to collect data. The data were collected at the SWING beamline (Soleil 
Synchrotron, France). The sample was thawed and centrifuged (20,000 x g, 5 min, room 
temperature). The sample was placed in a thermo-regulated quartz cell at 15˚C, and loaded 
onto a Superdex-200 column (GE Healthcare, increase 3.2/300), equilibrated with 100mM 
NaCl and 20mM Tris-HCl pH 7.5. The sample was eluted directly into the detection 
chamber, and illuminated with monochromatic X-ray beam of a wavelength of 1.022 Å. The 
sample was placed 1.79 m from the detector, and a total of 250 measurements were collected. 
Scattering measurements were collected for the protein buffer (100 mM NaCl, 20 mM Tris-
HCl pH 7.5) also, as the reference.  
The FOXTROT program was used to radially average the buffer-frames and subtract the 
averaged buffer-frame from each sample-frame. The buffer corrected sample-frames were 
averaged, and a final scattering curve was generated for analysis. The data were analysed 
using the ATSAS package (Petoukhov et al., 2012). The Rg value was determined from the 
slope of Guinier plot in PRIMUS wizard of the package (Konarev et al., 2003). The value of 
Dmax was calculated from the p(r) curve, by allowing it to reach back to zero. The ab initio 
model of the protein structure was generated using the DAMMIN programme (Svergun, 
1999). Ten models were generated which were averaged to create the final DAMFILT model. 
The figures were prepared with UCSF Chimera (Pettersen et al., 2004). Dr. Takashi Ochi 
helped in processing and analysing the data.  
4.4.2 Expression and Purification of Isotope-Labelled, Full-Length Orthologue of 
Rv3030 from M. smegmatis 
The recombinant orthologous protein of Rv3030 from M. smegmatis with N-terminal, 
cleavable SUMO tag was isotope-labelled, and purified from the soluble fraction. Two 
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batches of protein were labelled, expressed and purified. In one of the batch, the protein had 
15N isotope labelling, and in the other batch, the protein was double labelled with 15N and 13C 
isotopes. 
Culture growth and Expression: A loop of frozen BL21 cells of the expression clone was 
plated on LB-agar-kanamycin plate and incubated overnight at 37°C. All the cells were 
collected from the plate and inoculated in 250 ml LB media with kanamycin at final 
concentration of 30 μg/ml. The culture was grown overnight at 37°C, with constant shaking 
at 220 rpm. The culture was scaled up to 4 litres by adding 30 ml of the overnight culture in 
each of the fresh 1-litre LB media with kanamycin.  Cells were grown at 37°C till OD600 
reached 0.78, and the culture was spun (4200 x g, 4°C, 15 min). The pellet was washed by re-
suspending it in 1 X M9 salts and centrifuging (5000 x g, 4°C, 10 min). This wash step was 
repeated four-times to remove any residual LB media, before the expression of the isotope-
labelled protein.  
An expression media was prepared as described: 1X M9 salts, 2 mM MgSO4, 50 µM CaCl2, 
0.4% unlabelled glucose or 6 g/L 13C glucose (Sigma), 1 g/L 15NH4Cl (Sigma), 30 µg/ml 
kanamycin, 1 X micronutrients solution and 1 X vitamins solution (see appendix-VI for 
composition of stock solutions of micronutrients and vitamins). The washed pellet was re-
suspended in 1-litre expression media, and the cells were allowed to recover by incubating at 
20°C for 1.5 hours with constant shaking. The culture was induced with 0.5 mM IPTG for 
protein expression, and grown overnight (14-16 hours) at 20°C with constant shaking. 
Purification: The purification protocol of labelled protein was the same as that for the 
unlabelled protein, described in chapter-3, section 3.4.4.1. 
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4.4.3 NMR Spectroscopy of Apo Full-Length Orthologue of Rv3030 from 
M. smegmatis 
4.4.3.1 Sample Preparation, Data Collection and Processing of Apo-Protein 
 
The sample (600 μl) for NMR measurements contained 200 µM protein, 10% D2O (Sigma) in 
50 mM NaCl and 20 mM sodium phosphate pH 6.5, and 1 mM DTT. Samples were placed in 
5 mm NMR tubes for data acquisition. All spectra were recorded at 298 K on Bruker Avance 
III AV600 spectrometer equipped with HCNF probe and actively-shielded z-gradients, by         
Dr. Katherine Stott. The expriments recorded are listed in Table 4.1. The backbone 
experiments were acquired using non-uniform sampling and processed according to a 
compressed sensing protocol obtained from Dr. Mark Bostock (personal communication,             
Dr. Katherine Stott).  
Table 4.1    NMR experiments recorded on apo orthologue of Rv3030 from M. smegmatis in apo-state. 
                    FT: Fourier transformation; CS: compressed sensing 
 
Experiment Nucleus 
Field Strength 
( MHz) 
Water Supprssion 
Data 
Processing 
HSQC 1H, 15N 600 WATERGATE FT 
HSQC 1H, 13C 600 Presaturation FT 
HNCA 1H, 15N, 13C 600 WATERGATE CS 
HN(CO)CA 1H, 15N, 13C 600 WATERGATE CS 
HNCACB 1H, 15N, 13C 600 WATERGATE CS 
HN(CO)CACB 1H, 15N, 13C 600 WATERGATE CS 
HNCO 1H, 15N, 13C 600 WATERGATE CS 
15N-NOESY-HSQC 1H, 15N 600 WATERGATE FT 
15N-TOCSY-HSQC 1H, 15N 600 WATERGATE FT 
13C-NOESY-HSQC 1H, 13C 600 Presaturation FT 
HCCH-TOCSY 1H, 13C 600 Presaturation FT 
(H)CC(CO)NNH-TOCSY 1H, 15N, 13C 600 WATERGATE CS 
H(CCCO)NNH-TOCSY 1H, 15N, 13C 600 WATERGATE CS 
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4.4.3.2 Resonance Assignment and Restraint Generation 
 
The resonance assignment of the apo-protein was done using CCPNMR Analysis software.  
Backbone resonance assignments were obtained from multidimensional HNCO, HNCA, 
HN(CO)CA, HNCACB and HN(CO)CACB experiments, and also from the NOESY and 
TOCSY spectrum. Sidechains were assigned using various 3D TOCSY experiments: 15N-
TOCSY-HSQC, HCCH-TOCSY, (H)CC(CO)NNH-TOCSY and H(CCCO)NNH-TOCSY.     
Dr Katherine Stott taught and helped in doing the assignments. The dihedral angles were 
calculated using DANGLE (Cheung et al., 2010),  and ambiguous distance restraints were 
obtained by peak-picking the 3D NOESY spectra, by Dr. Katherine Stott.   
4.5 Results 
4.5.1 SAXS analysis of Full-Length Orthologue of Rv3030 from M. smegmatis  
 
A SEC-SAXS study was carried out to investigate about the overall size and shape of the full-
length orthologue of Rv3030 in M. smegmatis. The protein eluted as a single peak from the 
Superdex-200 column, immediately prior to X-ray irradiation. The data frames were collected 
for the peak and were averaged to generate the scattering intensity plot (Figure 4.3 A). 
The Guinier plot of ln (I(q)) against q2 was a perfectly straight line, demonstrating that the 
sample was not aggregated (Figure 4.3 B). The value of the radius of gyration calculated 
from the Guinier analysis is 20.25 ± 0.04 Å. The qRg limits used to determine the value of 
Rg from the plot were 0.533 to 1.18. The Kratky profile is bell-shaped (Figure 4.3 C) 
indicating that the protein is folded, as observed from the CD spectrum mentioned in chapter-
3. Furthermore, the pair-wise distribution function (P(r)) is a single, bell-shaped curve, which 
is the characteristic of a globular protein (Figure 4.3 D). This is consistent with the results of 
SV-AUC (in chapter-3), thereby, confirming that the protein exhibits a globular structure. 
The calculated Dmax is 68.87 Å.
 
The ab initio shape of the protein was constructed from the SAXS data. A total of 10 models 
were generated using DAMMIN, and the model scattering curves fitted well with the 
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experimental scattering curve, with Chi2 values between 3.42 and 6.07. The models were 
reasonably globular with a bulge at one side. The average features of the 10 models are 
represented in the single DAMFILT model, with mean NSD value of 0.521 (Figure 4.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4.3    SAXS data profiles for full-length orthologue of Rv3030 from M. smegmatis. 
A. 
B. 
C. 
D. 
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FIGURE 4.4    Ab initio shape reconstruction of orthologue of Rv3030 from M. smegmatis. 
A. 10 DAMMIN models constructed from experimental scattering curves. 
B. Averaged DAMFILT model, showing the overall shape of the enzyme. 
Molecular surface representated as spheres.  
Rotated 90˚ 
Along x-axis 
A. 
B. 
Chapter-4        Probing the Structural Features of Orthologue of Rv3030 from M. smegmatis by SAXS   
                        and NMR Spectroscopy 
171 
 
4.5.2 Expression and Purification of Isotope Labelled, Full-Length Orthologue of 
Rv3030 from M. smegmatis 
 
High-levels of the 15N labelled and double-labelled (15N, 13C) recombinant proteins with 
cleavable SUMO tag at the N-terminus were purified to homogeneity by affinity 
chromatography and the tag was subsequently cleaved. The trace from the gel-filtration run 
showed that the tag-less, labelled proteins behaved as a monomer in the solution, similar to 
the unlabelled protein (Figure 4.5 and Figure 4.6).  
 
 
 
 
 
 
 
 
 
FIGURE 4.5    Expression and purification of 15N labelled orthologue of Rv3030 from M. smegmatis. 
A. Metal affinity purification of labelled, SUMO tagged protein on Ni-sepharose column, cleavage 
of SUMO tag by UlpI protease and reverse binding on Ni-sepharose column. (MWM: molecular 
weight marker, L: cellular lysate, S: supernatant, FT1 and FT2: flow through, Pr1 and Pr2: 
tagged protein, 1: protein after Ulp1 cleavage of SUMO tag, 2: tag less protein obtained in the 
flow through after reverse binding). 
B. Gel filtration of tag-less labelled protein on Superdex-200 column.  
(MWM: molecular weight marker, F1 to F9: protein fractions).    
C. The gel filtration profile. 
C. 
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FIGURE 4.6    Expression and purification of 15N and 13C labelled orthologue of Rv3030 from 
        M. smegmatis. 
A. Metal affinity purification of labelled, SUMO tagged protein on Ni-sepharose column, cleavage 
of SUMO tag by UlpI protease and reverse binding on Ni-sepharose column (MWM: molecular 
weight marker, L: cellular lysate, S: supernatant, FT1 and FT2: flow through, Pr1 and Pr2: 
tagged protein, 1: protein after Ulp1 cleavage of SUMO tag, 2: tag less protein obtained in the 
flow through after reverse binding). 
B. Gel filtration of tag-less labelled protein on Superdex-200 column.  
(MWM: molecular weight marker, F1 to F10: protein fractions).     
C. The gel filtration profile. 
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4.5.3 Structural features of Apo Full-Length Orthologue of Rv3030 from                          
M. smegmatis determined by NMR Spectroscopy 
 
4.5.3.1 15N HSQC Spectrum 
 
The NMR measurements were made on protein at a concentration of 200 µM protein, in a 
buffer of 50 mM NaCl and 20 mM sodium phosphate pH 6.5 that contained 10% D2O and      
1 mM DDT. The 1H-15N HSQC spectrum of the protein showed that the peaks were well 
dispersed, in general had relatively narrow linewidths for a protein of this size (28 kDa), and 
were not severely overlapped (Figure 4.7). This confirmed that the protein was folded, and 
adopted a stable monomeric conformation under these conditions.   
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FIGURE 4.7    The 15N HSQC spectrum of apo-orthologue of Rv3030 from M. smegmatis. 
1H-15N HSQC spectrum of apo-orthologue of Rv3030 from M. smegmatis annotated with 
assignments of backbone and sidechain amides. Assignments of the peaks coloured purple and 
orange are shown on top left corner.  
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4.5.3.2 Resonance Assignment 
 
The resonance assignment was completed for the all the residues except for 113-115, 117-
118, and 156-164. The sidechain assignment was done using various 3D TOCSY experiments 
(Figure 4.8). The backbone resonances were assigned using a sequential assignment 
strategies based on 1H, 15N and 13C nuclei (Figure 4.9). The sequential assignment process 
was interrupted by presence of 15 prolines residues in the protein sequence, which was 
bridged by Dr. Katherine Stott, using connections apparent in the NOESY spectra.  
 
 
 
 
 
 
 
FIGURE 4.8    The HCCH-TOCSY spectrum, used for sidechain assignment.  
Representative 2D 1H-1H planes for Ala240. The 1H-13C-13C-1H cross peaks of the assigned 
residue are marked with red arrows.   
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FIGURE 4.9    Sequential backbone assignments.  
A stretch of six residues (175Glu-180Glu) of the orthlogue of Rv3030 from M. smegmatis. The 
sequential connections between the 13Cαs of the residues are marked with black arrows between 
HNCA (red) and HN(CO)CA (blue) spectra. The 13Cβ connections are marked with black 
dashed arrow between HNCACB (green) and HN(CO)CACB (purple) spectra.  
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4.5.3.3 Secondary Structure Characterisation and Protein Dynamics 
The secondary structures of Rv3030 orthologue in M. smegmatis were calculated using 
DANGLE, which gave a measure of backbone Phi and Psi angles (Figure 4.10). The 
measured secondary structures are mapped onto the sequence alignment between the M. tb 
and M. smegmatis protein (Figure 4.11).  
 
 
 
 
 
 
 
FIGURE 4.10    Measured torsion angles of the backbone of orthologue of Rv3030 from M. smegmatis. 
             Angles calculated from DANGLE. 
 
 
 
 
 
 
 
FIGURE 4.11    Sequence alignment between Rv3030 and its orthologue from M. smegmatis annotated    
                            with secondary structures calculated from DANGLE.  
                               Secondary structures are annotated as follows- α-helix: green rectangles, β-strands: maroon       
                               arrows. Motif- I and II of SAM-MTs are marked with yellow box. 
I II 
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The dynamics of apo-protein were measured using 1H-15N heteronuclear NOE (HetNOE). 
The results showed that, using a cut-off value of 0.6, residues 24-256 were relatively rigid. 
However, the residues 1-23 at the N-terminal of the protein showed a substantial decrease in 
the HetNOE values as compared to the rest of the protein, indicating high flexibity of the N-
terminus of the protein (Figure 4.12).  
The cross-peaks in 3D NOESY were assigned by Dr. Katherine Stott, and validated by 
presence of a return cross peak, where possible. Consistent stretches of long-range NOEs 
were observed between the β-strands. Using this information, the core β-sheet of the protein 
could be mapped out. There are 8 β-strands, of which two strands are anti-parallel, arranged 
in a topology typical of the Rossmann fold (Figure 4.13).  
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4.12    1H-15N 
heteronuclear NOEs for 
apo-orthologue of Rv3030 
from M. smegmatis. 
The decrease in the values 
of the heteronuclear NOE 
for residues 1-23 in the 
protein indicates that this 
region is disordered. 
 
FIGURE 4.13    β-sheet topology of orthologue of             
                            Rv3030 from M. smegmatis. 
The β-sheet topology of the enzyme 
was mapped using the calculated 
secondary structures and long range 
NOEs. Numbers represent the 
residue range. N: N-terminus, C: C-
terminus. 
 
Chapter-4        Probing the Structural Features of Orthologue of Rv3030 from M. smegmatis by SAXS   
                        and NMR Spectroscopy 
179 
 
4.5.3.4 Homology model of orthologue of Rv3030 in M. smegmatis based on NMR 
data 
In the light of experimentally derived information about the structural features of the enzyme, 
the three-dimensional structure was re-modelled. Distant homologues of known structures 
were used as the structural templates to construct a model of a large part of the structure of 
the M. smegmatis orthologue of Rv3030. The details of the templates used for model building 
is given in Table 4.2. 
The homology model shows that there are 7 β-strands, arranged in the typical Rossmann fold 
topology (Figure 4.14 A). The region between the residues 190-240 was modelled with low 
confidence, as it was the region with lowest identity and greatest structural divergence among 
the templates used for model building. It might be possible that the loop in this region 
(marked with a dashed box in Figure 4.14 A) could possibly form the additional anti-parallel 
β-strand of the β-sheet, as calculated from the NMR data. Supportively, the overall shape of 
the homology model of the enzyme exhibits high similarity with the ab initio shape 
reconstituted for the enzyme from the SAXS data (Figure 4.14 B).  
 
 
 
TABLE 4.2    Structural templates used for homology modelling of orthologue of Rv3030 from                             
                        M. smegmatis. 
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B.  
 
 
 
 
 
 
 
 
FIGURE 4.14    In silico modelling of three-dimensional structure of orthologue of Rv3030 from 
                            M. smegmatis 
A. Homology model of Rv3030 orthologue from M. smegmatis based on the findings on 
secondary structures of the enzyme determined by NMR.   
B. Homology model representated as the molecular surface (left) and the ab initio model from the 
SAXS study (right), shown in the same orientation. Both the models show high similarity in 
the overall shape of the enzyme.  
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4.6 Discussion 
The results in this chapter show that NMR and SAXS are viable methods to gain insights 
about overall structural properties of the enzyme, using orthologue of Rv3030 from              
M. smegmatis as the representative system. The analysis from SAXS demonstrated that the 
protein was folded and was globular in shape, with a bulge on one end. Initial investigation to 
determine the suitability of protein to carry out NMR-based structure determination was 
assessed by the 15N-HSQC spectrum, which showed that the peaks were well-dispersed. 
Based on this, further expression and purification of protein labelled with 15N and 13C 
isotopes was done to elucidate its three-dimensional structure. Although M. smegmatis 
orthologue of Rv3030 is a large protein, the resonance assignment process was relatively 
straightforward due to well-resolved peaks, and generated unambiguous data set. The 
secondary structures and backbone torsion angles of the protein were calculated using 
DANGLE. Long-range NOEs were observed for the 8 β-strands in the protein, which formed 
the core β-sheet, with a topology characteristic of the Rossmann fold. The structure 
calculation process is underway to determine the complete three-dimensional view of the 
protein’s architecture.  
The dynamics of this methyltransferse were studied using heteronuclear NOE, which 
depicted that the residues 1-23 of the N-terminus are disordered, as they had high 
heteronuclear NOE values. This experimental validation was reassuring, as the rationale was 
applied and truncations of this region were made to obtain well-diffracting crystals (discussed 
in chapter-3). The information gathered about the secondary structural features of the protein 
assisted in modelling the three dimensional structure of the protein, which exhibited the 
typical Rossmann fold architecture. The molecular suface of the model was similar to the ab 
initio shape reconstituted from the SAXS data.  
Overall, the on-going elucidation of the overall structure of the protein will be useful in 
understanding the basic molecular mechanisms, such as the mode of catalysis and substrate 
recognition, and will provide a structural scaffold for carrying out structure-based drug 
designing.  
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Given the central role of glycobiology to the cell wall of mycobacteria, the structure, 
biosynthesis and biology of saccharides have become central to the design of antimicrobials. 
The advantage of targets that are enzymes involved in biosynthesis has been further 
underlined by their relative accessibility to small molecules that might be effective in killing 
these important agents of infectious disease. In this thesis, I describe the fundamental 
biochemical and structural biology studies that provide the groundwork for assessing the 
tractability of two enzymes for structure-guided, fragment-based discovery of new 
therapeutic agents. 
Mycobacterial Trehalose-6-Phosphate Synthase 
Trehalose plays a pivotal role in defining the architecture of the cell wall and physiology of 
mycobacteria. Although M. tb possesses two independent routes for synthesis of trehalose, 
the prime OtsA-OtsB2 pathway is critical for therapeutic intervention targeting trehalose 
biosynthesis. This is because the inactivation of this pathway leads to pronounced growth 
defects and mortality of the bacilli, whereas knock-outs of the other pathway, TreyYZ, have 
no effects on in vitro growth (Murphy et al., 2005).  
The crystal structures of M. thermoresistibile OtsA described in this work provide the first 
information on a mycobacterial OtsA, giving a structural view of the M. tuberculosis enzyme, 
as both the enzymes share a high percentage of sequence identity, and the residues essential 
for catalysis are completely conserved. The structures, determined in apo and ligand-bound 
forms, present the catalytic site in both ‘open’ and ‘closed’ conformations. The apo-structure 
of mycobacterial OtsA, solved at 2.18 Å resolution, was the first structure of this retaining 
glycosyltransferase in the apo-form, with subsequent determination of the apo-structure of 
OtsA from B. xenovorans. The protein structure belongs to the GT-B structural class of 
glycosyltransferases, having the characteristic two Rosmann-fold domains. As observed for 
other GT-B glycosyltransferases, mycobacterial OtsA also exhibits different structural states 
defined by ligand binding, and vital for its trehalose-6-phosphate synthase activity.                      
M. thermoresistibile OtsA assembles as a tetramer in both solution and in the crystal 
structures obtained. However, this tetrameric organisation is not conserved among different 
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species and different oligomeric states have been reported. For example, E. coli OtsA exists 
both as a dimer and a tetramer in solution (Gibson et al., 2002a). 
Mycobacterial OtsAs can process different NDP-glucose donor-substrates (Pan et al., 1996, 
2002). The biochemical data of M. thermoresistibile OtsA showed that the enzyme has a 
predisposition for purine-derived NDP-glucoses, particularly for ADP-glucose. This is in 
contrast to E. coli OtsA, which prefers UDP-glucose as the donor substrate (Gibson et al., 
2002b). Important insights are gained from the donor-bound structures of                              
M. thermoresistibile OtsA, which exemplifies structural differences that could potentially 
contribute to different glucose-donor substrate preferences. The structural environment of the 
nucleotide-binding pocket defines the preference for ADP-glucose by M. thermoresistibile 
OtsA. The substitution of residues of the catalytic site (Ile295 and Phe399 in E. coli for 
Leu319 and Val363 in M. thermoresistibile, respectively) enlarges and deepens the catalytic 
site cleft, allowing the primary amine of the adenine ring to occupy a deep pocket, which 
might account for the strong preference for ADP-glucose by mycobacterial OtsAs. In support 
of this hypothesis, analysis of amino-acid conservation demonstrates that, although the 
catalytic core of the enzyme is conserved, a few residues of the donor-binding site, especially 
those interacting with the nitrogenous base of the donor-substrate, are not under the pressure 
of evolutionary conservation. These observations give clues as to how a sequence-structure 
relationship alters the substrate specificity.  
An early-stage drug discovery exercise, using a fragment-based approach, was carried out 
against this target. The screening of the fragment library by a fluorescence-based thermal-
shift assay led to identification of hits that bind to the enzyme, and have an inhibitory effect 
on the activity. However, various attempts to obtain fragment-bound crystal structures did not 
bear any fruit. The preliminary data on the fragments identified may serve as a starting point 
for potential structure-guided drug-designing campaign against this vital target. 
Overall, the structure-function analyses of M. thermoresistibile OtsA described in this thesis 
provide an in-depth knowledge of the mycobacterial enzyme. This knowledge, along with the 
preliminary data on prospective fragment hits, opens the avenues for further investigation of 
this target at the molecular level, and for rational development of specific inhibitors against it.  
The structural basis for donor-substrate specificity of OtsA presented in this thesis requires 
further experimental scrutiny. This could be achieved by creating mutations of the interacting 
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residues, particularly Leu319 and Val363, in the catalytic site. The effects on the structure of 
the enzyme can be studied by obtaining structures of the mutants bound with various glucose-
donor substrates, and important insights on how the catalysis is modulated, can be gained 
through the kinetic studies. The structures and functional assay of the wild type 
mycobacterial OtsA reported in this study can serve as a reference for the comparative 
analyses. 
Additionally, it is of great interest to understand whether formation of a tetrameric assembly 
by mycobacterial OtsA has any biological relevance, as it is not conserved among species. It 
is also of interest to investigate whether OtsA in mycobacteria forms any complex with 
OtsB2, the phosphatase in the pathway. The rationale for this is derived from the fact that in 
some organisms, such as S. cerevisae, OtsA and OtsB are part of a complex for trehalose 
biosynthesis (Bell et al., 1998). This is especially important for the drug-development 
targeting trehalose biosynthesis, as inhibitors might then be developed that target the entire 
complex and more effectively inhibit trehalose biosynthesis in M. tb, thereby seriously 
damaging the cell wall formation and viability of M. tb.  
The identification of chemical moieties that bind to and inhibit this mycobacterial OtsA has 
laid the foundation for initiating drug-discovery campaign against this target. This will 
provide a completely novel spectrum to combat the TB infection by targeting an 
indispensible saccharide in the context of biology of M. tb. Although it was not possible to 
obtain structural information with the current set of fragments tested, it would still be of 
interest to further screen these molecules by other biophysical methods, such as ITC or 
surface plasmon resonance to obtain their binding affinities. These fragments can then be 
modified by addition or substitution of different functional groups, and their potency can be 
measured. Alternately, virtual screening can also help in identification of analogues of current 
fragment hits or new chemical scaffolds can be identified. The structures of                          
M. thermoresistibile OtsA can serve as structural templates for performing the in silico 
identification of hits, which can be subsequently validated and optimised experimentally. 
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Rv3030: SAM dependent-methyltransferase in MGLP biosynthesis 
Polymethylated polysaccharides (PMPSs) are unique to mycobacteria, and of its two types, 
only MGLPs are found in the slow growing pathogenic mycobacteria. This makes this 
pathway interesting to study, especially in determining the structures of the essential enzymes 
involved in its biosynthesis and in designing a drug-development strategy against them. Of 
the many enzymes involved in this pathway, Rv3030, a SAM-dependent methyltransferase, is 
a critical target, as demonstrated by earlier knock-out studies of this enzyme, which showed 
low-levels of MGLP production and severe impaired growth of the bacteria. In the current 
study, this target was structurally evaluated using a combinatorial approach of various 
structure-determination techniques, and is a good example of how small contributions from 
different techniques can complement each other effectively to gain insights into an enzyme’s 
structural features.   
The initial investigation by crystallisation was not successful, as low-resolution diffraction 
crystals of the full-length orthologue of Rv3030 from M. smegmatis were observed only in 
one condition of the many that were trialled, and these took a long time to form and the 
condition was not reproducible. Data from circular dichroism indicated that the full-length 
protein was folded. This was reassuring in the absence of a biochemical assay to test the 
activity of the enzyme, due to lack of availability of its required substrate. The homology 
model of the structure of the protein indicated that the N-terminus of the protein was 
probably disordered, potentially interfering with crystallisation. These N-terminus residues 
were, therefore, truncated in order to make the protein ammeneable for crystallisation and 
several constructs were prepared with varying degrees of truncations. Although, there were 
no instability issues with the truncated proteins, and all the truncated proteins expressed in 
exceptionally high amounts with high purity, no crystals were produced.  
The analyses by AUC and SAXS demonstrated that the protein was monomeric, folded and 
globular. The overall shape of the protein conformed to a slightly elongated globular structure 
with a bulge on one end. With encouraging data about the shape and folding state of the 
protein, I explored NMR spectroscopy as a viable route to gain insights into the full-length 
structure of Rv3030 orthologue in M. smegmatis. Expression and purification of labelled 
protein was straightforward, similar to that of the unlabelled protein, with ample amount of 
labelled protein purified to homogeneity. The 15N-HSQC fingerprint of the protein revealed 
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that, even though the size of the protein was on the upper limit for NMR study, the spectrum 
was well resolved, with few severely overlapped peaks. This encouraged me to undertake 
advanced multi-dimensional NMR experiments, for thorough assessment of the structure of 
the full-length protein. The backbone and side-chain assignments proved feasible due to well-
resolved peaks in the spectra, and secondary structures were characterised. The structure 
calculations are still underway to gain a holistic picture of the three-dimensional structure of 
the methyltransferase.  
Nevertheless, some important information was gained from the NMR analysis through 
characterisation of the secondary structure and dynamic behaviour of the protein in solution. 
The protein has the β-sheet topology typical of the Rossmann-fold. The experimental data 
from 15N-heteronuclear NOEs pointed out to the N-terminal region being intrinsically 
disordered.  This was reassuring, and experimentally validated the observation from the in 
silico model, based on which truncated constructs had been prepared.  
Overall, SAXS and NMR spectroscopy have been shown to be feasible approaches for 
gaining structural insights into this protein. As many experienced structural biologists can 
attest to, these methods have been vital tools in gaining knowledge about intrinsically 
disordered proteins. The elucidation of complete three-dimensional structure of Rv3030 will 
answer some key questions. Firstly, it would be possible to determine if the disordered N-
terminus is making any interactions with rest of the structure, and if this region plays an 
important role in the overall protein stability. Secondly, it would also be possible to 
determine if this region defines the architecture of the catalytic pocket. This can be achieved 
by utilising the already prepared truncated constructs, and expressing and purifying the 
labelled, truncated proteins. The 15N-HSQC spectra of the full-length and truncated proteins 
can then be compared and evaluated for any observeable changes in the spectra, which can 
give a measure on the effects that the truncations might have on the overall protein folding. 
This may also be useful for fine-tuning the domain boundaries of the enzyme that can be used 
for crystallisation. Also, it would also be possible to determine if the residues in this region 
are part of the binding pocket, or if they facilitate ligand binding. This can be achieved by 
performing titration experiments with the co-factor, SAM, and measuring the chemical shift 
pertubations. In the broader context, given the essentiality of this enzyme in the bacilli, it 
might be useful to identify lead chemical molecules that target this enzyme, for the 
development of novel anti-TB therapies.  
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A final word  
It is essential to understand the basic molecular mechanisms of the potential drug-targets, to 
exploit their full potential in effective, targeted treatment of tuberculosis. A combined 
structural and functional approach should provide a comprehensive understanding and pave 
way for the development of specific and potent anti-TB drugs.   
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Appendix-I    Chemical Shift Assignments of Apo Rv3030 Orthologue from 
M. smegmatis 
The chemical shift assignments of the full-length apo Rv3030 orthologue in M. smegmatis 
(Chapter-4, Section 4.5.3.2) are listed in this appendix. All shifts are reported in ppm.  
RESIDUE 
NUMBER 
RESIDUE H N C CA OTHERS 
1 Met - - 174.58 54.46 4.47:Ha     2.09:Hb2    2.09:Hb3    
2.62:Hg2    2.62:Hg3    2.12:He*   
30.51:Cb    30.62:Cg    14.91:Ce 
2 Gly 8.61 110.78 171.69 43.12 3.90:Haa    4.04:Hab 
3 Asp 8.09 121.43 - 50.71 4.90:Ha     2.61:Hba    2.77:Hbb   
38.75:Cb 
4 Pro - - 174.99 61.72 4.45:Ha     2.34:Hb2    2.34:Hb3    
1.96:Hba    2.34:Hbb    2.04:Hg2    
2.04:Hg3    3.76:Hda    3.87:Hdb   
30.06:Cb    25.46:Cg    49.05:Cd 
5 Asp 8.41 119.3 174.21 52.7 4.59:Ha     2.64:Hba    2.71:Hbb   
39.09:Cb 
6 Asn 8.14 118.58 172.67 51.27 112.67:Nd2    4.70:Ha     
2.80:Hb2    2.80:Hb3    2.75:Hba    
2.83:Hbb    6.90:Hd2a   
7.67:Hd2b  37.15:Cb 
7 Ala 8.2 123.66 175.48 50.49 4.33:Ha     1.39:Hb*   17.42:Cb 
8 Leu 8.21 122.41 - 51.15 4.60:Ha     1.58:Hba    1.60:Hbb    
1.68:Hg     0.92:Hda*   0.93:Hdb*  
39.83:Cb    25.09:Cg    21.54:Cda   
23.17:Cdb 
9 Pro - - 174.96 61.45 4.44:Ha     1.95:Hba    2.31:Hbb    
2.04:Hg2    2.04:Hg3    3.64:Hda    
3.86:Hdb   30.12:Cb    25.66:Cg    
48.83:Cd 
10 Ser 8.28 115.11 172.21 56.39 4.39:Ha     3.87:Hb2    3.87:Hb3   
61.93:Cb 
11 Ala 8.24 125.38 - 50.22 4.38:Ha     1.34:Hb*   17.67:Cb 
11 Ala - - 175.19 -   
12 Leu 8.15 122.32 - 51.16 4.60:Ha     1.59:Hb2    1.59:Hb3    
1.58:Hba    1.60:Hbb    1.68:Hg     
0.92:Hda*   0.93:Hdb*  39.84:Cb    
25.09:Cg    21.54:Cda   
23.17:Cdb 
13 Pro - - 174.72 60.99 4.45:Ha     1.92:Hba    2.31:Hbb    
2.03:Hg2    2.03:Hg3    3.64:Hda    
3.86:Hdb   29.89:Cb    25.66:Cg    
48.60:Cd 
14 Leu 8.37 121.95 175.58 53.21 4.37:Ha     1.60:Hb2    1.60:Hb3    
1.67:Hg     0.87:Hda*   0.92:Hdb*  
40.18:Cb    25.08:Cg    21.58:Cda   
23.19:Cdb 
 
Appendix-I                        Chemical Shifts Assignments of Apo Orthologue of Rv3030 in M. smegmatis 
191 
 
RESIDUE 
NUMBER 
RESIDUE H N C CA OTHERS 
15 Thr 8.04 113.4 173.04 59.86 4.28:Ha     4.19:Hb     1.17:Hg2*  
67.96:Cb    19.62:Cg2 
16 Gly 8.35 110.57 172.04 43.3 3.82:Ha2    3.82:Ha3 
17 Glu 8.24 120.17 174.43 54.64 4.30:Ha     1.93:Hba    2.07:Hbb    
2.24:Hg2    2.24:Hg3   28.55:Cb    
34.46:Cg 
18 Arg 8.45 121.59 174.28 54.17 4.47:Ha     1.68:Hb2    1.68:Hb3   
29.03:Cb 
19 Thr 8.32 116.37 172.14 59.82 4.41:Ha     4.18:Hb     1.25:Hg2*  
68.15:Cb    20.09:Cg2 
20 Ile 8.27 123.24 - 56.55 4.46:Ha     1.79:Hb     1.12:Hg1a   
1.42:Hg1b   0.86:Hg2*   
0.80:Hd1*  37.12:Cb    24.54:Cg1   
15.40:Cg2   10.99:Cd1 
21 Pro - - 175.44 60.45 3.11:Ha     1.61:Hba    1.70:Hbb    
1.76:Hga    1.93:Hgb    3.52:Hda    
3.65:Hdb   30.11:Cb    25.25:Cg    
48.97:Cd 
22 Gly 7.82 107.02 171.67 44.06 3.60:Haa    3.85:Hab 
23 Leu 7.36 120.27 175.87 51.87 4.58:Ha     1.35:Hba    1.60:Hbb    
1.51:Hg     0.88:Hda*   0.91:Hdb*  
41.20:Cb    25.24:Cg    22.26:Cda   
22.72:Cdb 
24 Ala 8.95 132.64 177.06 54.32 4.00:Ha     1.28:Hb*   16.50:Cb 
25 Glu 9.39 112.88 176.15 57.26 3.38:Ha     1.85:Hb2    1.85:Hb3    
1.65:Hga    2.03:Hgb   27.32:Cb    
34.87:Cg 
26 Glu 7.34 115.96 175.44 53.37 5.02:Ha    29.00:Cb 
27 Asn 7.86 117.21 174.43 56.45 4.56:Ha     2.87:Hb2    2.87:Hb3   
38.82:Cb 
28 Tyr - - 173.1 -   
28 Tyr 8.36 117.13 - 61.18 3.96:Ha     2.94:Hb2    2.94:Hb3   
35.67:Cb 
29 Trp 6.86 119.1 175.63 57.18 128.32:Ne1    3.82:Ha     
3.33:Hba    3.45:Hbb    7.77:Hd1   
10.03:He1    7.66:He3    7.51:Hz2    
7.13:Hz3    7.25:Hh2   27.81:Cb   
126.84:Cd1  118.58:Ce3  
112.96:Cz2  119.78:Cz3  
122.85:Ch2 
30 Phe 8.69 117.97 176.07 59.52 4.27:Ha     2.96:Hba    3.31:Hbb    
6.56:Hd*    6.18:He*    6.42:Hz    
38.27:Cb   128.78:Cd*  
127.51:Ce*  125.57:Cz 
31 Arg 8.45 116.18 174.92 54.88 3.90:Ha     2.64:Hb2    2.64:Hb3   
27.44:Cb 
32 Arg 7.6 118.91 174.87 56.02 28.15:Cb 
33 His 7.4 115.39 175.71 54.18 4.59:Ha     3.34:Hba    3.48:Hbb   
27.99:Cb 
34 Glu 9.12 123.92 176.64 57.53 4.02:Ha     1.46:Hba    1.88:Hbb    
2.17:Hg2    2.17:Hg3   27.92:Cb    
34.34:Cg 
35 Val 8.02 116.2 172.96 63.47 3.69:Ha     1.99:Hb     0.68:Hga*   
1.07:Hgb*  29.37:Cb    17.40:Cga   
22.12:Cgb 
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36 Val 6.46 118.15 174.99 65.02 3.19:Ha     1.21:Hb    -0.12:Hga*   
0.49:Hgb*  29.28:Cb    20.13:Cga   
21.38:Cgb 
37 Tyr 6.57 114.22 175.81 61.01 3.97:Ha     2.93:Hba    3.15:Hbb    
7.11:Hd*    6.72:He*   37.77:Cb   
131.37:Cd*  116.72:Ce* 
38 Gln 8.21 113.3 178.3 57.4 111.32:Ne2    4.08:Ha     
2.19:Hb2    2.19:Hb3    2.40:Hga    
2.57:Hgb    7.01:He2a   
7.62:He2b  27.12:Cb    31.86:Cg 
39 Arg 8.58 114.51 175.85 55.12 84.82:Ne     4.39:Ha     1.83:Hba    
1.97:Hbb    1.84:Hga    1.98:Hgb    
3.22:Hda    3.38:Hdb    7.36:He    
27.98:Cb    25.85:Cg    40.34:Cd 
40 Leu 7.48 115.1 175.84 52.51 4.62:Ha     1.57:Hba    1.81:Hbb    
1.57:Hg     0.75:Hda*   0.78:Hdb*  
39.57:Cb    25.50:Cg    24.15:Cda   
21.05:Cdb 
41 Ala 7.7 123.85 177.78 54.65 3.81:Ha     1.55:Hb*   15.48:Cb 
42 His 8.73 113.23 176.27 57.34 4.38:Ha     3.15:Hba    3.27:Hbb   
26.54:Cb 
43 Arg 7.34 118.95 174.37 53.3 80.48:Ne     4.12:Ha     1.86:Hb2    
1.24:Hba    1.84:Hbb    0.95:Hga    
1.25:Hgb    2.98:Hda    3.26:Hdb    
7.34:He    26.66:Cb    25.47:Cg    
38.82:Cd 
44 Cys 8.08 112.71 172.5 56.72 4.06:Ha     2.77:Hba    3.20:Hbb   
27.15:Cb 
45 Ala 7 122.66 176.94 51.47 3.85:Ha     1.44:Hb*   16.16:Cb 
46 Gly 9.08 110.32 172.18 44.63 3.86:Haa    4.07:Hab 
47 Arg - - - -   
47 Arg 7.57 116.54 174.04 52.46 4.71:Ha     1.51:Hba    1.96:Hbb    
1.40:Hga    1.61:Hgb    3.00:Hd2    
3.00:Hd3   31.18:Cb    25.52:Cg    
41.40:Cd 
48 Asp 10.11 123.88 173.69 52.6 5.31:Ha     2.72:Hb2    2.72:Hb3   
39.06:Cb 
49 Val 9.03 126.45 171.96 58.85 4.95:Ha     2.08:Hb     0.84:Hga*   
0.88:Hgb*  33.58:Cb    19.13:Cga   
20.04:Cgb 
50 Leu 8.99 126.9 173.2 50.6 5.55:Ha     1.31:Hba    2.02:Hbb    
1.40:Hg     0.81:Hda*   0.93:Hdb*  
44.03:Cb    25.58:Cg    22.07:Cda   
25.34:Cdb 
51 Glu 9.61 127.28 172.56 53.44 5.13:Ha     1.36:Hba    1.84:Hbb    
1.67:Hga    2.02:Hgb   27.13:Cb    
34.34:Cg 
52 Ala 8.62 130.82 171.99 48.77 4.51:Ha     1.46:Hb*   16.31:Cb 
53 Gly 8.62 114.55 172.14 44.48 4.03:Haa    4.38:Hab 
54 Cys 8.2 117.18 173.27 56.46 4.45:Ha     2.36:Hba    3.00:Hbb   
27.47:Cb 
55 Gly 8.93 114.39 170.67 44.88 3.65:Haa    3.87:Hab 
56 Glu 8.5 122.68 174.52 57.58 3.91:Ha     2.10:Hba    2.57:Hbb    
2.37:Hga    2.56:Hgb   28.38:Cb    
34.45:Cg 
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57 Gly 7.23 98.3 171.61 43.72 3.25:Haa    4.34:Hab 
58 Tyr 7.86 119.17 175.56 58.92 36.10:Cb 
59 Gly 7.67 109.33 172.42 43.03 1.79:Haa    2.63:Hab 
60 Ala 7.49 125.96 177.42 52.96 3.79:Ha     1.35:Hb*   14.65:Cb 
61 Asp 7.57 116.84 175.42 55.57 4.01:Ha     1.74:Hba    1.97:Hbb   
41.50:Cb 
62 Leu 7.46 119.11 179.89 56.26 4.00:Ha     1.58:Hba    1.83:Hbb    
1.75:Hg     0.84:Hda*   0.92:Hdb*  
39.73:Cb    24.71:Cg    22.29:Cda   
24.20:Cdb 
63 Ile 8.16 120.21 176.3 62.65 3.57:Ha     2.09:Hb     1.22:Hg1a   
1.94:Hg1b   0.89:Hg2*   
0.93:Hd1*  35.11:Cb    27.43:Cg1   
17.25:Cg2   10.97:Cd1 
64 Ala 8.49 123.95 175.78 52.43 3.92:Ha     1.38:Hb*   14.87:Cb 
65 Asp 7.34 115.55 175.54 55.46 4.51:Ha     2.70:Hba    2.99:Hbb   
39.53:Cb 
66 Val 7.65 106.38 174.91 58.58 4.77:Ha     2.17:Hb     0.87:Hga*   
0.94:Hgb*  32.31:Cb    16.07:Cga   
19.85:Cgb 
67 Ala 8.36 127.2 175.09 50.49 4.83:Ha     1.39:Hb*   19.06:Cb 
68 Arg 8.97 122.74 175.25 57.3 4.19:Ha     1.43:Hba    1.67:Hbb    
1.51:Hga    1.67:Hgb    3.17:Hda    
3.31:Hdb   28.52:Cb    25.31:Cg    
42.05:Cd 
69 Arg 7.57 115.26 171.74 53.88 4.52:Ha     1.91:Hb2    1.90:Hb3    
1.65:Hg2    1.65:Hg3    3.20:Hd2    
3.20:Hd3   31.89:Cb    25.01:Cg    
42.03:Cd 
70 Val 9.06 124.08 172.07 59.32 4.90:Ha     1.88:Hb     0.81:Hga*   
0.81:Hgb*  32.28:Cb    18.54:Cga   
20.39:Cgb 
71 Ile 9.42 129.22 173.44 57.64 4.84:Ha     1.65:Hb     1.06:Hg1a   
1.39:Hg1b   0.80:Hg2*   
0.79:Hd1*  38.44:Cb    25.88:Cg1   
15.21:Cg2   12.45:Cd1 
72 Gly 8.82 113.22 169.04 41.69 3.14:Haa    5.10:Hab 
73 Leu 8.45 123.83 173.52 50.78 5.55:Ha     1.29:Hba    1.60:Hbb    
1.38:Hg     0.72:Hda*   0.77:Hdb*  
45.38:Cb    25.58:Cg    23.45:Cda   
24.97:Cdb 
74 Asp 8.56 124.88 172.04 52.53 4.81:Ha     2.49:Hba    2.57:Hbb   
45.57:Cb 
75 Tyr 7.85 120.3 174.06 55.16 4.96:Ha     3.09:Hba    3.37:Hbb    
7.10:Hd*    6.79:He*   37.30:Cb   
131.32:Cd*  116.31:Ce* 
76 Asp 8.75 124.22 174.29 51.42 5.02:Ha     2.48:Hba    2.98:Hbb   
40.99:Cb 
77 Glu 9.3 127.49 176.48 58.42 3.54:Ha     1.88:Hb2    1.88:Hb3    
1.88:Hga    1.99:Hgb   27.67:Cb    
34.50:Cg 
78 Ala 8.63 122.33 178.88 53.02 4.20:Ha     1.48:Hb*   15.96:Cb 
79 Thr 7.79 117.77 174.1 64.41 3.94:Ha     4.42:Hb     1.08:Hg2*  
66.41:Cb    20.91:Cg2 
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80 Val 7.83 121.64 174.94 64.86 3.45:Ha     2.15:Hb     0.88:Hga*   
0.96:Hgb*  29.36:Cb    18.72:Cga   
21.08:Cgb 
81 Ala 7.8 119.05 178.62 53.08 4.03:Ha     1.49:Hb*   16.06:Cb 
82 His 7.94 118.21 174.86 57.31 4.41:Ha     3.32:Hba    3.56:Hbb   
27.47:Cb 
83 Val 8.59 120.58 175.77 65.17 3.60:Ha     2.15:Hb     1.11:Hga*   
1.22:Hgb*  30.14:Cb    20.09:Cga   
21.74:Cgb 
84 Arg 8.2 117.63 175.91 56.43 4.27:Ha     1.83:Hb2    1.83:Hb3    
1.64:Hga    1.82:Hgb    3.20:Hda    
3.27:Hdb   28.45:Cb    25.84:Cg    
41.96:Cd 
85 Ala 7.16 116.25 176.94 51.61 4.17:Ha     1.42:Hb*   17.28:Cb 
86 Arg 7.95 116.7 174.18 55.05 84.79:Ne     3.96:Ha     0.82:Hba    
1.10:Hbb    0.56:Hga    0.81:Hgb    
2.92:Hd2    2.92:Hd3    7.06:He    
29.40:Cb    24.63:Cg    40.73:Cd 
87 Tyr 8.56 117.08 - 52.2 5.32:Ha     2.95:Hb2    2.95:Hb3    
7.02:Hd*    7.08:He*   36.29:Cb   
131.47:Cd*  115.78:Ce* 
88 Pro - - 175.86 62.4 4.61:Ha     1.94:Hba    2.44:Hbb    
2.00:Hg2    2.00:Hg3    3.30:Hd2    
3.30:Hd3   30.18:Cb    25.11:Cg    
48.52:Cd 
89 Arg 8.41 115.17 174.86 55.85 4.29:Ha     1.86:Hb2    1.86:Hb3   
28.91:Cb 
90 Val 8 119.94 172.91 60.72 3.74:Ha     2.19:Hb     0.67:Hg1*   
0.67:Hg2*   0.66:Hga*   
0.69:Hgb*  30.48:Cb    18.84:Cga   
19.07:Cgb 
91 Asp 8.62 128.29 172.96 50.88 4.83:Ha     2.70:Hba    3.18:Hbb   
37.67:Cb 
92 Ile 7.64 124.1 171.75 55.16 4.97:Ha     1.65:Hb     1.31:Hg1a   
1.52:Hg1b   1.08:Hg2*   
0.87:Hd1*  38.70:Cb    28.30:Cg1   
16.34:Cg2   12.58:Cd1 
93 Arg 8.91 125.98 171.87 51.96 85.39:Ne     4.75:Ha     1.61:Hba    
1.92:Hbb    1.59:Hga    1.72:Hgb    
2.93:Hda    3.15:Hdb    7.13:He    
30.98:Cb    24.83:Cg    41.77:Cd 
94 His 8.77 120.97 - 52.59 30.81:Cb 
94 His - - 173.8 - 5.38:Ha     3.12:Hb2    3.12:Hb3    
7.02:Hd2  115.74:Cd2 
95 Gly 7.71 113.32 167.74 43.74 3.65:Haa    3.92:Hab 
96 Asn 8.57 117.35 173.48 50.04 112.64:Nd2    4.65:Ha     
2.82:Hb2    2.82:Hb3    7.07:Hd2a   
7.67:Hd2b  38.17:Cb 
97 Leu 8.18 120.38 173.13 54.98 3.99:Ha     1.58:Hb2    1.58:Hb3    
1.58:Hg     0.60:Hda*   0.72:Hdb*  
38.83:Cb    26.88:Cg    21.88:Cda   
23.49:Cdb 
98 Ala 7.7 115.66 175.05 51.17 4.32:Ha     1.45:Hb*   17.59:Cb 
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99 Glu 7.42 117.39 173.27 52.49 4.40:Ha     1.77:Hba    1.89:Hbb    
2.06:Hg2    2.06:Hg3   29.30:Cb    
34.24:Cg 
100 Leu 9.57 124.33 - 50.66 4.52:Ha     1.81:Hba    1.85:Hbb    
1.52:Hg     0.72:Hda*   0.92:Hdb*  
39.63:Cb    25.27:Cg    24.64:Cda   
22.60:Cdb 
101 Pro - - 172.99 61.03 4.80:Ha     1.70:Hba    2.18:Hbb    
1.98:Hga    2.45:Hgb    3.30:Hda    
3.76:Hdb   26.43:Cb    30.17:Cg    
48.51:Cd 
102 Leu 8.03 121.61 - 50.55 4.90:Ha     1.16:Hba    1.78:Hbb    
1.52:Hg     0.82:Hda*   0.91:Hdb*  
42.90:Cb    26.91:Cg    24.49:Cda   
22.73:Cdb 
103 Pro - - 173.38 59.43 4.59:Ha     1.93:Hba    2.42:Hbb    
1.93:Hga    1.99:Hgb    3.53:Hda    
3.82:Hdb   30.76:Cb    25.26:Cg    
48.79:Cd 
104 Asp 8.33 120.06 173.76 52.74 4.02:Ha     2.48:Hba    2.66:Hbb   
37.56:Cb 
105 Ala 8.68 121.44 173.47 50.68 3.43:Ha     1.30:Hb*   15.31:Cb 
106 Ser 8.75 110.5 172.35 56.87 4.57:Ha     3.41:Hba    3.87:Hbb   
64.09:Cb 
107 Val 7.92 113.08 171.72 58.05 4.71:Ha     2.21:Hb     0.63:Hga*   
0.78:Hgb*  33.98:Cb    21.02:Cg2   
16.87:Cga   20.93:Cgb 
108 Asp 8.61 117.75 174 54.41 4.90:Ha     2.94:Hba    3.05:Hbb   
42.68:Cb 
109 Val 7.79 118.62 173.34 57.83 5.67:Ha     1.89:Hb     0.93:Hg1*   
0.93:Hg2*  35.90:Cb    19.67:Cg1   
19.67:Cg2 
110 Val 9.06 126.5 171.93 58.84 5.35:Ha     1.87:Hb     0.84:Hga*   
0.95:Hgb*  32.66:Cb    20.68:Cga   
20.12:Cgb 
111 Val 9.39 127.55 172.59 59 4.28:Ha     1.35:Hb    -0.25:Hga*   
0.58:Hgb*  32.36:Cb    18.26:Cga   
19.69:Cgb 
112 Asn 8.34 126.08 - 51.87 5.12:Ha     2.75:Hba    3.06:Hbb   
41.14:Cb 
113 Phe - - - -   
114 Gln - - - -   
115 Val - - - -   
116 Ile - - - 63.13 3.61:Ha     2.07:Hb     1.17:Hg1a   
1.54:Hg1b   0.64:Hg2*   
0.91:Hd1*  36.02:Cb    27.87:Cg1   
14.97:Cg2   12.82:Cd1 
117 Glu - - - -   
118 His - - - -   
119 Leu - - 176.59 52.11 4.61:Ha     1.34:Hba    1.77:Hbb    
1.78:Hg     0.24:Hda*   0.64:Hdb*  
40.72:Cb    24.00:Cg    24.00:Cda   
19.93:Cdb 
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120 Trp 8.83 123.88 174.81 57.34 128.70:Ne1    4.65:Ha     
3.19:Hba    3.46:Hbb    7.36:Hd1   
10.15:He1    7.77:He3    7.58:Hz2    
7.18:Hz3    7.32:Hh2   27.86:Cb   
125.30:Cd1  118.71:Ce3  
113.04:Cz2  120.09:Cz3  
123.09:Ch2 
121 Asp 8.52 120.01 175.04 50.67 4.99:Ha     2.53:Hba    3.08:Hbb   
37.76:Cb 
122 Gln 8.31 122.42 175.79 57.77 3.86:Ha     2.22:Hb2    2.22:Hb3    
2.37:Hga    2.48:Hgb   26.65:Cb    
32.95:Cg 
123 Ala 8.68 121.11 178.48 53.41 4.15:Ha     1.50:Hb*   16.03:Cb 
124 Gln 8.19 119.94 176.87 56.7 111.02:Ne2    4.09:Ha     
2.01:Hba    2.19:Hbb    2.41:Hga    
2.56:Hgb    7.02:He2a   
7.55:He2b  26.18:Cb    31.60:Cg 
125 Phe 7.68 119.23 175.66 59.3 4.36:Ha     3.04:Hba    3.38:Hbb    
7.25:Hd*    7.09:He*    6.91:Hz    
37.25:Cb   130.10:Cd*  
128.52:Ce*  128.31:Cz 
126 Val 8.5 117.84 176.25 65.61 3.30:Ha     2.23:Hb     1.19:Hga*   
1.23:Hgb*  29.35:Cb    21.73:Cga   
21.31:Cgb 
127 Ser 8.16 116.25 175.35 60.43 4.30:Ha     4.05:Hb2    4.05:Hb3   
60.87:Cb 
128 Glu 7.89 125.6 175.88 56.56 4.32:Ha     1.90:Hba    2.52:Hbb    
2.26:Hga    2.44:Hgb   29.09:Cb    
36.23:Cg 
129 Cys 7.47 118.18 172.86 61.82 3.55:Ha     1.12:Hba    2.40:Hbb   
23.80:Cb 
130 Phe 7.72 116.71 174.15 59.81 3.43:Ha     2.47:Hba    3.18:Hbb    
6.86:Hd*    5.87:He*    7.10:Hz    
36.83:Cb   128.38:Cd*  
129.67:Ce*  131.31:Cz 
131 Arg 7.77 116.55 177.86 57.51 3.97:Ha     1.88:Hb2    1.88:Hb3   
28.49:Cb 
132 Val 7.67 - - 61.43   
132 Val - 109.34 173.62 - 4.25:Ha     2.25:Hb     0.77:Hga*   
0.85:Hgb*  29.80:Cb    17.16:Cga   
20.42:Cgb 
133 Leu 7.08 123.67 174.88 52.93 4.32:Ha     1.65:Hb2    1.65:Hb3    
0.71:Hda*   0.79:Hdb*  41.33:Cb    
24.64:Cda   22.74:Cdb 
134 Arg 8 119.31 - 52.89 4.01:Ha     2.49:Hba    2.70:Hbb   
27.72:Cb 
135 Pro - - 176.05 62.78 4.01:Ha     1.83:Hba    2.49:Hbb    
2.14:Hg2    2.14:Hg3    3.53:Hda    
3.63:Hdb   29.38:Cb    26.29:Cg    
48.48:Cd 
136 Gly 9.34 116.92 172.65 43.62 3.70:Haa    4.20:Hab 
137 Gly 9.03 110.5 169.03 43.72 3.81:Haa    4.47:Hab 
138 Val 8.05 116.24 170.46 58.41 5.25:Ha     1.96:Hb     0.94:Hga*   
1.05:Hgb*  34.45:Cb    20.12:Cga   
19.95:Cgb 
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139 Phe 9.74 127.51 171 49.84 5.64:Ha     2.52:Hb2    2.52:Hb3    
6.41:Hd*    6.87:He*    6.98:Hz    
39.93:Cb   127.96:Cd*  
128.42:Ce*  126.70:Cz 
140 Leu 9.15 126.57 170.98 50.59 4.95:Ha     1.12:Hba    1.89:Hbb    
1.61:Hg     0.66:Hda*   0.81:Hdb*  
41.09:Cb    24.30:Cg    23.70:Cda   
24.28:Cdb 
141 Val 8.31 121.27 171.53 55.48 5.42:Ha     0.87:Hb     0.51:Hg1*   
0.51:Hg2*  32.63:Cb    18.72:Cg1   
18.72:Cg2 
142 Ser 8.74 118.8 172.24 53.48 5.87:Ha     3.21:Hba    3.61:Hbb   
65.75:Cb 
143 Thr 8.67 123.24 - 57.5 68.14:Cb 
144 Pro - - 174.09 61.53   
145 Asn 7.92 117.07 175.24 49.76 4.80:Ha     2.37:Hba    2.93:Hbb   
35.83:Cb 
146 Arg 8.89 127.59 174.57 57.3 4.18:Ha     1.43:Hba    1.67:Hbb    
1.52:Hga    1.66:Hgb    3.17:Hda    
3.31:Hdb   28.50:Cb    25.31:Cg    
42.05:Cd 
147 Ile 7.23 116.78 175.22 62.14 3.82:Ha     2.01:Hb     1.44:Hg1a   
1.71:Hg1b   1.08:Hg2*   
1.08:Hd1*  35.89:Cb    27.26:Cg1   
15.45:Cg2   11.02:Cd1 
148 Thr 7.04 104.03 174.31 59.37 4.55:Ha     4.24:Hb     1.32:Hg2*  
68.35:Cb    20.12:Cg2 
149 Phe 9.11 126.4 174.81 59.89 4.56:Ha     2.70:Hba    3.54:Hbb   
40.08:Cb 
150 Ser 7.9 113.52 - 52.92 4.87:Ha     3.95:Hb2    3.95:Hb3   
62.08:Cb 
151 Pro - - 177.3 61.63 4.44:Ha     1.96:Hba    2.31:Hbb    
2.04:Hg2    2.04:Hg3    3.76:Hda    
3.86:Hdb   29.67:Cb    26.02:Cg    
48.68:Cd 
152 Gly 9.01 110.26 172.03 44.21 3.84:Haa    4.03:Hab 
153 Arg 7.59 116.82 174.29 52.99 83.30:Ne     4.73:Ha     1.75:Hba    
2.19:Hbb    1.57:Hga    1.75:Hgb    
3.05:Hda    3.33:Hdb    7.18:He    
31.41:Cb    24.85:Cg    41.78:Cd 
154 Asp 8.8 120.03 173.3 52.59 4.76:Ha     2.70:Hba    2.85:Hbb   
39.67:Cb 
155 Thr 7.42 111.01 - 56.64 4.94:Ha     4.30:Hb     1.26:Hg2*  
68.22:Cb    19.85:Cg2 
156 Pro - - - -   
157 Leu - - - -   
158 Asn - - - -   
159 Pro - - - -   
160 Phe - - - -   
161 His - - - -   
162 Thr - - - -   
163 Arg - - - -   
164 Glu - - 173.44 -   
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165 Leu 9.76 121.5 174.58 52.49 5.06:Ha     0.73:Hd1*   0.73:Hd2*  
43.61:Cb 
166 Asn 8.37 116.42 173.71 48.58 108.17:Nd2    5.07:Ha     
2.53:Hba    3.83:Hbb    6.67:Hd2a   
6.91:Hd2b  37.80:Cb 
167 Ala 9.87 121.74 178.16 54.54 3.77:Ha     1.43:Hb*   16.70:Cb 
168 Ala 8.02 122.95 179.17 53.42 4.09:Ha     1.49:Hb*   15.92:Cb 
169 Glu 8.88 119.94 178.38 56.42 4.08:Ha     1.93:Hba    2.32:Hbb    
2.31:Hga    2.61:Hgb   28.60:Cb    
34.38:Cg 
170 Leu 8.82 122.31 175.5 56.18 4.08:Ha     1.24:Hba    2.02:Hbb    
1.34:Hg     0.61:Hda*   0.69:Hdb*  
39.74:Cb    24.83:Cg    24.48:Cda   
19.74:Cdb 
171 Thr 8.3 114.24 173.63 66.32 4.33:Ha     3.65:Hb     1.19:Hg2*  
66.21:Cb    19.41:Cg2 
172 Glu 8.01 121.13 177.16 57.94 4.22:Ha     2.12:Hb2    2.12:Hb3    
2.21:Hga    2.39:Hgb   27.69:Cb    
34.37:Cg 
173 Leu 7.94 121.52 177.26 56.27 4.05:Ha     1.89:Hb2    1.89:Hb3    
1.67:Hg     0.83:Hda*   0.87:Hdb*  
40.96:Cb    25.04:Cg    24.04:Cda   
22.55:Cdb 
174 Leu 7.71 116.06 177.21 56.1 4.17:Ha     1.12:Hba    1.98:Hbb    
1.99:Hg     0.55:Hda*   0.59:Hdb*  
39.44:Cb    24.53:Cg    23.70:Cda   
21.58:Cdb 
175 Glu 9.01 119.3 180.28 57.46 4.60:Ha     2.02:Hba    2.19:Hbb    
2.37:Hga    2.70:Hgb   27.57:Cb    
35.79:Cg 
176 Thr 8.76 117.67 173.38 64.55 3.95:Ha     4.38:Hb     1.26:Hg2*  
66.78:Cb    19.73:Cg2 
177 Ala 6.99 120.55 174.15 50.69 4.08:Ha     1.48:Hb*   18.15:Cb 
178 Gly 7.45 129.48 173.56 42.21 3.46:Haa    3.88:Hab 
179 Phe 7.66 116.53 173.95 58.52 4.68:Ha     2.80:Hba    2.99:Hbb   
38.64:Cb 
180 Glu 9.02 118.6 174.85 52.87 4.80:Ha     2.05:Hba    2.34:Hbb    
2.24:Hg2    2.24:Hg3   29.22:Cb    
34.47:Cg 
181 Val 9.64 127.32 173.67 26.16 3.99:Ha     2.19:Hb     0.81:Hga*   
0.99:Hgb*  29.26:Cb    19.76:Cga   
21.05:Cgb 
182 Glu 9.45 132.85 174.48 56.44 4.23:Ha     1.85:Hba    2.11:Hbb    
1.97:Hga    2.32:Hgb   29.41:Cb    
34.85:Cg 
183 Asp 7.94 114.23 172.49 51.51 4.99:Ha     2.34:Hba    2.67:Hbb   
42.79:Cb 
184 Thr 8.6 112.86 170.39 58.72 5.03:Ha     3.87:Hb     1.07:Hg2*  
68.94:Cb    19.81:Cg2 
185 Leu 9.78 122.41 171.62 51.72 5.04:Ha     1.28:Hb2    1.28:Hb3    
1.56:Hg     0.73:Hd1*   
0.73:Hd2*  44.52:Cb    25.67:Cg    
24.60:Cd1   24.60:Cd2 
186 Gly 8.69 105.98 170.78 41.88 3.32:Haa    5.19:Hab 
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187 Val 8.63 123.09 173.36 60.09 5.04:Ha     1.82:Hb     0.81:Hga*   
0.99:Hgb*  30.99:Cb    19.65:Cga   
19.54:Cgb 
188 Phe 9.4 124.08 174.63 54.45 4.96:Ha     2.62:Hba    3.26:Hbb    
7.26:Hd*   42.58:Cb 
189 His 9.72 121.14 174.26 54.61 4.62:Ha     2.98:Hba    3.35:Hbb    
6.75:Hd2    7.69:He1   27.08:Cb   
124.31:Cd2  134.70:Ce1 
190 Gly 8.96 114.54 171.98 41.41 3.90:Haa    4.32:Hab 
191 Ala 8.87 122.97 179.22 53.84 4.09:Ha     1.47:Hb*   16.39:Cb 
192 Gly 9.28 104.71 174.99 44.79 3.83:Haa    4.06:Hab 
193 Leu 7.1 121.9 176.2 55.46 4.01:Ha     0.79:Hba    1.44:Hbb    
1.09:Hg    -0.29:Hda*   
0.53:Hdb*  40.66:Cb    28.62:Cg    
23.13:Cda   23.13:Cdb 
194 Ala 8.67 122.72 179.47 53.28 4.57:Ha     1.56:Hb*   15.80:Cb 
195 Glu 7.65 117.41 176.59 57.09 4.12:Ha     2.03:Hba    2.10:Hbb    
2.24:Hga    2.38:Hgb   27.64:Cb    
34.34:Cg 
196 Leu 7.11 118.6 177.67 55.66 4.07:Ha     1.38:Hba    2.15:Hbb    
1.92:Hg     0.77:Hda*   0.85:Hdb*  
39.61:Cb    25.01:Cg    20.74:Cda   
23.35:Cdb 
197 Asp 8.86 119.76 177.04 56.54 4.26:Ha     2.86:Hb2    2.86:Hb3    
2.62:Hba    2.98:Hbb   38.86:Cb 
198 Ala 7.61 119.22 177.57 52.85 4.01:Ha     1.49:Hb*   16.08:Cb 
199 Arg 7.36 115.21 173.97 55.3 83.66:Ne     4.24:Ha     1.83:Hb2    
1.83:Hb3    1.61:Hba    1.84:Hbb    
1.58:Hg2    1.58:Hg3    1.37:Hga    
1.56:Hgb    3.02:Hda    3.16:Hdb    
7.79:He    28.97:Cb    25.22:Cg    
42.38:Cd 
200 His 7.46 118.65 174.02 52.92 4.85:Ha     2.55:Hba    3.20:Hbb    
7.37:Hd2    7.97:He1   27.47:Cb   
118.45:Cd2  137.15:Ce1 
201 Gly 8.14 107.16 172.39 44.71 3.83:Haa    4.07:Hab 
202 Gly 7.85 106.51 172.53 43.1 3.41:Haa    4.52:Hab 
203 Ser 7.54 112.03 172.31 54.63 4.81:Ha     3.71:Hba    4.08:Hbb   
61.60:Cb 
204 Ile 10.83 132 176.08 62.52 4.14:Ha     1.58:Hb     1.11:Hg12   
1.11:Hg13   0.58:Hg2*   
0.60:Hd1*  37.16:Cb    28.50:Cg1   
14.33:Cg2   12.84:Cd1 
205 Ile 7.89 125.38 175.39 64.31 3.30:Ha     1.60:Hb     0.72:Hg1a   
1.11:Hg1b   1.15:Hg2*   
1.12:Hd1*  37.26:Cb    27.89:Cg1   
15.92:Cg2   13.55:Cd1 
206 Glu 8.05 120.5 176.86 56.77 4.11:Ha     2.06:Hba    2.20:Hbb    
2.21:Hga    2.37:Hgb   27.50:Cb    
33.97:Cg 
207 Ala 7.94 119.13 178.89 53.25 4.16:Ha     1.57:Hb*   17.10:Cb 
208 Gln 7.32 115.37 176.82 57.38 3.84:Ha     2.51:Hba    2.66:Hbb    
2.21:Hga    2.66:Hgb   30.12:Cb    
35.10:Cg 
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209 Val 8.65 123.59 176.05 56.28 3.77:Ha     2.23:Hb     0.97:Hga*   
1.19:Hgb*  30.33:Cb    19.21:Cga   
20.51:Cgb 
210 Gln 8.78 117.19 176.97 56.46 111.93:Ne2    3.99:Ha     
2.06:Hb2    2.06:Hb3    2.48:Hga    
2.56:Hgb    6.81:He2a   
7.69:He2b  25.95:Cb    32.16:Cg 
211 Arg 7.22 118.63 176.15 57.14 3.92:Ha     1.32:Hba    1.74:Hbb    
1.41:Hga    2.06:Hgb   26.46:Cb    
29.81:Cg 
212 Ala 7.59 120.38 179.28 53.1 4.05:Ha     1.54:Hb*   16.35:Cb 
213 Val 8.44 118.2 175.23 63.55 3.75:Ha     2.10:Hb     1.01:Hg1*   
1.01:Hg2*   0.96:Hga*   
1.06:Hgb*  29.89:Cb    19.14:Cga   
20.36:Cgb 
214 Ala 7.33 119.82 174.89 50.08 4.33:Ha     1.42:Hb*   17.37:Cb 
215 Asp 7.98 120.09 172.98 52.82 4.24:Ha     2.41:Hba    3.10:Hbb   
37.89:Cb 
216 Ala 7.78 120.22 - 48.41 4.61:Ha     1.35:Hb*   16.81:Cb 
217 Pro - - 175.57 60.5 4.55:Ha     1.85:Hba    2.40:Hbb    
2.06:Hg2    2.06:Hg3    3.63:Hda    
3.85:Hdb   30.07:Cb    25.57:Cg    
48.57:Cd 
218 Trp 8.9 121.91 175.24 56.45 129.42:Ne1    4.09:Ha     
3.10:Hb2    3.12:Hb3    7.43:Hd1   
10.36:He1    7.31:He3    7.65:Hz2    
6.92:Hz3    7.52:Hh2   26.75:Cb   
125.09:Cd1  117.14:Ce3  
113.09:Cz2  118.45:Cz3  
122.94:Ch2 
219 Asp 8.72 125.95 174.78 52.16 4.71:Ha     2.77:Hba    2.92:Hbb   
41.08:Cb 
220 Glu 9.1 124.85 176.93 58.38 3.98:Ha     2.12:Hb2    2.12:Hb3    
2.39:Hg2    2.39:Hg3   27.85:Cb    
34.45:Cg 
221 Gln 8.55 119.23 176.01 56.29 115.27:Ne2    4.18:Ha     
2.31:Hb2    2.31:Hb3    2.50:Hg2    
2.50:Hg3    7.04:He2a   
7.84:He2b  26.89:Cb    32.14:Cg 
222 Leu 8.17 119.99 175.97 56.62 4.00:Ha     1.66:Hba    2.19:Hbb    
1.79:Hg     0.37:Hda*   0.74:Hdb*  
39.36:Cb    25.26:Cg    20.53:Cda   
24.18:Cdb 
223 Leu 8.43 117.68 175.84 55.89 3.99:Ha     1.46:Hba    1.76:Hbb    
1.37:Hg     0.04:Hda*   0.58:Hdb*  
39.56:Cb    24.65:Cg    19.64:Cda   
23.42:Cdb 
224 Ala 7.86 119.12 178.66 53.03 4.01:Ha     1.48:Hb*   16.05:Cb 
225 Asp 8.24 118.74 176.17 55.33 4.56:Ha     2.53:Hba    2.95:Hbb   
38.38:Cb 
226 Val 8.73 118.53 177.3 65.31 3.62:Ha     2.34:Hb     1.10:Hga*   
1.16:Hgb*  30.02:Cb    21.56:Cga   
20.33:Cgb 
227 Ala 8.52 120.67 175.64 52.41 4.09:Ha     1.44:Hb*   16.79:Cb 
228 Ala 7.43 117.92 176.54 50.25 4.34:Ha     1.59:Hb*   17.50:Cb 
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229 Val 6.99 119.32 173.06 62.95 3.65:Ha     1.95:Hb     1.06:Hga*   
1.27:Hgb*  30.14:Cb    21.78:Cg1   
21.78:Cg2   21.57:Cga   
22.01:Cgb 
230 Arg 9.27 128.24 175.85 51.77 84.75:Ne     4.84:Ha     1.70:Hba    
2.19:Hbb    1.91:Hg2    1.91:Hg3    
3.27:Hda    3.35:Hdb    7.43:He    
31.97:Cb    24.60:Cg    41.62:Cd 
231 Thr 9.4 114.59 175.06 64.62 3.98:Ha     4.17:Hb     1.35:Hg2*  
66.08:Cb    21.82:Cg2 
232 Asp 8 114.64 174.17 53.66 4.45:Ha     2.36:Hba    2.80:Hbb   
38.66:Cb 
233 Asp 7.62 116.03 172.26 54.06 4.53:Ha     2.45:Hba    2.60:Hbb   
39.33:Cb 
234 Phe 7.69 116.29 172.81 55.63 4.94:Ha     3.04:Hb2    3.05:Hb3    
6.50:Hd*    7.19:He*    7.43:Hz    
39.84:Cb   127.40:Cd*  
130.10:Ce*  130.10:Cz 
235 Asp 9.19 121.04 172.43 51.06 5.06:Ha     2.40:Hba    2.77:Hbb   
41.21:Cb 
236 Leu 8.38 123.17 174.1 52.35 5.42:Ha     1.06:Hba    1.95:Hbb    
1.40:Hg     0.69:Hda*   0.75:Hdb*  
41.61:Cb    26.06:Cg    23.29:Cda   
24.89:Cdb 
237 Thr 9.5 123.79 - 58.4 5.07:Ha     3.99:Hb     1.31:Hg2*  
70.12:Cb    21.91:Cg2 
238 Pro - - 174.94 61.7 4.84:Ha     2.19:Hba    3.06:Hbb    
2.02:Hga    2.20:Hgb    3.84:Hda    
4.14:Hdb   31.65:Cb    26.04:Cg    
50.70:Cd 
239 Ala 8.95 126.94 177.09 52.37 4.62:Ha     1.52:Hb*   16.80:Cb 
240 Ala 8.69 115.8 176.63 51.84 4.20:Ha     1.49:Hb*   17.16:Cb 
241 Glu 8.01 114.42 173.93 54.51 4.31:Ha     1.86:Hba    2.19:Hbb    
2.22:Hga    2.38:Hgb   29.93:Cb    
34.29:Cg 
242 Arg 7.54 120.25 171.55 54.3 85.99:Ne     4.22:Ha     1.24:Hba    
1.50:Hbb    1.05:Hg2    1.05:Hg3    
2.44:Hd2    2.44:Hd3    6.91:He    
31.41:Cb    24.48:Cg    41.37:Cd 
243 Asp 8.1 122.71 176.14 53.28 4.59:Ha     2.62:Hba    2.94:Hbb   
38.56:Cb 
244 Ile 9.27 131.62 175.97 60.29 4.33:Ha     1.91:Hb     1.20:Hg1a   
1.43:Hg1b   0.91:Hg2*   
0.83:Hd1*  37.35:Cb    27.79:Cg1   
15.31:Cg2   12.74:Cd1 
245 Asp 8.72 123.22 176.43 55.26 4.54:Ha     2.76:Hba    2.89:Hbb   
37.78:Cb 
246 Asp 7.93 119.55 173.54 52.29 4.77:Ha     3.11:Hb2    3.11:Hb3   
39.53:Cb 
247 Ser 7.69 114.98 172.73 57.49 2.82:Ha     3.26:Hba    3.43:Hbb   
63.53:Cb 
248 Leu 8.89 118.27 176.07 54.22 4.61:Ha     1.57:Hba    1.83:Hbb    
1.75:Hg     0.83:Hda*   0.92:Hdb*  
39.64:Cb    24.72:Cg    22.26:Cda   
24.27:Cdb 
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249 Asp 6.66 114.09 170.56 51.11 5.18:Ha     2.07:Hb2    2.07:Hb3   
42.43:Cb 
250 Leu 9.01 119.59 174.64 51.45 4.59:Ha     0.93:Hba    1.67:Hbb    
1.36:Hg     0.58:Hda*   0.76:Hdb*  
43.55:Cb    24.67:Cg    23.30:Cda   
21.92:Cdb 
251 Val 9.06 121.12 172.03 58.51 4.72:Ha     1.75:Hb     0.51:Hga*   
0.57:Hgb*  32.67:Cb    19.49:Cga   
19.19:Cgb 
252 Ala 9.32 126.51 172.2 48.3 5.13:Ha     1.02:Hb*   20.03:Cb 
253 Ile 8.1 118.63 172.45 58.59 4.49:Ha     1.66:Hb     0.79:Hg1a   
1.35:Hg1b   0.71:Hg2*   
0.77:Hd1*  37.50:Cb    24.69:Cg1   
15.22:Cg2   12.43:Cd1 
254 Ala 9.35 130.56 172.4 47.6 5.41:Ha     1.16:Hb*   20.60:Cb 
255 Val 9.5 120.76 174.1 58.61 5.20:Ha     2.10:Hb     0.97:Hg1*   
0.97:Hg2*   0.91:Hga*   
1.00:Hgb*  33.66:Cb    18.85:Cga   
19.70:Cgb 
256 Arg 9.01 130.77 - 51.16 86.60:Ne     4.57:Ha     1.18:Hba    
1.74:Hbb    0.86:Hga    1.45:Hgb    
2.02:Hda    2.44:Hdb    6.34:He    
28.97:Cb    24.90:Cg    41.10:Cd 
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Appendix-II    Expression and Purification of Ulp1 Protease 
This appendix describes the expression and purification protocol of the Ulp1 protease that 
cleaves the SUMO tag. The protease was used to cleave the tag (wherever mentioned) during 
purification of SUMO-tagged proteins described in this study. 
Expression and purification protocol 
Culture growth: A loop of frozen BL21 cells of the expression clone were plated on LB-agar 
kanamycin plate and incubated overnight at 37°C. All the cells were collected from the plate 
and inoculated in 100 ml LB media with 100 µg/ml kanamycin. The culture was grown 
overnight at 37°C, with constant shaking at 220 rpm. The culture was scaled up to 2 litres by 
adding 30 ml of the overnight culture in each 1-liter fresh LB media with kanamycin. Cells 
were grown at 37°C till OD600 reached 0.8, cooled down to 20°C and, induced with 0.5 mM 
IPTG for protein expression, and grown overnight at 20°C. 
Cell harvesting and Lysis: Cells were harvested by centrifugation (4200 x g, 30 min, 4°C) 
and the pellet was suspended in buffer (50 mM Tris-HCl pH 7.5, 20 mM Imidazole, 500 mM 
NaCl, cocktail of protease inhibitor), 10 μg/mL DNaseI and 5 mM MgCl2 were added to 
dissolved pellet. The cells were lysed by passing them through Emulsiflex four times, 
followed by centrifugation (20,000 x g, 25 min, at 4°C). 
Affinity purification: Pre-packed sepharose column (HiTrap IMAC FF, 5ml, GE Healthcare) 
was charged with 0.1M NiSO4, according to the manufacturer’s protocol, and equilibrated. 
Supernatant was bound to the column with help of a peristaltic pump at room temperature. 
Column was washed for 30 CV with wash buffer (50 mM Tris-HCl pH 7.5, 20 mM 
Imidazole, 500 mM NaCl), and 15 ml protein was eluted with elution buffer (50mM Tris-HCl 
pH 7.5, 500 mM Imidazole, 500 mM NaCl). The purity of the protein was determined by 
SDS-PAGE. Protein concentration was measured at 280 nm with NanoDrop 
spectrophotometer. 
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Buffer Exchange: Protein’s buffer was exchanged with the buffer containing 10% glycerol, 
75 mM Tris-HCl pH 8.0, 0.5 mM DTT and 1 mM EDTA by centrifugation (5000 x g, 30 
min, 4°C) in 10 kDa cutoff concentrators (Vivaspin, 20 ml, Satorius stedim). 12mg of protein 
was purified. 
Storage of protein- The protein was stored in the buffer containing 50% glycerol, 75 mM 
Tris-HCl pH 8.0, 0.5 mM DTT and 1 mM EDTA. Protein was aliquoted in 100 μl fractions, 
snap froze in liquid N2 and stored in -80°C. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure AII    Expression and purification of Ulp1 protease. 
Metal affinity purification of His6 tagged protein on Ni-sepharose column. (MWM: molecular 
weight marker, L: lysate, FT: flow through, S: supernatant, P1 and P2: protein)
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Appendix-III    Protein Analysis Data of OtsA and Rv3030  
This appendix reports the supporting information on the MALDI fingerprinting and intact 
mass analysis of OtsA and Rv3030. 
1. MALDI fingerprinting of M. tuberculosis OtsA (full-length, pHAT-4 construct) 
(Chapter-2, Section 2.5.2) 
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2. MALDI fingerprinting of M. thermoresistibile OtsA (full-length, untagged, pET-28a 
SUMO construct) (Chapter-2, Section 2.5.3) 
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3. MALDI fingerprinting of Rv3030 orthologue in M. smegmatis (unlabelled, untagged, 
full-length pET-28a SUMO construct) (Chapter-3, Section 3.5.4.1) 
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4. Intact mass analysis of 15N-labelled, full-length orthologue of Rv3030 in M. 
smegmatis (Chapter-4, Section 4.5.2) 
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5. Intact mass analysis of 15N, 13C-labelled, full-length orthologue of Rv3030 in  
M. smegmatis (Chapter-4, Section 4.5.2) 
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Appendix-IV    Composition of Commonly Used Reagents 
The culture media and solutions used during this study are described in this appendix. The 
media were autoclaved and solutions were filter sterilized before use. Filtered milliQ water 
was used to make the media and solutions. 
Luria-Bertani (LB) Medium 
10 g/L  Tryptone     
5 g/L  Yeast extract 
10 g/L  NaCl 
The pH was adjusted to 7.2 and autoclaved. 
Luria-Bertani Agar 
10 g/L  Tryptone     
5 g/L  Yeast extract 
10 g/L  NaCl 
20 g/L  Agar 
The pH was adjusted to 7.2 and autoclaved. 
20 X M9 Salts  
120 g/L Na2HPO4 
60 g/L  KH2PO4 
10 g/L  NaCl 
The solution was autoclaved. 
100 X Micronutrients Solution (200 ml) 
160 mg FeCl2  
324 mg MnCl2  
10 mg  ZnSO4 
3 mg  CoCl2  
2 mg  H3BO3 
Solution was filtered sterilized, and stored at 4°C. 
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1000 X Vitamins Solution (50 ml) 
50 mg  Thiamine Pyrophosphate 
50 mg  Niacinamide 
35 mg  Biotin 
Solution was filtered sterilized, and stored at 4°C. 
Antibiotic Solutions 
1. Ampicillin: 100 mg/ml stock solution was prepared in sterile milliQ water and filter 
sterilized. Stored in aliquots at -20°C. 
2. Kanamycin: 30 mg/ml stock solution was prepared in sterile milliQ water and filter 
sterilized. Stored in aliquots at -20°C. 
Agarose Gel 
1% agarose gel was prepared by dissolving 1 g agarose in 100 ml 1 X TBE buffer. 7.5 μl 
ethidium bromide was added for every 100 ml of the gel. 
SDS-PAGE Gel 
RESOLVING GEL (12%)                                    STACKING GEL 
                   
 
 
 
 
 
1. 30% Acrylamide Mix (Severn Biotech Ltd) 
Stored at 4°C. 
2. 25% Ammonium persulphate (APS) (Sigma) 
 per gel 
Water 2.47 ml 
Acrylamide 3 ml 
3M Tris-HCl  
pH 8.8 
1.87 ml 
10% SDS 150 μl 
25% APS 60 μl 
TEMED 15 μl 
 per gel 
Water 1 ml 
Acrylamide 310 μl 
0.5M Tris-HCl  
pH 6.8 
450 μl 
10% SDS 19.25 μl 
25% APS 8 μl 
TEMED 2.25 μl 
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2.5 g of APS was dissolved in 10 ml milliQ water. Solution was filtered sterilized, and 
stored in aliquots at -20° 
3. 10% Sodium Dodecyl Sulphate (SDS) (Fisher) 
5 g of SDS was dissolved in 50 ml milliQ water and was filtered sterilized. 
4. 3 M Tris-HCl pH 8.8 (for resolving gel) (Melford) 
36.34 g of Tris-HCl was dissolved in milliQ water. pH was adjusted to 8.8 and volume 
was made to 100 ml with milliQ water. Solution was filtered sterilized. 
5. 0.5 M Tris-HCl pH 6.8 (for stacking gel) (Melford) 
6.06 g of Tris-HCl was dissolved in milliQ water. pH was adjusted to 6.8 and volume 
was made to 100 ml with milliQ water. Solution was filtered sterilized. 
SDS-PAGE Running Buffer (1 X) 
3.02 g/L Tris-HCl Base 
14.4 g/L Glycine 
1 g/L  SDS 
4 X SDS-PAGE Loading Dye (containing β-mercaptoethanol) 
62.5 mM Tris-HCl.HCl pH 6.8 
2%   SDS 
10%   Glycerol 
10%   β-mercaptoethanol 
~ 0.2%  Bromophenol blue 
2 X SDS-PAGE Loading Dye (containing DTT) 
100 mM Tris-HCl.HCl pH 6.8 
200 mM DTT 
4%  SDS 
20%  Glycerol 
~ 0.2%  Bromophenol blue 
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1 X Coomassie Brilliant Blue-G Quick Stain 
10%  Ethanol 
30 mM  HCl 
0.01%  Coomassie Brilliant Blue-G 
Other Commonly Used Reagents 
1. 1 M IPTG stock 
2.383 g IPTG was dissolved in 10 ml sterile milliQ water. Solution was filter sterilized, 
and stored in aliquots at -20°C. 
2. 0.1 M nickel (II) sulphate hexahydrate [NiSO4.6H2O] 
1.31 g of NiSO4.6H2O was dissolved in 50 ml sterile milliQ water. Solution was filter 
sterilized.
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Appendix-V    Targets Rv3037c and Rv3038c of MGLP Biosynthetic      
                         Pathway 
AV.1 Objectives 
At the outset, these projects aimed at investigation of structural properties. This appendix 
reports analyses of the primary structures of the protein and its orthologues in order to 
understand the domain architecture and residue conservation, and homology modelling of the 
protein structure. The design of constructs of full-length and truncated proteins is also 
described, followed by attempts to purify soluble and un-degraded protein.  
AV.2 Methodology 
 
 
AV.2.1 Bioinformatics analysis of primary structure of target proteins 
The protein sequences of Rv3037c and Rv3038c were obtained from TubercuList database, 
and of their orthologues in M. smegmatis (MSMEG_2330 and MSMEG_2329, respectively) 
from SmegmaList database, by searching with their gene names. Orthologous proteins in     
M. thermoresistibile were identified by performing a protein-BLAST (blastp) search with 
respective M. tuberculosis protein sequences; and amino acid sequences were obtained from 
NCBI database. Sequences were aligned using Clustal Omega. Methyltransferase family and 
domain alignment coordinates were identified with Pfam.  
The physicochemical properties of proteins were calculated using ProtParam, and secondary 
structures and disordered regions of the protein were predicted using PSIpred and DisoPred, 
respectively. 
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AV.2.2 Protein Modeling 
Models of full-length orthologues of Rv3037c and Rv3038c in M. thermoresistibile were 
built using ModSuite, as described in section 3.4.2. 
AV.2.3  DNA, Bacterial Strains, Cloning and Expression Trials of Full-length     
             Rv3037c and Rv3038c and their orthologues 
Genomic DNA and E. coli strains were the same as mentioned in section 2.4.3.  Dr. Michal 
Blaszczyk and Dr. Sachin Surade provided the purified plasmids for Rv3037c (and 
orthologue in M. smegmatis) and Rv3038c (and orthologues in M. smegmatis and                 
M. thermoresistibile), respectively. The genes were cloned in BamHI and HindIII restriction 
sites in pET-28a SUMO vector. 
Expression trial: E.coli BL21 (DE3) competent cells were transformed with the plasmids and 
cells were plated on LB agar-kanamycin plates. A protein expression trial was conducted for 
full-length Rv3037c, Rv3038c and their orthologues, as described in section 2.4.4.1. The 
identity of proteins was confirmed by MALDI fingerprinting (PNAC facility, Department of 
Biochemistry). 
Additional expression trials were performed for Rv3037 and its orthologue in M. smegmatis 
by altering following parameters in the above-mentioned protocol, in different trials: 
1. 0.1% Triton X-100 was added in the resuspension buffer.  
2. Inducing the culture with 0.5 mM IPTG at 37°C for 4 hours. 
3. Inducing the culture with 0.5 mM IPTG overnight (14-16 hours) at 25°C. 
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AV.2.4 Cloning and expression trial of full-length Rv3037c orthologue in  
M. thermoresistibile 
The 1092 bp gene was PCR amplified from M. thermoresistibile genomic DNA with the 
following primer pair: 
Forward Primer: 5’-TTAGGATCCATGCCGCTGACCGACGCCAC-3’  
(containing BamHI restriction site- underlined) 
Reverse Primer: 5’-ACTAAGCTTTCACCGTGACGGACGGCATATG-3’ 
(containing HindIII restriction site- underlined) 
PCR was done as described in section 2.4.3, but with 15 sec annealing step at 55°C, and 40 
sec extension step at 70°C. The amplicon generated was cloned in BamHI and HindIII 
restriction sites pET28a SUMO vector. The gene and vector were digested with the BamHI 
and HindIII restriction enzymes (ThermoScientific), ligated and plasmid was purified 
(section 2.4.3). The identity of the insert was confirmed by sequencing (DNA Sequencing 
Facility, Department of Biochemistry).  
A protein expression trial was done as described in section 2.4.4.1, and the protein’s identity 
was confirmed by MALDI fingerprinting (PNAC facility, Department of Biochemistry). 
AV.2.5 Gene manipulation and expression trials  
 
AV.2.5.1  N- and C- terminal domains of Rv3037c orthologue in M. thermoresistibile 
A.  N-terminal domain of Rv3037c orthologue in M. thermoresistibile (Residues 1-216) 
The N-terminal domain was cloned in NcoI and XhoI restriction sites in pHAT5 vector.  The 
648 bp gene was amplified from the genomic DNA of M. thermoresistibile using following 
primer pair: 
Forward primer: 5’-ATTCCATGGTGCCGCTGACCGACGCCACC-3’   
(containing NcoI restriction site-underlined) 
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Reverse primer: 5’-ATACTCGAGGCGGCGGACGCCGGGTTCGG-3’                             
(containing XhoI restriction site-underlined. The stop codon was removed from the reverse 
primer to allow the translation of fusion protein containing C-terminal His6-tag.) 
PCR was done in the same conditions as described in section 2.4.3, but with annealing at 
58°C and 20 seconds extension at 70°C. Amplicon and vector were digested with NcoI and 
XhoI restriction enzymes, ligated and plasmid was purified (section 2.4.3). The fidelity of the 
insert was confirmed by sequencing (DNA Sequencing Facility, Department of 
Biochemistry). A protein expression trial was done (as described in section 2.4.4.1), and 
protein identity was confirmed by MALDI fingerprinting (PNAC facility, Department of 
Biochemistry). 
B. C-terminal domain of Rv3037c orthologue in M. thermoresistibile (Residues 217-
363) 
The 444 bp gene was amplified from the genomic DNA of M. thermoresistibile with the 
following primers:  
Forward primer: 5’-TATGGATCCCGGGCCACCATCCTGGACCG-3’  
(containing BamHI restriction site-underlined) 
Reverse primer: 5’-ATCAAGCTTTCACCGTGACGGACGGCATATG-3’  
(containing HindIII restriction site-underlined) 
 
PCR was done in the same conditions as described in section 2.4.3, but with annealing at 
58°C and 20 sec extension at 70°C. The amplicon generated was cloned in BamHI and 
HindIII restriction sites in pET28a SUMO vector. Amplified gene and vector were digested 
with BamHI and HindIII restriction enzymes, ligated and plasmid was purified as described 
in section 2.4.3. The identity of insert was confirmed by sequencing (DNA Sequencing 
Facility, Department of Biochemistry). A protein expression trial was carried out as detailed 
in section 2.4.4.1. Protein identity was confirmed by MALDI fingerprinting (PNAC facility, 
Department of Biochemistry). 
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AV.2.5.2     Truncation of Rv3038c orthologue in M. thermoresistibile  
An 891 bp gene (111bp less from 5’ end of full length 1kb gene), correlating to truncation of 
37 residues from N terminal of full-length protein, was cloned in BamHI and HindIII 
restriction sites in the MCS of pET-28a SUMO vector. Another construct was prepared, in 
which 38 residues were truncated from N terminal of full-length protein, and the 888 bp gene 
was cloned in NcoI and XhoI restriction sites in pHAT-5 vector. Construct details and 
primers used are mentioned in Table AV.1. 
 
TABLE AV.1    Truncated Rv3038c orthologue in M. thermoresistibile construct details and primers used 
     (3038M.thr refers to Rv3038c orthologue in M. thermoresistibile) 
The gene was amplified from the genomic DNA of M. thermoresistibile with relevant 
primers, using KOD Hot Start DNA polymerase, in the same condition as described in 
section 2.4.3, but with annealing at 58°C and 20 sec extension. Amplicons and vectors were 
digested with relevant restriction enzymes, ligated and plasmid was purified as described in 
section 2.4.3. The identity of the insert was confirmed by sequencing (DNA Sequencing 
Facility, Department of Biochemistry). Protein expression trials were carried out as detailed 
in section 2.4.4.1. Proteins’ identity was confirmed by MALDI fingerprinting (PNAC facility, 
Department of Biochemistry). 
Gene Cloning 
vector 
Residue 
range 
Restriction 
sites 
Primer sequence 
(Restriction sites underlined and bold) 
Truncated 
3038M.thr 
(37 residues 
truncated) 
 
pET-28a 
SUMO 
38-334 FP- BamHI 
RP- HindIII 
FP:5’-  ATTGGATCCCTCGCCCAGATCCTCTATCACG -3’ 
RP:5’-  ATTAAGCTTTCAGGACGGTTTGACCCCGG -3’ 
 
Truncated 
3038M.thr 
(38 residues 
truncated) 
 
pHAT-5 39-334 FP- NcoI 
RP- XhoI 
FP: 5’- ATACCATGGCCCAGATCCTCTATCACGACTG   -3’ 
RP: 5’- ATACTCGAGGGACGGTTTGACCCCGGTG -3’ 
(The stop codon was removed from the RP to allow the 
translation of a fusion protein containing a C-terminal His6-tag) 
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AV.2.6 Purification of Full-Length Recombinant Rv3038c orthologue in  
M. thermoresistibile  
The recombinant orthologous protein of Rv3038c in M. thermoresistibile, with N-terminal, 
cleavable SUMO tag was purified.  
Culture growth: A loop of frozen BL21 cells of the expression clone was plated on LB-agar-
kanamycin plate and incubated overnight at 37°C. All the cells were collected from the plate 
and inoculated in 250 ml LB media with 30 μg/ml kanamycin. The culture was grown 
overnight at 37°C, with constant shaking at 220 rpm. The culture was scaled up to 6 litres by 
adding 30ml of the overnight culture in each 1-litre fresh LB media containing 30 μg/ml 
kanamycin. Cells were grown at 37°C till OD600 reached 0.63, cooled down to 20°C and, 
induced with 0.5 mM IPTG for protein expression, and incubated overnight (14-16 hours) at 
20°C with constant shaking. 
Cell harvesting and Lysis: Cells were harvested by centrifugation (4200 x g, 30 min, 4°C) 
during the late exponential growth phase and the pellet was re-suspended in buffer (20 mM 
Tris-HCl pH 7.5, 20 mM Imidazole, 500 mM NaCl, cocktail of protease inhibitor), and 10 
μg/mL DNase I and 5 mM MgCl2 were added to the cell suspension. The cells were lysed by 
passing them through Emulsiflex four times, followed by centrifugation (20,000 x g, 30 min, 
4°C) to remove cell debris. Supernatant was collected and filtered using 0.2 μm syringe filter. 
Affinity purification: A pre-packed sepharose column (HiTrap IMAC FF, 5 ml, GE 
Healthcare) was charged with 0.1 M NiSO4, according to the manufacturer’s protocol, and 
equilibrated with purification buffers. Supernatant was bound to the column with the help of 
a peristaltic pump at room temperature. The column was washed for 30 CV with wash buffer 
(50 mM Tris-HCl pH 7.5, 20 mM Imidazole, 500 mM NaCl), and 30 ml protein was eluted 
using elution buffer (50 mM Tris-HCl pH 7.5, 500 mM Imidazole, 500 mM NaCl). The 
purity of the protein was determined by SDS-PAGE. Protein concentration was measured at 
280 nm with NanoDrop spectrophotometer. 
Cleavage of the tag and Dialysis:  Ulp1 protease was added to the eluted protein at a ratio of 
1 mg Ulp1 protease to 200 mg protein to cleave the SUMO tag. The protein-protease mixture 
Appendix-V                            Targets Rv3037c and Rv3038c 
221 
 
was then dialysed in 50 mM Tris-HCl pH 7.5, 20 mM Imidazole and 500 mM NaCl buffer, 
using 10 kDa MWCO dialysis membrane, and incubated overnight at 4°C.  
Gel Filtration: The overnight-digested protein was concentrated by centrifuging (4000 x g, 
30 min, 4°C) in 10 kDa MWCO concentrators. The protein was loaded onto a Superdex-200 
column, pre-equilibrated with 100 mM NaCl and 20 mM Tris-HCl pH 7.5. Purification was 
carried out at room temperature. The protein was eluted in 1 ml fractions and purity of 
fractions was determined by SDS-PAGE. The purest fractions were pooled and concentrated 
by centrifuging (4000 x g, 30 min, 4°C) in 10 kDa MWCO concentrators. The concentration 
of NaCl was reduced from 500 mM to 350 mM with 20 mM Tris-HCl pH 7.5 buffer. The 
purity of the protein was assessed with SDS-PAGE and final concentration was determined 
spectrophotometrically. The protein’s identity was confirmed by MALDI fingerprinting 
(PNAC facility, Department of Biochemistry, University of Cambridge, UK). 
In an alternative attempt of purification, only affinity purification and anionic exchange were 
performed. Protein was expressed and affinity purification was as described above. Then        
5 mM EDTA pH 8.0 was added to protein just after elution, and anionic exchange was done. 
Anionic Exchange- Protein was diluted with binding buffer (20 mM Tris-HCl pH7.5) and 
loaded into the column (HiTrap Q HP column, 5 ml, GE Healthcare). Column was washed 
with binding buffer. Protein was eluted in 5ml fractions by creating a linear gradient between 
the binding buffer and the elution buffer (20 mM Tris-HCl pH7.5, 1 M NaCl) over a period 
of 1 hour. 
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AV.3 Results 
 
AV.3.1    Target: Rv3037c 
 
AV.3.1.2     Expression trials of full-length Rv3037c and its homologs in M. smegmatis    
                    and M. thermoresistibile 
An initial expression trial of SUMO-tagged M. tuberculosis protein and orthologues at 20°C 
revealed that the protein is in the inclusion bodies as no soluble expression was observed. 
MALDI fingerprinting confirmed that bands observed around 58 kDa were of the respective 
target proteins (Figure AV.1). 
 
 
 
 
                            
 
          
                           
 
 
 
 
 
 
 
 
 
 
FIGURE AV.1     Expression trials of SUMO tagged Rv3037c and its orthologues.  
Thick bands (yellow arrows) were seen in the respective cell lysate lanes but nothing was 
seen in the supernatant (soluble fraction) lanes. (MWM: molecular weight marker, L: 
cellular lysate, S: supernatant, FT: flow through, P: protein).   
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Several expression trials were carried out in attempts to express the protein in the soluble 
fraction; these included altering the trial conditions, such as varying the induction 
temperature, varying the duration for which culture was induced, and mild detergent 
treatment (0.1% triton X-100). Unfortunately, the attempts were not successful. A small-scale 
purification of M. tuberculosis protein was done from 1-liter culture and mass fingerprinting 
analysis showed that instead of the target protein, the chaperone GroEL was purified (Figure 
AV.2). 
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FIGURE AV.2     Expression trials of SUMO tagged      
                               Rv3037c and its orthologue in 
                               M. smegmatis.  
A. 0.1% Triton X-100 was added to the cell 
lysate to obtain soluble protein. 
B. Protein purification of protein from 1 liter 
culture, induced at 37°C for 4 hours. 
Chaperon GroEL (marked with arrow) was 
obtained whereas the target protein 
remained insoluble. 
C. Trial of Rv3037c-SUMO by inducing at 
25°C overnight. Protein still remained 
insoluble. 
(MWM: molecular weight marker, L: 
cellular lysate, S: supernatant, FT: flow 
through, P: protein). 
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AV.3.1.3     Protein modeling of full-length Rv3037c orthologue in M. thermoresistibile 
The templates used for building model of target protein were methyltransferase proteins 
whose structures are available in PDB (PDB ID of templates- 3LL7, 3GDH, 3HM2).  
                                10        20        30        40        50   
3LL7        (   1 )    mlF-dekeIlaItrwaklyanqspdrIllgsNdIppeyraaVatQieLwp 
3GDH        ( 641 )     v---------------------------------pelakywaqryrlFs 
3HM2        (   3 )                                                       
3037cM.thr             MPLTDATRVADVAALRTRFGDR------------APVLVETTLLRRRAAA 
                                                                          
                                60        70        80        90        100  
3LL7        (  50 )    rLrnkLpqWAgissLyIPsrlsLeqssg-avTSsyKsrFIre-gt--kVV 
3GDH        ( 657 )    rfdd---------gIkL-dregwfsVTpekIAehIAgrVsqsfkCd-vVV 
3HM2        (   3 )                 g----------q----ltkqhvralAisaLapketLW 
3037cM.thr             KFDDP-SRW-------LFTDEALQQATAAPVARHRARRLTGR-----KVH 
                                               a    aaaaaa            bbb 
 
                                110       120       130       140       150  
3LL7        (  96 )    DLtGgLGidFiaLM-sk-AsqGIYIerndetAvAArHNIpll-lnegkdv 
3GDH        ( 696 )    DAfCgVGGnTIQFA-lt-gMrVIAIdidpvKialArnNAevYgiad-k-I 
3HM2        (  28 )    DIgggSgsiAIeWLrstpqTtAvCFEiseerrerIlsnAinlgvsd-r-I 
3037cM.thr             DVTCSIGAELAAL--RLTAAQLVGSDIDPVRLQMARHNL-------GPGV 
                       b      aaaaaaa      bbbbb   aaaaaaaaaaaa         b 
 
                                160       170       180       190       200  
3LL7        ( 143 )    niltgdfkeylplIktf-hPdyIYVdParrrvyaIadCepd-LipLateL 
3GDH        ( 742 )    eFicgdFll---lAsfl-kAdVVFLsPp----wg----gpd-yat-ae-t 
3HM2        (  76 )    avqqgAp-rAFddvp--dnPdVIFIGg------gLta--pg-vfaaAwkr 
3037cM.thr             ALCRADALRPITR-------DTVVVADPARRSGGRRRFDPRAHTPPLDAL 
                       bbb                  bbbb                          
 
                                210       220       230       240       250  
3LL7        ( 196 )    LpfCs-SILAkL---spmIdlwdTLqsLlhVQeLHVVAAhgevkELLVrM 
3GDH        ( 777 )    FdI-r-tmMsp----dGf-eIFrlSkkI--tnnIVYFLP----r----nA 
3HM2        ( 114 )    Lpv-ggrLVAnAvtveSeqmLwalrkqfgg--tIssfa-------isheh 
3037cM.thr             FDVYRGR--DSVVKCAPGIE-FGALGAVGFDGEVEVVSLAGSVREACLWS 
                                           aaaaaaa      bbbb              
 
                                260       270       280       290       300  
3LL7        ( 242 )    SlneatippekVpIhAInllletvipfiFtmeeersisIpyTdsIdkyVY 
3GDH        ( 810 )    did--qVasLagp------------------------------------- 
3HM2        ( 154 )    tvg----------------------------------------------- 
3037cM.thr             --GSLTEPGVRRRATILDR------SEVITDAEPGECPVA---AAGRWII 
                                                                          
                                310       320       330       340       350  
3LL7        ( 293 )    EPhtALlkAgAfkTVAyrlgLrKLhpnShLYTseayesaFpgrtFvleei 
3GDH        ( 821 )    -----------------------------------------ggqveieqN 
3HM2        ( 157 )    ------------------------------------------sfitmkpa 
3037cM.thr             DPDGAVVRAGLVRHYAARHGLWQLDPDIAYLSGDRLPAGVRG--FEVLEE 
                                                                    bbbb  
 
                                360       370       380       390       400  
3LL7        ( 343 )    ipfstsvLkqLrkv--VpqAsIscrnFplspieLrqrSkMadggekTLMG 
3GDH        ( 830 )    f-Lnn------------klktITAY-Fg----dLir               
3HM2        ( 165 )    l----------------pvhQWtVv-ka                       
3037cM.thr             LPYRERRLRQALAAHDAGAVEILVRGVDVDPDRLRTRLRLRGRHPLAVVI 
                                           bbbbb                          
 
                                410       420  
3LL7        ( 391 )    TTMad---gkkvLLLLrkAe 
3GDH                                        
3HM2                                        
3037cM.thr             TRIGSKHASRATAFICRPSR 
 
Solvent inaccessible    UPPER CASE X  hydrogen bond to main chain amide  bold x     
Solvent accessible      lowercase x  hydrogen bond to main chain carbonyl underline x 
α-helix       red  x  310 helix    maroon x 
β-strand                      blue  x               positive phi                italic x       
A. 
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FIGURE AV.3   Model of three-dimensional structure of Rv3037c orthologue in M. thermoresistibile. 
A. Structural alignment of target protein and templates (produced by FUGUEALI) (3037cM.thr  
refers to Rv3037c orthologue in M. thermoresistibile). 
B. Model of the target protein. Probable methyltransferase domain at the N-terminus is shaded 
teal and the C-terminus domain is shaded pink. 
 
  
Table AV.2    Structural templates used for homology modelling of orthologue of Rv3037c in  
    M. thermoresistibile. 
 
 
 
 
PDB ID PROTEIN ORGANISM 
3HM2_G Putative Precorrin-6Y C5,15-Methyltransferase 
Targeted Domain 
Corynebacterium 
diphtheriae 
3GDH_C Methyltransferase domain of human 
Trimethylguanosine Synthase 1 (TGS1) bound to 
m7GTP and adenosyl-homocysteine (active form) 
Homo sapiens 
3LL7_A Putative methyltransferase PG_1098 Porphyromonas 
gingivalis W83 
B. 
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Due to low sequence similarity of Rv3037c orthologue in M. thermoresistibile protein with 
available structures (around 23% identity, determined by protein BLAST search), the model 
building of full-length protein was challenging. Only one template (3LL7) aligned fairly well 
with the entire protein, while others aligned only to the N-terminal region of the target 
protein. The structural alignment was not convincing, but gave a rough idea that the target 
protein probably has two domains: an N-terminal domain and C-terminal domain. Since the 
methyltransferase domain of the templates aligned with the N-terminal domain of the protein, 
it is probable that this is the methyltransferase domain of the protein. The C-terminal region 
is likely an auxiliary domain that may help in substrate binding. However, exact domain 
alignment coordinates are not available in the databases (search in Pfam did not yield 
significant matches). Thus, both the domains were individually modeled in order to get a 
clear overall view of the protein’s three-dimensional structure.  
AV.3.1.4     Protein modeling of individual domains of Rv3037c orthologue in  
                    M. thermoresistibile 
A.  Modeling of the N-terminal domain  
The templates used for building model of N-terminal domain were methyltransferase proteins 
whose structures are available in PDB (PDB ID of templates- 3LL7, 3GDH, 3CGG). 
3CGG_A is a TehB-like SAM-dependent methyltransferase (NP_600671.1) from 
Corynebacterium glutamicum ATCC 13032. 
 
 
 
 
 
A. 
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                                10        20        30        40        50   
3CGG        (   9 )    ------------------------------dnnp----ahsen----yaq 
3GDH        ( 634 )                                    lppeI-aavpeLakywaq 
3LL7        (   1 )    mlFdekeIlaItrwaklyanqspdrIllgsndIppeyraaVatQieLwp- 
3037cM.thr-NT          MPLTD----A-TRVADVAAL--RTR---FGD------RAPVLVETTLL-- 
                                                                    aaaaa 
 
                                60        70        80        90        100  
3CGG        (  24 )    rwrnlaaagn--------------diy--geArlIdamAprgA---kILD 
3GDH        ( 650 )    ryrlFsrfdd---gIkL-dregWfsVTpekIAehIAgrVsqsFkcdvVVD 
3LL7        (  50 )    rLrnkLpqWAgissLyIPsrlsLeqssgavTSsyKsrFIregt---kVVD 
3037cM.thr-NT          RRRAAAKFDDPSRWL-FTDEA-L-QQATAAPVARHRARRLTGR---KVHD 
                        aaaa                        aaaaa            bbbb 
 
                                110       120       130       140       150  
3CGG        (  52 )    AgCgqGrIGGyLSkqgHdVlGTdldpilIdyAkqdf-p-------e-ArW 
3GDH        ( 697 )    AfCgVGGNTIQFAltgMrViAIdidpvKialArnNAe--vYgiadk-Ief 
3LL7        (  97 )    LtGgLGidFiaLMskAsqGIYIerndetAvAArHNIp--lllnegkdvni 
3037cM.thr-NT          VTCSIGAELAALRLTAAQLVGSDIDPVRLQMARHNL--------GPGVAL 
                             aaaaaaa    bbbbbb  aaaaaaaaaa             bb 
 
                                160       170       180       190       200  
3CGG        (  93 )    vvgdlsv--dqisetdFdLIVsAgnv----mgfla--------edgrepaL 
3GDH        ( 744 )    icgdFlllAsflk---AdVVFLs-PpwggpdyataetFdIrtmMspdGfeI 
3LL7        ( 145 )    ltgdfkeylplIktfhPdyIYV-dParr---rvya-IadCe----pdLipL 
3037cM.thr-NT          CRADAL--RPITR----DTVVVADPARRSGGRRRF---DPRAHTPP-LDAL 
                       bb                bbbb                        aaaa 
 
                                210       220       230       240       250  
3CGG        ( 129 )    aNIhrA-LgadGrAVIGFgagrgWvfgdFleVAervg---Lelenafesw- 
3GDH        ( 791 )    FrlSkkIt--n-nIVYFLPr--nAdidqVasLagp-ggq-veieqNfLn-- 
3LL7        ( 192 )    ateLLpfC--s-SILAkLsp--mIdlwdTlqsL----lhvqeLhvvaah-- 
3037cM.thr-NT          FDVYRGR----DSVVKCAPGI---EFGALGAVGFD-G--EVEVVSLAGSVR 
                       aaaa         bbbbb       aaaaaa         bbbb       
 
                                260        
3CGG        ( 179 )    dlkpfvqgSefLVAVFtkk--------- 
3GDH        ( 833 )    ------nklktITAYFgd----------  
3LL7        ( 232 )    ------gevkELLVrMSln---------    
3037cM.thr-NT          EACLWSGSLTEPGV---RRRATILDRSE 
                              bbbbbb       
 
Solvent inaccessible    UPPER CASE X  hydrogen bond to main chain amide  bold x                           
Solvent accessible      lowercase x  hydrogen bond to main chain carbonyl underline x 
α-helix       red  x  310 helix    maroon x 
β-strand                      blue  x  positive phi   italic x     
         B. 
 
FIGURE AV.4    Model of three-dimensional structure of N-terminal domain of Rv3037c orthologue in    
                             M. thermoresistibile. 
A. Model of the N-terminal domain.  
B. Structural alignment of target protein and templates (produced by FUGUEALI) (3037cM.thr- 
         NT refers to N-terminus domain of Rv3037c orthologue in M. thermoresistibile).  
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B.  Modeling of the C-terminal domain  
No significant sequences were obtained from the BLAST search, which could serve as 
templates to model the C-terminal domain of the protein. Thus, only a part of a putative 
methyltransferase was used as a template for modeling (PDB ID- 3LL7).  
                                10        20        30        40        50   
3LL7        ( 266 )    vipfifteeersisIpyTdsidkyVYePhtaLlkagAfkTVAyrlgLrKL 
3037cM.thr-CT          ---VITDAEPGECPVA---AAGRWIIDPDGAVVRAGLVRHYAARHGLWQL 
                               aaaa           bbbbb aaaaaa  aaaaaaaa  bbb 
 
                                60        70        80        90        100  
3LL7        ( 317 )    hpnShlYTseayesaFpgrtFvleeiipfstsvLkqLrkvvpq--AsIsc 
3037cM.thr-CT          DPDIAYLSGDRLPAGV--RGFEVLEELPYRERRLRQALAAHDAGAVEILV 
                       b  bbbbbb        bbbbbbbbbbb  333333333       bbbb 
 
                                110       120       130       140     
3LL7        ( 365 )    rnFplspieLrqrskadgge------ktLGTTadgkkvLLLlrkAe 
3037cM.thr-CT          RGVDVDPDRLRTRLRLRGRHPLAVVITRIGSKHASRATAFICRPSR 
                       b     aaaaaaaa            bbbbb      bbbbbbb   
 
Solvent inaccessible    UPPER CASE X  hydrogen bond to main chain amide  bold x                           
Solvent accessible      lowercase x  hydrogen bond to main chain carbonyl underline x 
α-helix       red  x  310 helix    maroon x 
β-strand                      blue  x  positive phi   italic x     
A. 
 
 
                              
 
 
 
 
 
 
 
 
 
FIGURE AV.5    Model of three-dimensional structure of C-terminal domain of Rv3037c orthologue in  
                              M. thermoresistibile 
A. Structural alignment of target protein and 3LL7 (produced by FUGUEALI) (3037cM.thr-CT 
refers to C-terminal domain of Rv3037c homologue in M. thermoresistibile).  
B. Model of the C-terminal domain. 
B. 
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It is plausible that the full-length protein was found in inclusion bodies because the domains 
didn’t fold properly. Thus, an attempt was made to express both domains individually in 
order to obtain the protein in the soluble form. 
AV.3.1.5     Expression trial of N-terminal domain of Rv3037c orthologue in  
        M. thermoresistibile  
An expression trial of the N-terminal domain, with a C-terminal His6 tag in E. coli indicated 
that there was no expression of the construct. The bands seen on the gel were of E.coli 
proteins, as analyzed by MALDI fingerprinting. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
FIGURE AV.6    Expression trial of N-terminal domain of Rv3037c orthologue in M. thermoresistibile   
                             tagged with His6. 
                             Bands marked with arrows are of E. coli proteins.  
(MWM: molecular weight marker, L: cellular lysate, S: supernatant, P: pellet, FT: flow                      
through, Pr: protein).              
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AV.3.1.6     Expression trial of C-terminal domain of Rv3037c orthologue in  
        M. thermoresistibile  
It was possible to get expression of C-terminal domain, with a SUMO tag at its N-terminus, 
in the soluble fraction.  
 
                                                                  
                                                               
 
 
 
 
 
 
 
 
 
FIGURE AV.7    Expression trial of C-terminal domain of Rv3037c orthologue in M. thermoresistibile   
 tagged with SUMO. 
                             SUMO tagged C-terminal domain is seen around 30 kDa.                            
                             (MWM: molecular weight marker, L: cellular lysate, S: supernatant, P: pellet, FT: flow    
                             through, Pr: protein)              
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AV.3.2      TARGET: Rv3038c 
AV.3.2.1   Bioinformatic Analysis 
 
TABLE AV.3    Alignment coordinates of the methyltransferase domain in Rv3038c and its orthologues. 
     As given in Pfam database. 
 
 
AV.3.2.2     Expression trials of full length Rv3038c and its orthologues in M. smegmatis  
                    and M. thermoresistibile 
Trials for expression of the SUMO-tagged proteins indicated the M. smegmatis and                      
M. thermoresistibile proteins expressed in the soluble fraction, but the M. tuberculosis protein 
was not identified in the soluble fraction. Bands at lower molecular weight (around 25 kDa), 
initially thought to be of some chaperone, were of SUMO tag along with some residues from 
N-terminus of the target protein that got naturally clipped when proteins were expressed in          
E. coli. This was confirmed by MALDI fingerprinting after doing large-scale expression and 
purification of M. thermoresistibile protein (discussed below). 
 
 
 
 
 
 
 
 
 
PROTEIN 
METHYLTRANSFERASE DOMAIN 
ALIGNMENT COORDINATES (RESIDUE 
RANGE) 
Rv3038c 82-179 
Rv3038c homologue in M. smegmatis 81-178 
Rv3038c homologue in M. thermoresistibile 89-186 
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FIGURE AV.8   Expression trials of SUMO tagged Rv3038c and its orthologous proteins.  
For Rv3038c, thick band (red arrow) was seen in the cell lysate lane but not in the supernatant 
(soluble fraction) lane. For homologous proteins, soluble expression was seen (yellow arrows). 
Bands at 25 kDa (blue box) were of SUMO tag with a part of the protein that got clipped at the 
N-terminus during expression.  
(MWM: molecular weight marker, L: cellular lysate, S: supernatant, FT: flow through, P: 
protein).   
AV.3.2.3     Expression and purification of full-length SUMO-tagged Rv3038c  
       orthologue in M. thermoresistibile 
High levels of expression of the orthologous M. thermoresistibile gene in E. coli were 
observed. However, during its expression in E. coli, there was partial clipping of a section at 
the N-terminus conjoint to SUMO tag.  
The tag was cleaved off from the protein eluted by Ulp1 protease and several bands seen on 
the gel were analyzed by mass fingerprinting. It was inferred that there were two types of 
clipping of protein: 
       M. tuberculosis            M. smegmatis      M. thermoresistibile 
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1. First clipping during expression: partial clipping of few residues from N-terminus of 
protein conjoint to SUMO tag during expression of full-length protein (Figure AV.9 
A).  
2. Second clipping during Ulp1 cleavage: when SUMO-tag was cleaved from purified 
full-length protein by Ulp1 protease, tag got cleaved; but a few residues at the N-
terminus not conjoint to the tag also got clipped (Figure AV.9 B). 
 
The gel filtration profile showed that the SUMO-tagged protein eluted just at the void 
volume, probably indicating its aggregation or higher molecular assembly.  
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FIGURE AV.9    Expression and purification of Rv3038c orthologue in M. thermoresistibile 
A. Metal affinity purification of SUMO tagged protein on Ni-sepharose column. Strong bands (red arrow) of 
full-length protein with SUMO tag seen at MW higher (MW of protein- 36.6 kDa, MW of SUMO tag-13.8 
kDa, total MW of tagged protein-50.4 kDa). Due to column overloading, some of the tagged-protein 
flowed through. N-terminal part of protein with SUMO tag getting clipped seen at 25kDa (yellow arrows). 
Tag-less truncated protein left after clipping (green arrow) seen at 46 kDa. (MWM: molecular weight 
marker, L: cellular lysate, FT: flow through, S: supernatant, P1 to P2: protein). 
B. Cleavage of SUMO tag by UlpI protease and reverse binding on Ni-sepharose column. 1: tagged protein, 
2: tag-less protein obtained in the flow through, 3: SUMO tag. Due to column overloading, entire quantity 
of SUMO tag didn’t get reversely bound and flowed through along with the tag-less truncated target 
protein. Full length protein with SUMO is marked by red arrow; N-terminal region with SUMO tag getting 
clipped during expression is marked by a yellow arrow; tag-less truncated protein left after UlpI cleavage 
is marked by orange arrows; SUMO tag is marked by blue arrow; chaperone GroEL is marked by white 
arrow. 
C. Gel filtration of tag less protein on Superdex-200 column. Bands in white box: GroEL, bands in orange 
box: tag-less truncated protein after clipping during UlpI cleavage. (MWM: molecular weight marker, F1 
to F8: protein fractions). 
D. Gel filtration profile. 
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An alternate purification strategy was adopted to address the problem of clipping during 
expression. In this, affinity chromatography, treatment of full-length protein with EDTA and 
anionic exchange were performed. The clipping of a part of N-terminal conjoint to the 
SUMO tag during expression and thus, loss in yield of purified protein remained a problem, 
although the full-length tagged protein produced was pure enough. 
 
 
  
 
 
 
 
 
 
 
                                                     
 
 
                                                                                                                                                
 
 
 
 
 
 
 
 
 
FIGURE AV.10   Expression and purification of SUMO-tagged Rv3038c orthologue in 
                              M. thermoresistibile  
A. Metal affinity purification of SUMO tagged protein on Ni-sepharose column. (MWM-molecular 
weight marker, L-lysate, FT-flow through, S-supernatant, P1 to P2-protein) 
B. Anionic exchange chromatography. Full length protein with SUMO tag (F4-F12) is marked by red 
arrow, N-terminal region with SUMO tag getting clipped (F1-F3) is marked by yellow arrow, 
chaperone GroEL (F8-F12, upper band) is marked by white arrow (MWM-molecular weight marker, 
F1 to F12-protein fractions) 
C. Anionic exchange chromatography profile. 
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AV.3.2.4     Protein modeling of Rv3038c orthologue in M. thermoresistibile 
The templates used for building model of orthologous protein of Rv3038c were 
methyltransferase proteins with structures available in PDB (PDB ID of templates- 3EGE, 
3SM3, 1VE3, 3BKW, 3BUS).  
PDB ID PROTEIN ORGANISM 
1VE3_A PH0226 protein Pyrococcus horikoshii OT3 
3BKW_B S-adenosylmethionine dependent 
methyltransferase (NP_104914.1) 
Mesorhizobium loti 
MAFF303099 
3EGE_A Putative methyltransferase from antibiotic 
biosynthesis pathway (YP_324569.1) 
Anabaena variabilis ATCC 
29413 
3SM3_A SAM-dependent methyltransferases 
Q8PUK2_METMA 
Methanosarcina mazei Go1 
3BUS_B Rebeccamycin sugar 4'-O-methyltransferase 
RebM 
Lechevalieria aerocolonigenes 
Table AV.4    Structural templates used for homology modelling of orthologue of Rv3038c in  
   M. thermoresistibile. 
 
Model of the M. thermoresistibile protein indicated that the N-terminus region clipped is 
disordered. This is supported by the prediction with DisoPred. Based on these observations, 
this part of protein was truncated to retrieve the remaining protein. 
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                              10        20        30        40        50   
3EGE      (  12 )                                                s----- 
3SM3      (  18 )                                                       
1VE3      (   2 )                                                Gfkeyy 
3BKW      (  24 )                                                       
3BUS      (  26 )                                                    en 
3038cM.thr           MTETTEPGIGSEGAGDLPAPNPHATAEQVEAAMRDSKLAQILYHDWEAES 
                                                                        
                              60        70        80        90        100  
3EGE      (  13 )    -----qtrvpD---irIVnaIinlLn--lpkg---svIADIgAgtGgySv 
3SM3      (  18 )            ld------LypiIhnyLq----ed---deILDIGCgsGkiSl 
1VE3      (   8 )    rvfptyTdInsqeYrsrietLeplLmkyMkkr---gkVLDLaCgVGGFSF 
3BKW      (  24 )           gld---gaaeWpaLramLpe-Vg-g---lrIVDLgCgfGwFCr 
3BUS      (  28 )    LhFGywesvd-datdrLTdeMialLd--Vrsg---drVLDVgCgiGkpAv 
3038cM.thr           YDDKWSISYDQRCVDYARGRFDAIVPDHVQRELPYDNALELGCGTGFFLL 
                                      aaaaaaa            bbbbb     aaaa 
 
                              110       120       130       140       150  
3EGE      (  50 )    aLAnqgL-fVyAVe-psivmrqqav--------vhp---qVewftgyAen 
3SM3      (  47 )    eLaskgy-sVtGId-inseairlAetaarspglnqktgGkAeFkvEnAss 
1VE3      (  55 )    lLedygF-eVvGVd-isedmIrkAreyaks--reS----nVeFivgdArk 
3BKW      (  59 )    wAhehgAsyVlGLd-lsekmLarAraagpd--------tgItYeradldk 
3BUS      (  78 )    rLAtardVrVtGIs-isrpqvnqAnarAtaagla----nrVtFsyadAmd 
3038cM.thr           NLIQSGVARRGSVTDLSPGMVRVATRNGRSLGLD------VDGRVADAEG 
                     aaaa    bbbbbb   aaaaaaaaa               bbbb      
 
                              160       170       180       190       200  
3EGE      (  87 )    LaLpdksVdGVISIlaIhhfs--h-lekSFqeMqrIIrdgtIVLLTfD-- 
3SM3      (  95 )    LsfhdssFdFAVMQafLTsvpdpkeRsrIIkeVfrVLkpgayLYLVEF-- 
1VE3      (  97 )    LsfedktFdYVIFIdsIvhfe-pleLnqVFkeVrrVLkpsGkFIMyFt-- 
3BKW      ( 100 )    LhLpqdsFdLAYSslalHyVe---dvarlFrtVhqALspgghFVFSte-- 
3BUS      ( 123 )    LpfedasfdAVWAlesLHhmp---drgrALreMarVLrpgGtVAIADfVl 
3038cM.thr           IPYDDNTFDLVVGHAVLHHIP---DVELSLREVVRVLRPGGRFVFAGEPT 
                            bbbbbbb  333      aaaaaaaaaaabbbbbbbbbbbb   
 
                              210       220       230       240       250  
3EGE      ( 132 )    IrlAqrIWLydYFpFLwedalrflpldeQinlLqenTkrrVeaipflLph 
3SM3      ( 143 )    gQ-N---w-h--lklyrkrYlh------Dfpitk-e-eGSflard---pe 
1VE3      ( 144 )    Dl-------rellprlk----------------eis---kvipdqeertV 
3BKW      ( 145 )    HPiy---mAPa-rpgwaig-------------------rrtWpid--ryl 
3BUS      ( 170 )    lapVeg-akkeavdafragg-gVlslg-gideYesdVr------------ 
3038cM.thr           TVGNSYARALSTLTWHVATTVTRLPGLQGWRRPQAELDESSRAAALEAVV 
                                                                        
                              260       270       280       290       300  
3EGE      ( 182 )    dLsDlFaAAAWrrpelYlkaeVragIssFal-anqdlvekGlelLta-dl 
3SM3      ( 175 )    t-g-etefiaHHFt-----------------------ekeLvflLtd--c 
1VE3      ( 177 )    vIefsfrVrfnVWg-----------------------kt-gVellAk--l 
3BKW      ( 173 )    -----vegpRktdwla-----------kgvvkhHr-tvgttlnaLir--S 
3BUS      ( 205 )    qAeLvvtstvdisaqAr--pSLvktAeafen-----arsqvepfmga--- 
3038cM.thr           DLHTFEPSDLERMARNAGAVEVATASEEFTAAMLGWPVRTFEAAVPPGKL 
                            bbb                           aaaaaaaaa     
 
                              310       320       330       340    
3EGE      ( 230 )    n--------ng-----eWirkygeihhlqeIdIGyrFIyTt-l   
3SM3      ( 198 )    rFeidyfrvkeLe---t--r-tg-----nkI-lGfVIIAqk-lle 
1VE3      ( 206 )    yFtkeaeekvg------------------ny-syLTVYnPk     
3BKW      ( 204 )    gFaiehveeFcPt--daqitarpelaeeldGfLLVsArr     
3BUS      ( 245 )    e------------gLdrmiatFrgLAeVpea-gYVLIgArkp    
3038cM.thr           GWNWAKFAFGSWTALSWVDANVWRRVMPKGWFYNVMVTGVKPS-- 
                                                      bbbbbbb      
Solvent inaccessible    UPPER CASE X  hydrogen bond to main chain amide  bold x                           
Solvent accessible      lowercase x  hydrogen bond to main chain carbonyl underline x 
α-helix       red  x  310 helix    maroon x 
β-strand                      blue  x  positive phi   italic x     
       A. 
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FIGURE AV.11    Model of three-dimensional structure of Rv3038c homologue in M. thermoresistibile 
A.    Structural alignment of the target protein and templates (produced by FUGUEALI). The 
part of N- terminus of the target protein that was clipped (highlighted in yellow) is not 
aligned to any secondary structure element. The methyltransferase domains of all the 
proteins align fairly well. (3038cM.thr refers to Rv3038c homologue in M. 
thermoresistibile) 
B.    Model of the target protein. Strand at the N-terminus of the protein getting naturally clipped     
  (corresponding to the yellow highlighted part in the structural alignment above) is shaded     
   red. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
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AV.3.2.5     N-terminal truncation of Rv3038c orthologue in M. thermoresistibile 
Expression trial of SUMO-tagged truncated Rv3038c orthologue in M. thermoresistibile  
The trial of truncated protein tagged with SUMO at its N-terminal illustrated that the protein 
was found in the pellet fraction and there was still clipping of a few residues from the N-
terminus of the truncated protein. This was confirmed by MALDI fingerprinting of the bands. 
 
FIGURE AV.12    Expression trial of SUMO-tagged       
                               truncated Rv3038c orthologue in  
                               M. thermoresistibile. 
       
                                                     Truncated SUMO tagged protein (yellow arrow) is seen in the                  
                                                                pellet fraction. N-terminal part of the protein along with the 
                                                                SUMO tag is still getting clipped as seen at 25 kDa (red 
arrow).   
                                                                Band observed at 46 kDa (green arrow) is of E. coli protein. 
                                                                (MWM: weight marker molecular, L: cellular lysate, S:  
                                                                supernatant, P: pellet, FT: flow through, Pr: protein) 
 
                                                                  
 
 
  
  
Expression trial of His6-tagged truncated Rv3038c orthologue in M. thermoresistibile 
The trial of truncated protein tagged with His6 at its C-terminal showed that the protein is 
found in inclusion bodies, although there was no clipping at N-terminal. A band observed in 
the soluble fraction was of a protein in E. coli, as shown by the MALDI fingerprinting of the 
bands. 
                                                                     FIGURE AV.13  Expression trial of His6-tagged        
                                                                                                                truncated Rv3038c orthologue  
                                                                                                                in M. thermoresistibile. 
                                                                                   
          Truncated target protein (yellow arrow) is seen in the pellet   
          fraction.  Band observed in supernatant lane (green arrow) 
is                      of E. coli protein. 
                                                                                    (MWM: molecular weight marker, L: cellular lysate, S:  
                                                                                    supernatant, P: pellet, FT: flow through, Pr; protein) 
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